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The TET enzymes oxidize 5-methylcytosine to 5-
hydroxymethylcytosine, which can lead to DNA demethylation. However, direct 
connections between TET-mediated DNA demethylation and transcriptional 
output are difficult to establish due to challenges of distinguishing global 
versus locus-specific effects. Here we show that TET1/2/3 triple knockout 
(TKO) human embryonic stem cells (hESCs) exhibit prominent bivalent 
promoter hypermethylation without overall corresponding gene expression 
decrease in the undifferentiated state. Focusing on the bivalent PAX6 locus, 
we find that increased DNMT3B binding is associated with promoter 
hypermethylation, which precipitates a neural differentiation defect and failure 
of PAX6 induction during differentiation. dCas9-mediated locus-specific 
demethylation and global inactivation of DNMT3B in TKO hESCs partially 
reverses the hypermethylation at the PAX6 promoter and improves 
differentiation to neuroectoderm. Taken together with further genome-wide 
methylation and TET1 and DNMT3B ChIP-Seq analysis, we conclude that 
TET proteins safeguard bivalent promoters from silencing by de novo 
methylation to ensure robust lineage-specific transcription upon differentiation.  
 
 
 
  
	 iii	
BIOGRAPHICAL SKETCH 
 
Nipun Verma was born in New Delhi, India. She moved to the United 
States when she was four and grew up in Miami, Florida. She attended Cornell 
University and graduated in 2010 after majoring in Biological Sciences and 
minoring in Chemistry. She moved to New York City to attend medical school 
at Weill Cornell Medical College (WCMC). After her first year in medical school 
Nipun volunteered in Dr. Danwei Huangfu’s lab as part of the WCMC Clinical 
and Translational Science internship program. Then after returning to medical 
school for a year, Nipun decided to work full time in the Dr. Huangfu’s lab as 
part of the Howard Hughes Medical Institute Fellowship Program. During the 
fellowship year Nipun transferred into the Weill Cornell/Rockefeller/Sloan 
Kettering Tri-Institutional MD-PhD program and worked as a PhD graduate 
student in Dr. Huangfu’s lab for 4 more years. While in Dr. Huangfu’s lab 
Nipun has focused on the role of the TET proteins in hESC pluripotency and 
differentiation. In this project Nipun has found that the TET proteins are 
necessary to protect bivalent promoters from abnormal hypermethylation in 
human embryonic stem cells. This enables the differentiation-associated 
genes that typically have bivalent promoters to be efficiently activated and 
expressed during differentiation and development. This establishes a crucial 
new function of the TET proteins during development and opens up questions 
on whether they play a similar function in other stem cell populations in which 
they are abundant. After completing her thesis and finishing medical school 
Nipun will embark on a career that combines clinical practice and biomedical 
research. 
 
		
	 	iv	
 
ACKNOWLEDGEMENTS 
 
Thanks to my mentor, Dr. Danwei Huangfu, for excellent and unique 
ideas that have been fun to ponder and investigate during these past five 
years. Thank you for your guidance, support and optimism and for pushing me 
to become a better scientist. And also thank you for helping me improve my 
skills in presenting and communicating my work. I am grateful for your 
consistent and attentive mentorship throughout my PhD. 
I want to thank my committee members Dr. Lorenz Studer, Dr. Todd 
Evans and Dr. Kitai Kim for your advice and support throughout my years as a 
graduate student. Your insights have been invaluable for my research and 
having you on my committee has given me additional wonderful scientific role 
models.  
Thank you to the members of Dr. Danwei Huangfu’s lab both past and 
present. I have learned a lot from each and every one of you. Thank you all for 
your kind support and your useful criticisms that have been vital for me in 
completing my PhD. Thank you to Federico for sharing your vast knowledge 
on research and always being very generous with your time. Big thanks to 
Virginia, Qing and Daniela, I am very grateful to have met and worked with 
you. You have helped me get through some of the toughest points of the PhD 
with your generosity, kindness and support. 
The most profound thanks to my family. To my siblings, Nupur and Neil, 
and my parents, Usha and Ashok. Thank you for your love and support 
throughout my PhD. Thank you for pushing me to work hard but also 
		
	 	v	
reminding me to have fun and enjoy what I am doing. Thank you for always 
believing in me. I could not have done it without you all. 
		
	 	vi	
TABLE OF CONTENTS 
 
BIOGRAPHICAL SKETCH ............................................................................... iii	
ACKNOWLEDGEMENTS ................................................................................. iv	
LIST OF FIGURES ........................................................................................... ix	
LIST OF TABLES ............................................................................................. xi	
CHAPTER 1: Introduction ................................................................................. 1	
1.1	 EPIGENETICS .......................................................................................... 1	
1.1.1	 Noncoding RNA ................................................................................. 2	
1.1.2	 Histone Modifications ......................................................................... 3	
1.1.3	 DNA Methylation ................................................................................ 4	
1.2	 DNA METHYLATION AND DEMETHYLATION PROTEINS .................... 6	
1.2.1	 DNA Methylation ................................................................................ 6	
1.2.2	 DNA Demethylation ............................................................................ 7	
1.3	 TET-MEDIATED DNA DEMETHYLATION ............................................... 9	
1.3.1	 Passive Replication-Dependent Dilution ............................................ 9	
1.3.2	 Active DNA Demethylation Through DNA Repair ............................ 11	
1.3.3	 Enzymatic Decarboxylation of 5caC ................................................ 13	
1.3.4	 Dehydroxylation by DNMT Enzymes ............................................... 13	
1.4	 DNA METHYLATION AND TRANSCRIPTIONAL REGULATION .......... 14	
1.4.1	 Promoters ......................................................................................... 14	
1.4.2	 Gene Bodies .................................................................................... 18	
1.4.3	 Enhancers ........................................................................................ 18	
1.4.4	 Insulators .......................................................................................... 19	
1.5	 ADDITIONAL FUNCTIONS OF DNA METHYLATION ........................... 23	
1.5.1	 Transposons .................................................................................... 23	
1.5.2	 Pericentromeric Repeats .................................................................. 23	
1.5.3	 X-Chromosome Inactivation ............................................................. 23	
1.5.4	 Imprinted Genes ............................................................................... 24	
1.6	 5HMC MAPPING IN THE MAMMALIAN GENOME ............................... 25	
1.6.1	 Promoters ......................................................................................... 27	
1.6.2	 Gene Bodies .................................................................................... 27	
1.6.3	 Enhancers ........................................................................................ 28	
1.7	 DNA METHYLATION DURING DEVELOPMENT .................................. 28	
1.7.1	 Demethylation in the Early Zygote ................................................... 29	
1.7.2	 Methylation Changes in the Early Embryo ....................................... 31	
1.7.3	 Methylation Changes in Primordial Germ Cells ............................... 34	
1.8	 PHENTOTYPES OF DNMT- AND TET-DEFICIENT MICE .................... 36	
		
	 	vii	
1.9	 PHENTOTYPES OF DNMT- AND TET-DEFICIENT MESCS ................ 39	
1.10	 ROLE OF TET PROTEINS IN REPROGRAMMING ............................ 42	
1.11	 THESIS AIMS ....................................................................................... 44	
CHAPTER 2: TET Protein Requirement and Function of Oxidized     
Methylcytosines in hESCs ............................................................................... 46	
2.1	 INTRODUCTION .................................................................................... 46	
2.2	 RESULTS ............................................................................................... 40	
2.2.1	 Bivalent Promoter Hypermethyaltion in TKO hESC…………………40	
2.2.2	 Hypermethylation of the PAX6 P0 Promoter…………………………48	
2.2.3	 Impaired Neural Differentiation of TKO hESCs ................................ 74	
2.2.4	 Promoter Hypermethylation Hinders PAX6 Expression Upon 
Differentiation ............................................................................................... 84	
2.2.5	 De novo methylation causes PAX6 promoter hypermethylation ...... 97	
2.3	 DISCUSSION ....................................................................................... 110	
2.4	 MATERIALS & METHODS ................................................................... 113	
2.4.1	 hESC Culture ................................................................................. 113	
2.4.2	 Generation of TET mutant hESCs ................................................. 114	
2.4.3	 hESC Differentiation ....................................................................... 117	
2.4.4	 Dot Blot .......................................................................................... 120	
2.4.5	 Mass Spectrometry Quantification of 5mC and 5hmC ................... 121	
2.4.6	 Pluripotency and Lineage Marker Staining .................................... 121	
2.4.7	 FACS Analysis ............................................................................... 122	
2.4.8	 Quantitative RT-qPCR ................................................................... 123	
2.4.9	 Epimark .......................................................................................... 125	
2.4.10	 RNA-Seq ...................................................................................... 126	
2.4.11	 5hmC Profiling .............................................................................. 126	
2.4.12	 Whole Genome Bisulfite Sequencing (WGBS) and Enhanced 
Reduced Representation Bisulfite Sequencing (ERRBS). ......................... 127	
2.4.13	 ChIP-Seq ...................................................................................... 130	
2.4.14	 5mC Methylation Analysis by MassArray ..................................... 131	
2.4.15	 PAX6 Overexpression Lentivirus Construct and Generation of 
PAX6 Overexpression hESCs ................................................................... 134	
2.4.16	 Colony Forming Assay ................................................................. 135	
2.4.17	 Cloning dCas9 TET1 Catalytic Domain Fusion and Site-Directed 
Mutagenesis .............................................................................................. 136	
2.4.18	 Targeting dCas9-TET1CD into TKO hESCs ................................ 136	
2.4.19	 Generation of TET1-3xFlag tagged hESCs ................................. 138	
2.4.20	 ChIP-qPCR .................................................................................. 138	
2.4.21	 Statistical Analysis ....................................................................... 139	
2.4.22	 Data Availability ............................................................................ 139 
CHAPTER 3: Conclusions & Perspectives .................................................... 140	
3.1	 SUMMARY ........................................................................................... 140	
		
	 	viii	
3.2	 FUTURE DIRECTIONS ........................................................................ 142	
3.2.1	 Identify Proteins that may be Involved in the Recruitment of DNMT3B 
and TET1 to Bivalent Promoters ................................................................ 142	
3.2.2	 Investigate Changes in Chromatin Environment Upon TET 
Inactivation ................................................................................................. 144	
3.2.3	 Investigate the Mechanisms Underlying Heterogeneity in the Gain of 
Methylation after TET Inactivation ............................................................. 144 
3.3	 CONCLUSIONS ................................................................................... 146 
CHAPTER 4: Generation of Pluripotency Reporter hESCs .......................... 115	
4.1	 INTRODUCTION .................................................................................. 115	
4.2	 RESULTS ............................................................................................. 117	
4.2.1	 CRISPR/Cas-Mediated Targeting of the OCT4 Locus ................... 117	
4.2.2	 Selection-free Targeting of the OCT4 Locus using a Mini-vector 
Donor.. ....................................................................................................... 120	
4.2.3	 Selection-free Targeting of the NANOG Locus .............................. 125	
4.3	 DISCUSSION ....................................................................................... 128	
4.4	 MATERIALS & METHODS ................................................................... 131	
4.4.1	 Generation of constructs ................................................................ 131	
4.4.2	 Cell culture ..................................................................................... 133	
4.4.3	 In vitro transcription of gRNAs ....................................................... 135	
4.4.4	 Electroporation ............................................................................... 135	
4.4.5	 Transfection ................................................................................... 136	
4.4.6	 Assessment of indel mutations using SURVEYOR nuclease ........ 137	
4.4.7	 Southern Blot ................................................................................. 138	
4.4.8	 Immunofluorescence staining ........................................................ 139	
4.5	 CONCLUSIONS ................................................................................... 139 
5.0					APPENDIX ........................................................................................... 150 
5.1					REFERENCES ..................................................................................... 164 
 
 
 
 
 
 
 
  
		
	 	ix	
LIST OF FIGURES 
 
 
Figure 2.1……………………………………………………………………………50 
Figure 2.2……………………………………………………………………………51 
Figure 2.3……………………………………………………………………………54 
Figure 2.4……………………………………………………………………………55 
Figure 2.5……………………………………………………………………………59 
Figure 2.6……………………………………………………………………………61 
Figure 2.7……………………………………………………………………………65 
Figure 2.8……………………………………………………………………………66 
Figure 2.9……………………………………………………………………………68 
Figure 2.10…………………………………………………………………………..71 
Figure 2.11…………………………………………………………………………..72 
Figure 2.12…………………………………………………………………………..77 
Figure 2.13…………………………………………………………………………..78 
Figure 2.14…………………………………………………………………………..80 
Figure 2.15…………………………………………………………………………..82 
Figure 2.16…………………………………………………………………………..83 
Figure 2.17…………………………………………………………………………..86 
Figure 2.18…………………………………………………………………………..87 
Figure 2.19…………………………………………………………………………..90 
Figure 2.20…………………………………………………………………………..91 
Figure 2.21…………………………………………………………………………..94 
Figure 2.22…………………………………………………………………………..96 
Figure 2.23…………………………………………………………………………..99 
		
	 	x	
Figure 2.24…………………………………………………………………………100 
Figure 2.25…………………………………………………………………………101 
Figure 2.26…………………………………………………………………………104 
Figure 2.27…………………………………………………………………………106 
Figure 2.28…………………………………………………………………………109 
 
  
		
	 	xi	
LIST OF TABLES 
 
 
Table 2.1…………………………………………………………………………..115 
Table 2.2…………………………………………………………………………..117 
Table 2.3…………………………………………………………………………..124 
Table 2.4…………………………………………………………………………..131 
Table 2.5…………………………………………………………………………..134 
Table 2.6…………………………………………………………………………..135 
Table 4.1…………………………………………………………………………..158 
Table 4.2…………………………………………………………………………..164 
Table 4.3…………………………………………………………………………..165 
Table 4.4…………………………………………………………………………..165 
Table 4.5…………………………………………………………………………..165 
 
 
	 1	
CHAPTER 1: Introduction 
 
1.1 EPIGENETICS 
 
The phenotype of a cell and ultimately the entire organism is 
determined by the underlying DNA sequence of its genes. Epigenetics 
spans the divide between genotype and phenotype by influencing the final 
outcome of a genetic locus without changing its DNA sequence. Despite 
sharing the same genetic information, epigenetic controls enable different 
cell types within an organism to express unique collections of genes, leading 
to their specialized morphology and function. Furthermore, stabilization of 
these gene expression patterns allows them to be recapitulated in progeny 
of the same lineage.  
Eukaryotic chromatin consists of genomic DNA, proteins and RNA 
packaged into a series of layers. At the base of this organization are 
nucleosomes, which consist of 147 bp of DNA wrapped around a histone 
octamer (2 histone proteins each of H2A, H2B, H3 and H4). The DNA and 
histone proteins can be epigenetically modified by the addition of certain 
chemical groups, which then affects how compact and inaccessible the 
chromatin is (Felsenfeld and Groudine, 2003). Histone variants (H2A.Z) can 
also replace the core histones and nucleosome positioning along the 
chromatin fiber can be modified to further alter DNA accessibility (Zlatanova 
and Thakar, 2008). Lastly the chromatin is organized into a 3-dimensional 
structure that enables the interaction between distal genomic sites and 
compartmentalizes chromatin regions into certain areas of the nucleus 
(Bonev and Cavalli, 2016). 
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Epigenetics is critical for the proper development of specialized cells 
from the fertilized zygote. Gene expression is directed by the binding of 
transcription factors but is also regulated by heritable, epigenetic 
modifications to DNA and histones that impact developmental decisions. 
Thus development and differentiation processes have become an 
exceptional setting in which to study how epigenetic processes can 
influence cell fate conversion (Cantone and Fisher, 2013). Previous work 
has focused primarily on three modes of epigenetic regulation: non-coding 
RNAs, covalent and non-covalent modifications of histone proteins and DNA 
methylation. Although often divided into separate categories it is important to 
note that there is significant interaction between these different methods of 
epigenetic regulation (Molina-Serrano et al., 2013). Also, unlike changes to 
the DNA sequence, epigenetic modifications are reversible and the 
modifications present are influenced by the cellular context and 
environment. At the moment, it is clear that proper epigenetic control is 
necessary for successful development; however, questions on how these 
modifications are interpreted and inherited, what genomic regions they act 
upon and how they impact gene expression before, during and after cell-fate 
transitions still remain.  
 
1.1.1 Noncoding RNA 
Non-coding RNAs (ncRNA) are RNAs that do not encode for proteins. 
Short ncRNAs (typically <30 nucleotides) have been found to regulate 
imprinting, promote heterochromatin formation and silence genes by post-
transcriptional RNA interference pathways (RNAi). Longer ncRNAs (>200 
nucleotides), can recruit chromatin modifying proteins to produce dramatic 
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changes in chromatin structure (Kowalczyk et al., 2012). This is seen most 
clearly with the Xist lncRNA, which recruits epigenetic proteins that compact 
chromatin, leading to long-term silencing of the X chromosome that can be 
inherited after cell division (Plath et al., 2002).  
 
1.1.2 Histone Modifications 
Histone proteins can be epigenetically modified by the addition or 
removal of covalent groups including the phosphorylation, acetylation, 
methylation (mono, di- and tri-) and ubiquitination of specific histone 
residues. Charge-altering modifications, such as phosphorylation and 
acetylation, can change the physical properties of the chromatin molecule 
and thus affect its overall structure (Zhou et al., 2011). Histone modifications 
can also promote the recruitment of additional chromatin modifiers that can 
reinforce a particular chromatin state. For example H3K9 methylation is 
recognized by heterochromatin protein 1 (HP1), which then promotes further 
H3K9 methylation, DNA methylation and gene silencing (Lomberk et al., 
2006). Previous work has produced extensive genome-wide profiles of 
histone modifications in a variety of cell types. These maps have enabled us 
to identify regulatory elements in the genome that impact gene expression, 
and draw correlations between the distribution of these histone marks and 
the specific gene expression profiles of pluripotency, cellular differentiation 
and disease states (Consortium, 2012).  
Non-covalent histone modifications include chromatin remodeling and 
the incorporation of histone variants into nucleosomes. ATP- dependent 
chromatin remodelers alter the position of nucleosomes along the chromatin 
fiber. Areas of the chromatin that become depleted of nucleosomes typically 
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become more open and accessible, whereas nucleosome rich areas 
become more compact (Jiang and Pugh, 2009). Histone variants, such as 
H3.3 and H2A.Z, can be exchanged for the core nucleosomal histones and 
often carry their own covalent modification patterns (Kamakaka and Biggins, 
2005). Subunits involved in nucleosome remodeling and incorporation of 
histone variants can occur in the same effector protein, suggesting a 
mechanistic link between these two processes (Jin et al., 2005). Together 
covalent and non-covalent modifications of the histone proteins produce a 
wide array of possible epigenetic states and enable fine-tuned control of 
transcription. 
 
1.1.3 DNA Methylation 
DNA methylation refers to the methylation of the fifth position of 
cytosine to form 5-methylcytosine (5mC). This methylation primarily occurs 
at CpG dinucleotides and is present in plant, fungal and animal species (Goll 
and Bestor, 2005). The distribution of DNA methylation is described in 
further detail below, but generally DNA methylation follows a bimodal 
distribution in mammalian cells. Isolated CpGs are generally 
hypermethylated (60-90% depending on cell type), whereas clusters of 
CpGs together (200-500 base pair regions of high CpG density) called CpG 
islands are predominantly hypomethylated. The effect of DNA methylation 
on gene expression is context dependent, as methylation of CpG islands 
has clearly been shown to lead to reduced gene expression whereas the 
transcriptional outcome of methylation of isolated CpGs is less understood 
(Jones, 2012) (Figure 1.1).  
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Figure 1.1 Genomic distribution of CpG dinucleotides and the transcriptional 
effect of DNA methylation. (A) Within the genome CpG dinucleotides (depicted 
as lollipop objects in the diagram) can be present in clusters called CpG islands 
(CGIs). CGIs can occur within promoters that are upstream of genes (represented 
by the grey box) or away from genes as “orphan” CGIs. CGIs typically have low 
levels of DNA methylation (shown as empty circles on the lollipop objects). CpGs 
dinucleotides that occur outside of clusters are called isolated CpGs. Isolated 
CpGs typically show high levels of DNA methylation (shown as filled circles on the 
lollipop objects). (B) Three different promoter types (low CpG density, 
intermediate CpG density and high CpG density) are shown. Generally DNA 
methylation of intermediate and high CpG density promoters is associated with 
transcription repression. In contrast DNA methylation of low CpG density 
promoters does not typically affect gene transcription. 
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Similar to other epigenetic modifications, DNA methylation can be 
inherited following cellular division and dynamically altered by demethylation 
processes. During development as cells are directed towards certain 
differentiation lineages, DNA methylation serves as an epigenetic barrier to 
stabilize the acquired cell fate and prevent regression to undifferentiated 
cells. DNA methylation is also necessary for X-chromosome inactivation to 
maintain sex chromosome dosage, the repression of retrotransposons and 
the coordinated expression of imprinted genes (Smith and Meissner, 2013).  
 
1.2 DNA METHYLATION AND DEMETHYLATION PROTEINS 
 
1.2.1 DNA Methylation 
There are 3 DNA-methyltransferases, DNMT1, DNMT3A and 
DNMT3B, which catalyze the transfer of a methyl group from S-adenosyl-l-
methionine to the fifth position of cytosine nucleotides in DNA. DNMT1 
functions as a maintenance methyltransferase that reproduces methylation 
marks on nascent DNA strands following DNA replication (Goll and Bestor, 
2005). DNA methylation typically occurs at CpG sites, which are 
palindromes and are symmetrically methylated. Thus, DNA replication 
produces two new DNA strands that each have hemimethylated CpG sites. 
The protein UHRF1 recognizes these hemimethylated sites and recruits 
DNMT1, which then methylates the reciprocal CpG site on the newly-
synthesized DNA and thus maintains DNA methylation patterns following 
cellular replication (Sharif et al., 2007). Due to its function in maintaining 
methylation patterns DNMT1 is almost ubiquitously expressed in all cell 
types. 
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  DNMT3A and DNMT3B are identified as the de novo 
methyltransferases (Okano et al., 1999). Although primarily responsible for 
establishing novel methylation patterns, studies in mouse embryonic stem 
cells (mESCs) have also found that they are involved in DNA methylation 
maintenance (Chen et al., 2003; Liang et al., 2002). During early 
development DNMT3A is maternally provided and is highly expressed in 
oocytes and early preimplantation embryos (Kaneda et al., 2004). DNMT3B 
first appears during zygotic gene activation and is then robustly expressed 
during the blastocyst stage and later in the epiblast. The expression of 
DNMT3A and DNMT3B varies depending on the cell type during later 
development and in the different somatic lineages (Watanabe et al., 2002). 
 DNMT3L lacks the N-terminal catalytic domain found in the other 
DNA methyl-transferases (Bourc'his et al., 2001). DNMT3L functions as a 
stimulating cofactor for DNMT3A/DNMT3B mediated methylation and has 
been found to be required for the DNA methylation of imprinted genes in 
gametes (Bourc'his and Bestor, 2004).  
 
1.2.2 DNA Demethylation 
Recently the TET (Ten-Eleven Translocation) proteins were 
discovered and speculated to play a role in DNA demethylation. TET1, the 
founding member of the TET family, was discovered as the fusion partner of 
Mixed Lineage Leukemia 1 (MLL1) in rare cases of acute myeloid and 
lymphocytic leukemia that harbor the ten-eleven translocation 
(t(10;11)(q22;q23)) (Lorsbach et al., 2003). A later computational screen 
searching for mammalian analogues of JBP1, a trypanosome protein that 
modifies DNA, identified the three mammalian TET proteins, TET1, TET2 
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and TET2, as potential DNA modifiers (Iyer et al., 2008). All three TET 
proteins are Fe2+ and 2-oxoglutarate-dependent dioxygenases that 
successively oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine 
(5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) in DNA (Ito et 
al., 2011; Tahiliani et al., 2009). The possible pathways for DNA 
demethylation after these oxidation steps are described in further detail 
below. 
 The TET proteins are expressed during early mouse development 
and are believed to play a role during several stages of demethylation. The 
expression of the individual TET proteins varies during embryonic 
development and in adult tissues. For example, TET3 is present in the 
zygote after fertilization and is involved in the global demethylation of the 
paternal nucleus (Gu et al., 2011b). Following this, TET1 and TET2 increase 
in expression in the blastocyst and epiblast stages and function in modifying 
de novo methylation patterns (Ruzov et al., 2011). TET1 and TET2 are also 
expressed in developing germ cells where they may play a role in the 
genome-wide demethylation and loss of imprint methylation marks (Hajkova 
et al., 2010). Within the adult, expression of the individual TET genes can 
vary depending on the specific tissue, for instance TET2 is the most highly 
expressed TET gene in hematopoietic cells and is frequently mutated in 
hematological malignancies (Abdel-Wahab et al., 2009). 
 The three oxidized forms of 5mC (5hmC, 5fC and 5caC) are found in 
numerous tissues; however, their abundance can vary between different cell 
types. 5hmC is most abundant in Purkinje neurons where it’s level is 
approximately 40% of 5mC (Kriaucionis and Heintz, 2009), it is also found in 
embryonic stem cells (5-10% of 5mC) (Tahiliani et al., 2009) and some 
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immune cell populations (1% of 5mC) (Ko et al., 2010). 5fC and 5caC are 
found in similar cell types as 5hmC but typically at much lower levels. For 
instance, in embryonic stem cells 5fC and 5caC represent .03% and .01% of 
5mC in embryonic stem cells (Ito et al., 2011). It is possible that this low 
abundance could result from the active removal of these oxidation products. 
 
1.3 TET-MEDIATED DNA DEMETHYLATION 
The TET proteins have generated great interest, in part because they 
may play a role in DNA demethylation. The TET proteins oxidize 5mC to 3 
successive oxidation products: 5hmC, 5fC and 5caC. These oxidation 
products could then be removed and replaced by unmodified cytosines, 
producing demethylation. There are four postulated mechanisms through 
which TET proteins could mediate DNA demethylation. 
 
1.3.1 Passive Replication-Dependent Dilution 
 
DNA demethylation can occur through passive means without the TET 
proteins. During cell division mitotic cells can lose DNA methylation by 
downregulating or excluding the maintenance methyltransferase (DNMT1) 
or its recruitment factor (UHRF1) from the nucleus (Figure 1.2). This passive 
demethylation process is believed to be involved in the demethylation of the 
maternal nucleus after fertilization as well as contribute to the genome wide 
demethylation of developing germ cells (Kagiwada et al., 2013; Ratnam et 
al., 2002).  
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Figure 1.2 Passive 
demethylation. DNMT1 is 
responsible for copying 
methylation patterns onto the 
newly synthesized DNA strand 
following DNA replication. In 
the absence of DNMT1 
methylation will be passively 
lost following each round of 
DNA replication. Adapted from: 
Messerschmidt et al., 2014. 
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Although passive demethylation is not dependent on the TET 
proteins, they could facilitate passive demethylation by producing 5hmC. 
Binding of UHRF1 to 5hmC is tenfold less efficient than binding to 5mC 
(Hashimoto et al., 2012). Furthermore the activity of recombinant DNMT1 in-
vitro is reduced 12-50 fold at sites of hemi-5hmC versus hemi-5mC 
(Valinluck and Sowers, 2007).  It is important to note that this passive 
demethylation is restricted to cells that are mitotically active. Thus it cannot 
account for the rapid loss of DNA methylation in slowly dividing or non-
dividing cells.  
 
1.3.2 Active DNA Demethylation Through DNA Repair 
Active removal of DNA methylation through DNA repair has been 
proposed to function through two pathways that are independent of DNA 
replication and cell division. Both pathways use TET-mediated oxidation and 
base excision repair (BER) (Figure 1.3). The first proposes that the 5fC and 
5caC oxidation products are removed by the glycosylase TDG. The resulting 
empty site is then filled with an unmodified cytosine residue via BER, 
resulting in demethylation. 
 Binding of TDG to 5caC has been confirmed by electrophoretic 
mobility shift assays and structural studies (Zhang et al., 2012). Furthermore 
the depletion of TDG in embryonic stem cells results in a 2-10 fold increase 
in the levels of 5fC and 5caC, suggesting it is acting to remove these 
products. On the other hand the overall levels of 5fC and 5caC are very low 
in ESCs even when TDG is depleted, suggesting that this pathway has 
limited function in these cell types (Shen et al., 2013). 
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Figure 1.3 Active demethylation. Possible DNA demethylation pathways are 
presented. Pathways for which there is experimental evidence are shown by black 
arrows. These include conversion of 5mC (5-methylcytosine) to thymidine by AID 
followed by BER (base excision repair) to replace with cytosine. The TET proteins 
can oxidize 5mC to 5hmC (5-hyrdoxymethylcytosine), 5fC (5-formylcytosine) and 
5caC (5-carboxylcytosine), which can be replaced with unmodified cytosine directly 
by BER or through AID conversion to 5hmU (5-hyrdoxymethyluracil) followed by 
BER. Pathways that currently have limited or no evidence are shown in grey. 
These include direct removal of 5mC, 5fC or 5caC by either a demethylase, a 
deformylase or a decarboxylase, respectively. Adapted from: Messerschmidt et al., 
2014.  
De novo Methylation 
Active Demethylation 
Adapted from: 
Messerschmidt et al. 2014  
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The second active demethylation process involves conversion of 
5hmC to 5-hydroxyuracil (5hmU) by AID and APOBEC family enzymes. 
5hmU is then removed by SMUG1 (Single-strand-selective Monofunctional 
Uracil DNA Glycosylase 1) or the TDG glycosylase and replaced with an 
unmodified cytosine by BER (Rai et al., 2008) (Figure 1.3). Compared to the 
first mechanism this pathway is more controversial, as AID enzyme typically 
acts on single stranded DNA and recombinant AID and APOBEC enzymes 
have negligible activity on 5hmC (Nabel et al., 2012). On the other hand, 
TDG can excise 5hmU:G mismatches in vitro, and primordial germ cells 
derived from AID- deficient mice do show increased methylation at CpG 
island promoters (Cortazar et al., 2011; Cortellino et al., 2011; Nabel et al., 
2012). Thus it is difficult to rule out that these individual pathways function in 
DNA demethylation but their contribution in vivo is still unclear. 
 
1.3.3 Enzymatic Decarboxylation of 5caC 
It is possible that 5caC may be decarboxylated to produce an 
unmodified cytosine. Currently the proteins involved in this pathway are 
unknown and evidence consists of a single report in which an 
oligonucleotide containing 5caC was incubated with ES cell lysate and 
showed a small but detectable direct conversion of 5caC to cytosine without 
BER (Schiesser et al., 2012).  
 
1.3.4 Dehydroxylation by DNMT Enzymes 
In-vitro experiments have indicated that the DNMT enzymes can 
remove the hydroxymethyl group of 5hmC to produce the unmodified 
cytosine. The catalytic function of DNMT3A depends on the reaction 
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conditions, with reducing conditions favoring the typical methyltransferase 
activity and oxidizing conditions promoting dehydroxymethylation (Chen et 
al., 2012; Liutkeviciute et al., 2009). It is unknown whether this process also 
occurs in vivo.  
 
1.4 DNA METHYLATION AND TRANSCRIPTIONAL REGULATION 
The mammalian genome contains approximately 28 million CpGs, of 
which 60-80% are methylated. 10% of CpGs occur together in CpG dense 
regions called CpG islands (Smith and Meissner, 2013). CpG islands are 
prevalent at transcription start sites and are found in approximately 60% of 
genes (Jones, 2012). In contrast to isolated CpGs, the CpGs within CpG 
islands are hypomethylated (Smith and Meissner, 2013). During 
development bulk genomic methylation patterns are typically static across 
different tissues with the exception of the genome-wide demethylation 
events in the fertilized zygote and developing primordial germ cells. Specific 
localized changes in DNA methylation are observed between different 
tissues depending on the activation or repression of certain genes. The 
distribution and function of DNA methylation patterns in the genome is 
incompletely understood, but I will describe the current views below (Figures 
1.3, 1.4).  
 
1.4.1 Promoters 
As described above, approximately 60% of human genes contain a 
CpG island (CGI) in their promoter. These include active, bivalent and silent 
promoters. Active promoters are associated with expressed genes and their 
typical features are: hypomethylated CGIs, nucleosome-depletion, 
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trimethylation of histone H3 at lysine 4 (H3K4me3), and the presence of the 
histone variant H2A.Z (Kelly et al., 2010) (Figures 1.4, 1.5). The level of 
gene expression is controlled by the binding of transcription factors and 
gene expression can be repressed by loss of transcription factor binding, the 
acquisition of particular histone modifications (H3K27me3) or by DNA 
methylation (Illingworth and Bird, 2009) (Figure 1.6).  
Inactive promoters that have a CGI are held in a stable repressed 
state by H3K27me3 and H3K9me3 histone marks and often DNA 
methylation (Figure 1.4). DNA methylation leads to the recruitment of 
methylated DNA binding proteins and histone deacetylases leading to 
further compaction (Bartke et al., 2010). 
In ESCs approximately 20% of promoters with CGIs are marked by 
H3K4me3 and H3K27me3 histone marks and low DNA methylation. 
Although the genes associated with these bivalent promoters are not 
expressed these promoters are termed poised as they contain both 
activating (H3K4me3) and repressive (H3K27me3) chromatin marks (Figure 
1.4). They are enriched for developmental regulators and upon 
differentiation to the associated lineage the repressive histone mark is 
usually removed and the gene is expressed (Voigt et al., 2013).  
The CpGs within CGIs are typically hypomethylated regardless of the 
expression level of the gene (Jones, 2012; Smith and Meissner, 2013). 
Stably repressed inactive promoters, such as the promoters of germ-cell 
specific genes, are the exception as they can show DNA methylation at their 
CGIs (Farthing et al., 2008). Interestingly the methylation of genomic regions 
surrounding CGIs (termed CGI shores) is found to be far more dynamic than 
within the CGIs themselves, and is also associated with gene repression 
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(Irizarry et al., 2009). At the moment it is clear that methylation of CGIs and 
CGI shores leads to gene repression, but it is unclear how prevalent this 
mechanism of repression is during normal development.  
It is also unclear whether DNA methylation is the initial silencing 
event. Previous work has shown that de novo methylation is inhibited by the 
H3K4me2 and H3K4me3 marks (Balasubramanian et al., 2012; Ooi et al., 
2007), and the H2A.Z variant (Zilberman et al., 2008), all of which are 
present at the CGIs of active and bivalent promoters. Furthermore DNA 
methylation requires the presence of nucleosomes, which are typically 
depleted in active promoters (Jiang and Pugh, 2009). Lastly, both active and 
bivalent promoters show enrichment of TET1 binding which may oxidize and 
ultimately remove any spurious 5mC (Williams et al., 2011; Wu et al., 2011; 
Xu et al., 2011). Thus it seems difficult for DNA methylation to occur at 
active or bivalent promoters and then precipitate gene silencing. On the 
other hand, there have been observations that suggest that these molecular 
protectors of DNA hypomethylation may break down. Bivalent promoters, in 
particular, can show de novo methylation during immortalization (Jones et 
al., 1990) and oncogenic transformation (Ohm et al., 2007; Schiesser et al., 
2012; Widschwendter et al., 2007).   
In contrast to promoters with CGIs, approximately 80% of promoters 
lacking CGIs are DNA methylated in ESCs (Jones, 2012; Smith and 
Meissner, 2013). These promoters do show substantial fluctuations in the 
promoter methylation levels among different cell types (Farthing et al., 
2008). The consequences of methylation changes on transcription are 
unclear as there are relatively few CpG dinucleotides present in these 
promoters and previous genome-wide studies correlating methylation and  
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Figure 1.4 Epigenetic features of different promoter types. Active, silent 
and bivalent promoters are three promoter types found in numerous cells. 
Active promoters are associated with genes that show productive gene 
transcription. They show low levels of DNA methylation and have the 
activating histone mark H3K4me3. Silent promoters are associated with 
genes that have negligible gene transcription. Silent promoters are 
characterized by high levels of DNA methylation and the repressive histone 
mark H3K27me3. Bivalent promoters are found in numerous stem cell and 
progenitor cell populations. These promoters are enriched for development or 
differentiation associated genes. Bivalent promoters show negligible gene 
transcription and are characterized by both activating (low DNA methylation 
and H3K4me3 histone mark) and repressive (H3K27me3 histone mark) 
epigenetic features.  
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gene expression have produced contradictory conclusions (Gal-Yam et al., 
2008; Weber et al., 2005). The current understanding is that methylation at 
these promoters will not repress transcription.  
 
1.4.2 Gene Bodies 
Gene bodies are generally CpG-poor, extensively methylated and 
typically this DNA methylation correlates with higher gene expression. Some 
gene bodies can contain CGIs, which may represent alternative promoters; 
however, methylation of these CGIs does not impede transcription 
elongation even if these methylated CGIs are marked by H3K9me3 and 
bound by methyl-CpG-binding proteins (Hellman and Chess, 2007; Wolf et 
al., 1984). This emphasizes that the effects of DNA methylation depend on 
the genomic context. Within mammalian cells transcription initiation not 
transcription elongation is sensitive to DNA methylation, as methylation of 
CGIs in promoters is inversely correlated with gene expression whereas 
methylation within the gene body is generally positively correlated with gene 
expression (Figure 1.5). 
 
1.4.3 Enhancers 
Enhancers are genomic regions that can recruit transcription factors, 
RNA polymerase II and chromatin modifiers to impact gene expression at 
distally located promoters. Enhancers are identified by the presence of 
certain histone marks (H3K4me1, H3K27ac) and co-activators (p300) and 
the depletion of H3K4me3 (Shlyueva et al., 2014). Enhancers are generally 
CpG-poor and have variable methylation levels (Stadler et al., 2011). This 
may be due to dynamic cycles of methylation followed by demethylation or 
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inefficient maintenance of methylation following DNA replication. Previous 
studies have found differentially methylated regions (DMRs) within the 
enhancers of differentiation genes, in which methylation of the enhancer 
correlated with suppression of gene expression (Schmidl et al., 2009) 
(Figures 1.5, 1.6). In addition 5hmC and TET proteins can be detected in 
these regions suggesting they may be sites of dynamic DNA methylation 
and demethylation (Ficz et al., 2011; Williams et al., 2011). Currently how 
DNA methylation of CpG poor enhancer regions is regulated and how it 
affects transcription factor binding and gene expression requires further 
study. 
 
1.4.4 Insulators 
Insulators are genomic regions that block the interaction between 
distally located enhancers and promoters. These include genomic 
sequences that are bound by the CTCF protein, such as a site within the 
IGF2-H19 locus. Methylation of the insulator within this locus blocks CTCF 
binding which leads to a disruption in the enhancer-promoter interaction 
(Bell and Felsenfeld, 2000). Methylation of other CTCF sites, such as within 
exon 5 of the CD45 gene, can also affect CTCF binding and affect gene 
splicing (Shukla et al., 2011). In other cases CTCF binding in CpG poor 
locations are not altered by DNA methylation levels and rather induce local 
DNA demethylation upon binding (Stadler et al., 2011). At the moment there 
are no universal conclusions on the effect of DNA methylation on insulator 
function, CTCF binding and gene transcription.  
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Figure 1.5 DNA methylation at genomic regulatory regions. Actively 
expressed genes with CGIs in their promoters typically have nucleosome 
deleted regions (NDR), low DNA methylation, H3K4me3 and the H2A.Z 
histone variant. In the gene body DNA methylation correlates with gene 
transcription and could function to regulate gene splicing. Enhancers are 
typically CpG poor with variable and changing DNA methylation possibly 
due to TET activity. In insulator regions DNA methylation may function to 
inhibit CTCF binding and thus enable interaction between distal regulatory 
regions and promoters. Adapted from: Jones et al., 2012. 
		
	 	21	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 DNA methylation is associated with repression of gene 
transcription. Enhancers are distally located from the genes that they regulate. 
Enhancers typically show low CpG density but the methylation of these CpGs is 
associated with repression of gene transcription. Promoters are directly upstream 
of the genes that they regulate. Promoters typically have higher CpG density than 
enhancers and approximately 60% of promoters have a CGI. DNA methylation of 
promoters is also associated with repression of gene transcription. 
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Figure 1.7 Additional functions of DNA methylation. In addition to 
regulating gene transcription DNA methylation is involved in silencing of 
transposons and centromeric repeats, X chromosome inactivation and the 
regulation of imprinted regions. 
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1.5 ADDITIONAL FUNCTIONS OF DNA METHYLATION 
1.5.1 Transposons 
Approximately 40% of the mammalian genome consists of 
endogenous transposable elements of three major classes: long 
interspersed nuclear elements (LINEs), short interspersed nuclear elements 
(SINEs) and long terminal repeat (LTR)-containing endogenous retroviruses. 
The promoters for these transposable elements are hypermethylated, which 
is believed to prevent transcriptional expression and retrotransposition as 
well as changes in the expression of neighboring genes (Figure 1.8) (Lander 
et al., 2001; Walsh et al., 1998).  
 
1.5.2 Pericentromeric Repeats 
Pericentromeric repeats are required for centromeric assembly during 
cell division and enable proper chromosome alignment and segregation. 
The pericentromeric minor and major satellites extend from the centromere 
as tens of thousands tandem copies. These elements have latent 
transcriptional activity that is suppressed by DNA methylation (Figure 1.8). 
DNMT3B in particular is recruited to these regions to produce DNA 
methylation, and is even found at pericentromeric repeats in metaphase 
chromosomes, suggesting a continued requirement for silencing during 
mitosis. Missense mutations in DNMT3B lead to the immunodeficiency, 
centromeric instability and facial anomaly (ICF) syndrome in which 
transcription from pericentromeric repeats causes chromosome 
misalignments during mitosis (Xu et al., 1999). 
 
1.5.3 X-Chromosome Inactivation 
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X chromosome inactivation in females is necessary for gene dosage 
control. X chromosome inactivation is triggered by the noncoding RNA Xist, 
which coats the X chromosome, displaces transcription factors and induces 
chromatin changes. Ultimately DNA methylation occurs as a final step to 
stabilize silencing (Figure 1.8) (Hellman and Chess, 2007).  
 
1.5.4 Imprinted Genes 
Imprinted genes show parent-of-origin specific expression, which is 
dictated by differential DNA methylation at imprinting control regions (ICRs) 
of the maternal and paternal alleles. This results in allele specific gene 
expression in which either the maternal or paternal allele is expressed. 
Differential methylation at ICRs is introduced during gametogenesis. During 
the genome-wide demethylation events that occur upon fertilization 
methylation at ICRs are preserved. DNA methylation at ICRs is only 
removed during primordial germ cell formation and then re-established in an 
allele-specific manner in developing gametes. DNMT3A, DNMT3B and 
DNMT3L are involved in the generation of genomic imprinting marks and 
dysregulation of these imprinting patterns is associated with numerous 
developmental defects (Bartolomei, 2009; Ferguson-Smith, 2011).  
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Figure 1.8 Additional functions of DNA methylation.  DNA methylation functions 
to repress transcription at transposons (de-repression can also result in the 
activation of neighboring genes), centromeric repeats, and reinforce silencing of 
one X chromosome. 
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1.6 5HMC MAPPING IN THE MAMMALIAN GENOME 
The generation of 5hmC genome wide maps is in many ways more 
challenging then whole genome mapping of 5mC.  5hmC is approximately 
14-fold less abundant than 5mC and the levels can vary dramatically 
between different tissue types. The traditional method to investigate 5mC 
distribution, bisulfite sequencing, cannot distinguish 5mC from 5hmC and 
thus cannot be used for 5hmC mapping. Several methods for 5hmC profiling 
have been developed. The first category consists of capture-based 
technologies such as antibody-based hydroxymethylated DNA 
immunoprecipitation followed by sequencing (hMeDIP-Seq) and enrichment 
by hydroxymethyl selective chemical labeling (hMeSeal). Although widely 
used, the key disadvantage of these techniques is that they produce low-
resolution 5hmC maps.  In contrast whole genome oxidative bisulfite in 
combination with conventional bisulfite sequencing (WG Bis/OxBis-seq) and 
TET-assisted bisulfite sequencing (TAB-seq) can produce base pair 
resolution maps of 5hmC distribution (Booth et al., 2012; Song et al., 2012; 
Yu et al., 2012).  
In general 5hmC profiling maps from ESCs have found that 5hmC is 
enriched at promoter CGIs and gene bodies of actively expressed genes. 
5hmC is also present at the bivalent promoters of developmental regulators 
and within CpG poor enhancers (Pastor et al., 2011). TET protein binding 
does not overlap perfectly with 5hmC peaks but in general is found at the 
TSS of CpG rich promoters (Deplus et al., 2013; Williams et al., 2011; Wu et 
al., 2011; Xu et al., 2011). I have emphasized observations taken from 
ESCs below, but it is important to note that 5hmC distribution can vary in 
different cell types. Because 5hmC is produced from 5mC this variability 
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may be due to changes in the distribution of 5mC or due to changes in the 
abundance of the individual TET proteins.  
 
1.6.1 Promoters 
5hmC is enriched at CGIs within promoters in human and mouse 
ESCs (hESCs and mESCs), mouse neural progenitor cells, mouse neurons 
and adult mouse cerebellum. The 5hmC at promoters typically shows 
bimodal peaks, with a 5hmC peak occurring 500-2000 bases before and 
after the TSS (Szulwach et al., 2011). Notably 5hmC is depleted at the TSS 
itself. 5fC and 5caC are also found at the same promoters as 5hmC and 
their levels increase upon TDG depletion indicating that some active 
demethylation is occurring at these loci (Shen et al., 2013). TET1 binding, 
which has been most extensively investigated in ESCs, shows enrichment at 
the TSS of CpG rich promoters. TET1 peaks are located at the TSS of these 
promoters and are then flanked on either side by the 5hmC peaks (Williams 
et al., 2011; Wu et al., 2011; Xu et al., 2011). TET2 and TET3 also show 
enrichment at CpG rich promoters (Chen et al., 2013; Deplus et al., 2013). 
The association of TET1 and TET3 with CGIs could be due to their CXXC 
DNA binding domain. Interestingly previous studies have found a repressive 
role for TET1 in gene transcription in mESCs due to its association with the 
repressive histone deacetylase complex MBD3-NURD and the repressive 
complex SIN3A (Wu et al., 2011; Yildirim et al., 2011).  
 
1.6.2 Gene Bodies 
In almost all cell types studied, including mESCs and hESCs, 5hmC 
is enriched within gene bodies (Wu and Zhang, 2011). Presence of 5hmC in 
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gene bodies shows a positive correlation with gene expression in mESCs 
but not in hESCs (Mellen et al., 2012). The mechanisms by which 5hmC 
within the gene body affects RNA elongation are currently unclear.   
 
1.6.3 Enhancers 
5hmC is strongly enriched in enhancer regions in mammalian cells 
(Stroud et al., 2011; Szulwach et al., 2011). Enhancers are typically CpG-
poor regions that show high levels of DNA methylation, which could possibly 
explain the enrichment of 5hmC. Base pair resolution 5hmC profiling has 
shown that 5hmC is enriched at the borders of transcription factor binding 
sites in enhancers. Notably 5hmC is depleted at the exact transcription 
factor binding site, possibly due to exclusion of DNMTs and TET proteins by 
transcription factor binding (Yu et al., 2012). It is unknown whether 5mC 
oxidation functions to open up the chromatin at enhancers to make them 
more accessible to transcription factor binding or if the transcription factors 
themselves recruit TET proteins to these loci. It is possible that a 
combination of these two mechanisms are involved. Similar to the results at 
promoter regions, 5fC and 5caC are enriched within enhancers and their 
levels increase upon TDG depletion in ESCs. This indicates that active 
demethylation is occurring at enhancers, but the extent of demethylation 
seems to be less than seen at promoters (Shen et al., 2013). Upon 
differentiation of ESCs the 5hmC levels at poised enhancers increases and 
precedes or coincides with the appearance of the active enhancer mark, 
H3K27 acetylation (Serandour et al., 2012). 
 
1.7 DNA METHYLATION DURING DEVELOPMENT 
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DNA methylation levels and distribution are dramatically changed 
during embryonic development. Following fertilization both the maternal and 
paternal nucleus undergo genome-wide demethylation to erase previous 
methylation marks, with the exception of methylation at imprinting control 
regions. As a result, by the time of the early blastocyst stage (32-64 cells) 
methylation levels in the embryo are at the lowest levels. This is followed by 
a progressive increase in methylation levels and the establishment of new 
methylation patterns as the embryo develops into the inner cell mass and 
then the epiblast. A second wave of genome-wide demethylation occurs in 
the developing primordial germ cells (PGCs). Demethylation in developing 
PGCs is much more absolute than in the zygote, as now even imprinting 
control regions lose methylation. Notably the TET proteins are abundant and 
may play a role during each of these global DNA demethylation events. The 
TET proteins are also present in the late blastocyst, inner cell mass and 
epiblast stages as new DNA methylation configurations are established, 
suggesting that they may play a role in fine-tuning this process 
(Messerschmidt et al., 2014). 
 
1.7.1 Demethylation in the Early Zygote 
Immediately after fertilization the maternal and paternal DNA undergo 
global DNA demethylation. The rates of demethylation for the maternal and 
paternal DNA, and the mechanisms underlying them appear to be different. 
The paternal DNA undergoes more rapid demethylation, which involves 
5mC oxidation by maternally derived TET3 (Figure 1.5). Immunostaining of 
the paternal nucleus shows the presence of 5hmC and the rapid loss of 
5mC (Mayer et al., 2000). Notably this 5hmC is lost upon siRNA knockdown 
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of TET3 and in TET3 deficient oocytes (Gu et al., 2011b; Wossidlo et al., 
2011), indicating that TET3 is uniquely necessary among the TET proteins 
for this oxidation event. It is unclear whether TET3 mediated oxidation leads 
to active or passive DNA demethylation. Some loss of 5mC is observed prior 
to any replication event and BER has been observed in the male 
pronucleus, suggesting that active DNA demethylation in which TDG 
removes the oxidized product and BER inserts an unmodified cytosine may 
be occurring (He et al., 2011). It is unlikely, however, that active DNA 
demethylation with BER accounts for the majority of DNA demethylation as 
substantial levels of 5hmC, 5fC and 5caC are retained at least through the 
8-cell stage (Inoue and Zhang, 2011). Furthermore increased frequency of 
BER in the early embryo would be considered deleterious to survival as it 
may increase rates of mutation. More likely the oxidized 5hmC is lost by 
passive dilution following DNA replication. This is supported by the 
observation that maintenance methylation is inefficient in the early embryo 
as DNM1O (a splice variant of DNMT1) is excluded from the nucleus 
(Ratnam et al., 2002). In this case TET3 mediated oxidation serves to 
accelerate the removal of 5mC from the paternal DNA. TET3 deficient 
oocytes fertilized with wild-type sperm produce embryos that have delayed 
activation of the paternal alleles for genes involved in the establishment of 
the pluripotent epiblast. Approximately half of these embryos develop 
normally, but the rest fail to develop past E11.5 (Gu et al., 2011b). Thus it 
seems that TET3 oxidation of the paternal DNA accelerates demethylation 
and enhances survival of the embryo, but is not absolutely necessary. 
In contrast the maternal DNA does not undergo TET mediated 
oxidation. The maternal DNA loses methylation through passive means, as 
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maintenance methylation is inefficient due to the cytoplasmic localization of 
DNM1O. The maternally derived DPPA protein (also known as STELLA) 
protects maternal DNA and some imprinted loci in the paternal genome from 
TET3 mediated oxidation. In the absence of DPPA the maternal genome 
shows 5mC oxidation and the developing embryos show abnormalities at 
the 2 or 4-cell stage (Nakamura et al., 2007).  
 
1.7.2 Methylation Changes in the Early Embryo 
In the early preimplantation embryo the sequence of methylation 
changes occur as follows: global demethylation of the paternal pronucleus, 
global demethylation of the maternal pronucleus and then progressive de 
novo methylation beginning at the blastocyst stage (Figure 1.9). This 
sequence is conserved in numerous mammalian species including humans. 
The beginning of de novo methylation coincides with the appearance of 
DNMT1, DNMT3A and DNMT3B within the nucleus. The TET proteins, in 
particular TET1 and TET2, are also present and are believed to regulate the 
addition of new methylation marks. The initiation of de novo methylation also 
coincides with the appearance of the first two distinct cell lineages: the inner 
cell mass (ICM) and the trophectoderm. The outer cell layers of the 
blastocyst are biased towards forming the trophectoderm, which will 
ultimately develop into the placenta. The inner cell layers are biased towards 
forming the inner cell mass, which will later develop into the embryo proper. 
Although DNA methylation occurs in both cell populations it is interesting to 
note that greater DNA methylation occurs in the future ICM cells, whereas 
the cells of the future TE remain relative hypomethylated (Messerschmidt et 
al., 2014; Pastor et al., 2011). The unequal levels of DNA methylation may 
		
	 	32	
indicate the first epigenetic barrier between two different cell lineages.  
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Figure 1.9 Demethylation in the early embryo. There are distinct 
patterns of demethylation of the maternal and paternal genomes 
following fertilization. The maternal genome undergoes passive 
demethylation whereas the paternal genome is actively demethylated 
with the appearance of oxidized derivatives (5hmC, 5fC/5caC). DNA 
methylation increases during the formation and implantation of the 
blastocyst. Adapted from: Messerschmidt et al., 2014. 
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1.7.3 Methylation Changes in Primordial Germ Cells 
The second global DNA demethylation event occurs in the developing 
primordial germ cells (PGCs). In mice PGCs are first identified at E6.5 in the 
proximal epiblast. Beginning on E7.5, PGCs begin to migrate along the 
embryonic and extra-embryonic boundary towards the developing gonad 
(McLaren and Lawson, 2005). Prior to their migration the future PGCs 
display methylation patterns that are similar to other neighboring somatic 
cells. They become demethylated between E9.5 (as determined by 
immunohistochemical analysis) and E10.5-E11.5 (by locus-specific bisulfite 
sequencing). Genome-wide analysis of PGCs show that the DNA 
demethylation is almost completely global and includes erasure of imprinted 
marks. Furthermore germline-specific genes that are hypermethylated in 
somatic cells become demethylated during PGC specification and are 
ultimately expressed (Hayashi et al., 2007).  
The role of the TET proteins during this process is controversial. 
TET1 and TET2 are expressed in developing PGCs and there is significant 
conversion of 5mC to 5hmC. There is no detectable 5fC or 5caC indicating 
that 5hmC is ultimately lost by passive dilution instead of active removal 
(Hackett et al., 2013). Notably TET1 knockout mice show full germline 
competence, which may be due to redundant effects of TET2 or due to 
alternative mechanisms for DNA demethylation in PGCs (Dawlaty et al., 
2011).  During PGC development expression of UHRF1 is decreased, 
indicating that maintenance methylation may be inefficient. Furthermore de 
novo methylation is decreased as DNMT3B levels are reduced (Kagiwada et 
al., 2013). Recent studies have indicated that the TET proteins may not be 
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necessary for the global DNA demethylation observed but instead play a 
role in facilitating the activation of germline-associated genes and erasure of 
imprinting marks during PGC formation, as 5hmC is particularly enriched at 
the promoters of these genes and at imprinting loci (Cortellino et al., 2011) 
(Figure 1.10).  Deamination by AID may also play a role as AID deficient 
PGCs show elevated DNA methylation, although they are still dramatically 
demethylated when compared to their cell of origin (Popp et al., 2010).  
Currently the importance of inefficient maintenance methylation, decreased 
de novo methylation and hydroxymethylation for demethylation in PGCs is 
unclear. 
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Figure 1.10 Methylation dynamics in developing primordial 
germ cells (PGCs). PGCs emerge at approximately E6.5 with 
high methylation levels, similar to other somatic cells. In this 
model there are two stages of demethylation, the first is passive 
demethylation possibly due to decreased expression of UHRF1. 
This is followed by active demethylation as oxidized derivatives 
such as 5hmC increase. Adapted from: Messerschmidt et al., 
2014. 
		
	 	37	
1.8 PHENTOTYPES OF DNMT- AND TET- DEFICIENT MICE 
Clearly DNA methylation during embryonic development is quite 
dynamic and suggests a crucial role for the DNA methylation and 
demethylation machinery. Previous studies have sought to understand the 
developmental importance of the DNMT and TET proteins by inactivating 
these genes in mouse embryos. Deletion of Dnmt1 in mouse embryos is 
embryonic lethal with defects arising around gastrulation as a result of global 
loss of DNA methylation; this is also seen with depletion of its recruiting 
cofactor Uhrf1 in mouse embryos (Bostick et al., 2007; Li et al., 1992). 
Dnmt3a-/- mice developed to term and appeared normal at birth, but then 
died at about 5 weeks after birth. Embryos with deletion of Dnmt3b-/- 
developed normally until E9.5 but then showed multiple developmental 
defects, including growth retardation, and did not produce any viable mice at 
birth (Okano et al., 1999). As expected combined deletion of Dnmt3a and 
Dnmt3b led to more severe embryonic defects that were similar to those 
observed in Dnmt1-/- embryos. These mice showed smaller size and 
abnormal morphology by E8.5, shortly after gastrulation, and died before 
E11.5 (Okano et al., 1999). Inactivation of Dnmt3l, the non-catalytic cofactor 
for DNMT3A and DNMT3B proteins, in mouse embryos produced viable 
mice; however, due to defects in de novo methylation of the germline, male 
Dnmt3l-/- mice were sterile and female Dnm3tl-/- mice produced embryos 
that died early in development (Bourc'his and Bestor, 2004; Bourc'his et al., 
2001). 
Tet1, Tet2 and Tet3 have been individually and in combination 
inactivated in mouse embryos. The phenotype of Tet1-/- mice is 
controversial. The earliest works of Tet1-/- and Tet1-/-Tet2-/- embryos 
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showed that viable and fertile mice could be obtained (Dawlaty et al., 2013; 
Dawlaty et al., 2011). However a more recent study found that targeting the 
N-terminus of TET1 led to promiscuous expression of differentiation genes 
within the epiblast, morphological embryonic defects as early as E8.0 and 
ultimately embryonic lethality by E9.5 in 129P2/OlaHsd mice. Intriguingly 
this study found that the severity of embryonic defects was dependent on 
the strain of mice used, with reduced penetrance in inbred C57BL/6 (B6) 
embryos and complete lethality in non-inbred mice, 129P2/OlaHsd 
(Khoueiry et al., 2017). The reasons underlying the differences in phenotype 
based on mice strain are currently unknown. Tet1 has also been shown to 
be necessary for proper gamete formation. Female Tet1 gene trap mutants 
have smaller litters. This is due to arrest of developing female gametes 
(E16.6-E18.5) because of defects in meiotic synapsis. As a result these 
mice have only half the normal number of gametes, which could explain 
their reduced fertility (Yamaguchi et al., 2012). Inactivation of the paternal 
Tet1 led to aberrant hypermethylation of paternally expressed imprinted 
genes during gametogenesis.  
Tet2 inactivation in C57BL/6 and non-inbred strains produce viable 
and fertile mice. These offspring show clear hematological abnormalities 
such as increased number of hematopoietic stem cells with increased 
proliferation rates (Quivoron et al., 2011). One strain of these Tet2−/− mice 
developed a condition similar to human chronic myelomonocytic leukemia 
(Li et al., 2011; Moran-Crusio et al., 2011), which is interesting considering 
the frequency of TET2 mutations in human hematological malignancies. 
Inactivation of Tet1 and Tet2 in mice of the C57BL/6 × 129 strain can 
produce viable, fertile offspring but approximately half of the litter die 
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perinatally for unknown reasons (Dawlaty et al., 2013). Approximately half of 
embryos derived from Tet3-/- oocytes show early embryonic lethality. This 
could be due to hypermethylation of pluripotency genes in the paternal 
allele, which utilizes TET3 to promote DNA demethylation after fertilization. 
Interestingly the Tet3-/- mice that survive embryonic development die 
perinatally for unknown reasons (Gu et al., 2011b). 
In order to remove any possible compensation among the TET 
proteins investigators have generated Tet TKO embryos in which all three 
Tet genes are inactivated.  A recent study found that Tet TKO embryos 
displayed dramatic gastrulation defects. They found that excessive Nodal 
signaling produced an aberrant increase in mesendoderm formation from 
the epiblast. The promoter or enhancer of the signaling antagonists for 
Nodal, Lefty1 and Lefty2 were hypermethylated, leading to their reduced 
expression (Dai et al., 2016).  
 
1.9 PHENTOTYPES OF DNMT- AND TET- DEFICIENT MESCS 
ESCs are used as a platform to study early development in a cell 
culture system. ESC lines have been generated from cells of the inner cell 
mass in mouse and human embryos. Despite having originated from similar 
stages in development, mESCs and hESCs show differences in growth, 
genetic requirements and epigenetic features. mESCs are characterized as 
displaying a “naïve” pluripotency that is similar to the inner cell mass of the 
preimplantation blastocyst. In contrast hESCs reflect a “primed” pluripotency 
stage that is similar to the post-implantation blastocyst. Regardless of these 
differences both mESCs and hESCs display the properties of indefinite self-
renewal and the ability to differentiate into all somatic cell types (Ginis et al., 
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2004; Schnerch et al., 2010). Thus they are an ideal platform to study the 
role of the TET proteins in the cell fate conversion that occurs during the 
formation of somatic tissues.  
The DNMT genes have been inactivated in mESCs and hESCs. 
Inactivation of DNMT3A and DNMT3B individually or in combination has no 
effect on self-renewal or pluripotency marker expression in mESCs and 
hESCs. Dnmt3a-/-Dnmt3b-/- mESCs progressively lose DNA methylation. 
Interestingly early passage Dnmt3a-/-Dnmt3b-/- mESCs, which still contain 
significant levels of DNA methylation are able to differentiate into the germ 
layer and form teratomas. This ability is lost in later passages, upon greater 
loss of DNA methylation, indicating that although DNA methylation is not 
required for ESC proliferation, a certain level is required for proper 
differentiation of mESCs (Okano et al., 1999). Inactivation of DNMT1 has 
different phenotypes in mESCs versus hESCs. Dnmt1-/- mESCs are 
significantly hypomethylated but are still viable (Lei et al., 1996). In fact 
Dnmt1-/-Dnmt3a-/-Dnmt3b-/- mESCs have been generated that display 
normal stem cell proliferation and euploidy (Tsumura et al., 2006). In 
contrast knockout of DNMT1 in hESCs is lethal and produces global DNA 
demethylation, DNA damage and cell cycle arrest (Liao et al., 2015). It is 
possible that because hESCs show properties of a later developmental 
stage they are more sensitive to loss of DNMT1. As all somatic cells require 
DNMT1 for survival hESCs may represent the first developmental period at 
which DNA methylation maintenance becomes essential. 
 The three Tet genes have been inactivated individually and in 
different combinations in mESCs. Thus far none of the TET genes has been 
inactivated in hESCs. Notably inactivation of the individual Tet genes, or all 
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3 Tet genes together, has no impact on the self-renewal capacity of mESCs. 
However inactivation of the Tet genes does produce differentiation defects 
that become more severe as a greater number of Tet genes are mutated 
(Dawlaty et al., 2014; Dawlaty et al., 2013; Dawlaty et al., 2011; Lu et al., 
2014). Depletion of Tet1 singly or together with Tet2 showed mild 
differentiation defects. For example teratomas from these cells contain 
tissues from all three germ layers but are also enriched for extraembryonic 
trophoblastic cells. This suggests that in wildtype cells TET1 may function to 
suppress extra embryonic differentiation. Tet1 depletion leads to increased 
expression of key extra embryonic markers such as caudal-type homeobox 
2 (CDX2), eomesodermin (EOMES) and E74 Like ETS Transcription Factor 
5 (ELF5). At the same time Tet1-/- and Tet1-/-Tet2-/- mESCs contribute 
efficiently to chimeras when injected into blastocysts showing that the 
increased extraembryonic potential can be suppressed in the normal 
developmental environment. Furthermore upon in-vitro differentiation, Tet1-
/- and Tet1-/-Tet2-/-  mESCs can form all three germ layers (Dawlaty et al., 
2013; Dawlaty et al., 2011). It is possible that in these DKO mESCs, Tet3 
can compensate for the loss of Tet1 and Tet2. In fact TKO mESCs, in which 
all three Tet genes have been inactivated, show strong impairment in their 
ability to differentiate by spontaneous embryoid body differentiation and 
teratoma formation assays. Furthermore TKO mESCs show poor chimeric 
contribution to embryos and cannot support embryonic development by 
tetraploid complementation assays (Dawlaty et al., 2014). The overall 
conclusion from these studies is that the TET proteins may not be necessary 
to support ESC proliferation and self-renewal but are required for the proper 
activation of differentiation programs.  
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 The mechanisms underlying the observed differentiation defect of 
TKO mESCs are currently unclear. Measurement of total 5mC show a 
modest increase in total methylation upon Tet inactivation in TKO mESCs 
(Dai et al., 2016; Dawlaty et al., 2014; Lu et al., 2014). Although the overall 
increase in methylation is small it is possible that concentration of this 
hypermethylation in regulatory regions could explain the dramatic 
differentiation defects of TKO mESCs. Genome-wide methylation analysis of 
TKO mESCs has thus been performed to uncover specific loci that gain 
methylation upon Tet inactivation. Interestingly a number of regulatory 
regions gained hypermethylation in TKO mESCs including enhancers and 
promoters. Hypermethylation of enhancers leads to a decrease in 
expression of associated genes (Lu et al., 2014). A more recent study found 
that TET1 and 5hmC localize to similar developmental enhancers in 
xenopus, zebrafish and mouse embryos during early embryonic 
development. This 5hmC signal is associated with increased chromatin 
accessibility and activation of enhancers as determined by H3K27ac and 
p300 enrichment. Knockdown of tet1 in zebrafish was associated with 
increased methylation at these particular enhancers and reduced chromatin 
accessibility (Bogdanovic, 2017). 
 
1.10 ROLE OF TET PROTEINS IN REPROGRAMMING 
Somatic cells can be converted into cells with similar characteristics 
as ESCs, termed induced pluripotent stem cells (iPSCs), by the transfection 
of certain combinations of transcription factors. The classic combination 
includes OCT4, SOX2, KLF4 and MYC (OSKM) (Takahashi et al., 2007). 
For successful reprogramming the promoters and enhancers of pluripotency 
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genes, which are typically hypermethylated in somatic cells, need to be 
demethylated to enable activation of expression (Lee et al., 2014). This is 
supported by previous investigations in which 5-azadeoxycytidine, a 
compound that inhibits DNMT activity, promotes reprogramming and 
reduces the number of transcription factors required (Huangfu et al., 2008; 
Mikkelsen et al., 2008). Supporting the role of demethylation, previous work 
has shown that TET proteins could potentially be involved with 
reprogramming. One such study found that the promoter of the pluripotency 
gene Nanog is hydroxymethylated and demethylated early during 
reprogramming and that depletion of Tet2 impedes reprogramming into 
iPSCs (Doege et al., 2012). Another investigation found that TET1 and 
TET2 interact with Nanog in ESCs, and co-transfection of Nanog with either 
Tet1 or Tet2 increased the efficiency of reprogramming using the original 
OKSM cocktail, possibly by demethylating the endogenous Oct4 and Esrrb 
genes (Costa et al., 2013). A final study found that the addition of Tet1 alone 
could increase the efficiency of reprogramming using the OSKM 
combination (Gao et al., 2013). These previous studies indicate that 
demethylation of pluripotency associated loci increases the efficiency of 
reprogramming of somatic cells to iPSCs. Notably the most recent study 
suggested a different mechanism by which the TET proteins regulate 
reprogramming. The investigators found that Tet deficient MEFs could not 
be reprogrammed into iPSCs due to impairment of the mesenchymal-to-
epithelial (MET) transition. This impairment was partly due to reduced 
demethylation and reduced expression of miRNAs that promote MET (Hu et 
al., 2014).  
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1.11 THESIS AIMS 
Previous studies have inactivated the three Tet genes in mESCs. Tet 
mutant mESCs showed defects in differentiation ability, which increased in 
severity as a greater number of Tet genes were inactivated. TKO mESCs 
also showed hypermethylation at regulatory regions such as promoters and 
enhancers. It is clear from these studies that the Tet genes are required for 
proper differentiation of mESCs; however, the molecular mechanisms 
underlying the differentiation defects are unclear. 
 
Aim 1: Inactivate all three TET genes in hESCs. 
None of the TET genes have previously been mutated in hESCs. In 
contrast to mESCs, hESCs represent a later stage in development, the post-
implantation epiblast. This is believed to underlie differences in growth 
requirements, proliferation rate and pluripotency marker expression between 
mESCs and hESCs. Furthermore mESCs and hESCs show different genetic 
requirements, with some genes (e.g. DNMT1) that are readily inactivated in 
mESCs proving to be lethal in hESCs. Our first aim was to inactivate all 
three TET genes in hESCs (TKO hESCs) and evaluate the self-renewal and 
pluripotency characteristics of these cells. 
 
Aim 2: Investigate methylation changes between WT and TKO hESCs 
using genome-wide approaches. 
Our second aim was to analyze methylation changes between WT 
and TKO hESCs on a genome-wide level. We decided to complete this aim 
using two approaches: whole genome bisulfite sequencing and enhanced 
reduced representation bisulfite sequencing. Our goal was to determine 
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whether we could identify robust and reproducible methylation changes 
between WT and TKO hESCs that could possibly explain the differentiation 
defect of TKO hESCs.  
 
Aim 3: Investigate whether a differentiation defect of TKO hESCs into a 
particular lineage can be attributed to a specific methylation change 
between TKO and WT hESCs. 
In this aim we were interested in 3 questions: whether a locus-
specific aberrant hypermethylation in TKO hESCs affected expression of the 
associated gene upon differentiation, if restoring expression of this gene 
could rescue differentiation into the associated lineage and if targeted 
demethylation of the hypermethylated locus in TKO hESCs would restore 
proper expression of the associated gene after differentiation. 
 
Aim4: Determine the mechanisms underlying the aberrant gain of 
methylation in TKO hESCs. 
 This aim involved determining which of the DNMT proteins were 
responsible for hypermethylation in TKO hESCs and whether variability in 
the gain of methylation between loci was reflected by variability in the 
recruitment or activity of the DNMT proteins. 
 
  
		
	 	46	
CHAPTER 2: TET Protein Requirement and Function of Oxidized 
Methylcytosines in hESCs 
 
 
2.1 INTRODUCTION 
DNA methylation during early embryonic development is a very 
dynamic process and involves the erasure of established DNA methylation 
marks and the generation of new patterns. Although the most dramatic 
examples are the global demethylation that occurs after fertilization and 
during the development of primordial germ cells, DNA demethylation also 
occurs during the formation and implantation of the blastocyst. DNA 
demethylation during this period is believed to fine-tune the establishment of 
new DNA methylation patterns. These patterns will allow the proper 
differentiation into the embryonic germ layers and then ultimately into all of 
the somatic cells of the adult organism (Jones, 2012; Pastor et al., 2013; 
Smith and Meissner, 2013).  
During the formation and implantation of the blastocyst both the de 
novo DNMTs and the TET proteins are abundant and there are high levels 
of 5mC and its oxidized derivatives. Mouse embryonic stem cells (mESCs), 
which are derived from the pre-implantation blastocysts, are used to study 
this developmental stage in vitro. The Tet genes have been inactivated 
previously in mESCs (TKO mESCs). Generally these studies found that loss 
of the TET proteins led to differentiation defects that became more severe 
as more TET proteins were depleted (Dawlaty et al., 2014; Dawlaty et al., 
2013; Dawlaty et al., 2011). Moreover inactivation of Tet genes in mouse 
embryos led to defects in gastrulation, which is when the three germ layers 
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are specified (Dai et al., 2016). Whole genome methylation analysis of TKO 
mESCs showed that these cells had locus-specific hypermethylation that 
was enriched at regulatory regions such as promoters and enhancers (Lu et 
al., 2014). Another recent study found that enhancers that typically undergo 
DNA demethylation during development also show TET1 binding and 5hmC 
enrichment. Morpholino depletion of TET1 in zebrafish led to 
hypermethylation of such enhancers, reduced chromatin accessibility and 
reduced gene expression (Bogdanovic, 2017). 
We were interested in whether changes in the methylation state of 
promoters could also explain the differentiation defects of hESCs after TET 
inactivation. Approximately 60% of human genes contain a CpG island 
within their promoter. These promoters are typically DNA hypomethylated 
and DNA methylation correlates with gene repression. Active promoters are 
protected from aberrant DNA methylation by the chromatin changes and 
protein binding that accompanies transcription (Jones, 2012; Smith and 
Meissner, 2013). However, it is unclear how the DNA hypomethylation of 
non-expressed promoters, such as bivalent promoters, is preserved. 
Bivalent promoters are particularly significant because they are enriched for 
lineage regulators and signaling components that are critical for proper 
development.  
Here we have inactivated the three TET genes in hESCs, individually 
and in various combinations. To our knowledge this is the first study that has 
genetically knocked out any of the TET genes in hESCs. Fortunately we 
were able to generate and propagate TET TKO hESCs in which all three 
TET genes have been inactivated. Although there was complete depletion of 
5hmC in these cells we did not observe any differences in total 5mC. Upon 
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whole genome methylation analysis, however, we did observe locus specific 
hypermethylation in TKO hESCs. Furthermore bivalent promoters showed 
the greatest gain in methylation after TET inactivation. We found that this 
bivalent promoter hypermethylation contributes to the differentiation defect 
of TKO hESCs and is the result of aberrant hypermethylation by the de novo 
methyltransferases.  Our study suggests that the DNA methylation state of 
these promoters is critically important for the proper activation of bivalent 
genes upon differentiation. Furthermore the TET proteins and de novo 
DNMTs compete to regulate the methylation level at these promoters. 
 
2.2 RESULTS 
 
2.2.1 Bivalent Promoter Hypermethylation in TKO hESCs 
Since all three TET genes are expressed in hESCs (Figure 2.1A), 
and none has been genetically deleted previously, we used the iCRISPR 
platform developed in our lab (Gonzalez et al., 2014) to generate a panel of 
TET1/2/3 knockout lines in the HUES8 hESC background. The CRISPR 
gRNAs we used targeted the beginning of the catalytic domain for each of 
the 3 TET genes and were efficient at producing indel mutations (Figure 
2.1B-D). hESCs in which all 3 TET genes have been inactivated (TKO 
hESCs) were karyotypically normal (Figure 2.1E) and had no detectable 
5hmC signal by immunofluorescence (Figure 2.1F) and dot blot (Figure 
2.1G). TKO hESCs showed no difference in morphology, self-renewal 
capacity or pluripotency marker expression when compared to wild-type 
(WT) hESCs (Figure 2.2A-C). However, TKO hESCs showed a complete 
inability to form teratomas and diminished expression of differentiation 
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genes upon spontaneous embryoid body differentiation, suggesting that TET 
proteins may be particularly important for the regulation of cellular 
differentiation (Figure 2.2D-E).  
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Figure 2.1 Generation of TET TKO hESCs. (A) TET expression in WT hESCs by 
RNA-Seq. n= 2 independent experiments. (B) TET knockout mutants were 
generated using CRISPR gRNAs (arrowheads) that target the beginning of the 
catalytic domain of TET1, TET2 and TET3. (C) Targeting sequence for TET 
gRNAs. All TET gRNAs targeted the beginning of the TET catalytic domain. Red 
indicates the putative DNA binding domain and blue indicates the catalytic domain. 
The HUES8 TKO line was generated using CrT1A, CrT2A, CrT3A. The MEL1 TKO 
line was generated using CrT1B, CrT2A, CrT3B. (D) T7 Endonuclease showing 
indel formation by the TET gRNAs. (E) Karyotyping results for HUES8 and MEL1 
TKO lines. (F) Immunofluorescence for 5hmC in HUES8 TET mutants. (G) Analysis 
of 5hmC levels in WT and knockout hESCs by 5hmC dot blot. Human fibroblasts 
(Fib CTRL) are used as a negative control. 
		
	 	51	
 
  
TRA-1-60 TRA-1-81
TKOWT Unstained
A
0
20
40
60
80
100
0
20
40
60
80
100
C
el
l N
um
be
r (
%
)
D1 D2 D3 D4 D5
0
2
4
6
8
C
el
l N
um
be
r
(r
el
at
iv
e 
to
 D
1)
WT TKO
TRA-1-60 TRA-1-81
0
50
100
Po
si
tiv
e 
C
el
ls
 (%
)
WT TKO
W
T
TK
O
Brightfield AP DAPI NANOG OCT4 SOX2 Merge
B ns ns
C
D E
GS
C
BR
AC
HY
UR
Y
SO
X1
7
FO
XA
2
OT
X2
PA
X6
SO
X1
FO
XG
1
SO
X1
0
0
1
2
3
4 WT TKO
ns
ns
ns * * * ns * ***
EB
 D
5
WT TKO
m
R
N
A
 e
xp
re
ss
io
n
   
 (R
el
at
iv
e 
to
 W
T)
Ectoderm MesodermEndoderm
      WT
     TKO       0/20 Mice formed teratomas
     TKO-r1
Figure 2.2 Characteristics of TET TKO hESCs. (A) Growth curves for WT and TKO 
hESCs. n= 3 independent experiments. (B) FACS analysis for pluripotency associated 
surface markers, TRA-1-60 and TRA-1-81, in WT and TKO hESCs; fluorescence intensity 
(left panel) and percent positive cells (right panel) are shown. n= 3 independent 
experiments. (C) Brightfield and alkaline phosphatase (AP) staining in WT and TKO 
hESCs. The scale bar indicates 100 μm. (D) Hematoxylin and eosin staining of teratoma 
sections from WT teratomas. Arrows point to representative tissues for the respective germ 
layers. No teratomas were obtained 6 months after injection of TKO hESCs. (E) Phase-
contrast images of embryoid body formation by WT and TKO hESCs at D5 (top panel). 
Expression for markers of mesoderm (GSC, BRACHYURY), endoderm (SOX17, FOXA2), 
neuroectoderm (OTX2, PAX6, SOX1, FOXG1) and neural crest (SOX10) at D12 of 
spontaneous embryoid body differentiation. Data are mean ± STD. ns, not significant by 
Student’s t test (B, E). 
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Loss of the TET genes results in locus-specific hypermethylation 
rather than a global gain of methylation. Mass spectrometry analysis 
(performed by Louis Dore) showed a negligible amount of 5hmC in TKO 
hESCs but did not show a difference in 5mC levels between TKO and WT 
hESCs (Figure 2.3A) similar to previous reports in mESCs (Dawlaty et al., 
2014; Lu et al., 2014). Instead, we identified 3,523 hypermethylated 
differentially methylated regions (regions with at least 5 hypermethylated 
CpGs, that have at least 10% methylation difference between samples, 
hyper-DMRs) by whole genome bisulfite sequencing (WGBS) when 
comparing TKO to WT hESCs (computational analysis performed by Heng 
Pan). We also observed a similar number (3,832) of hypomethylated 
differentially methylated regions (hypo-DMRs) (Figure 2.3B). These hypo-
DMRs primarily occurred at CpGs outside of CpG islands (CGI) (Figure 
2.3D). They could be a direct result of TET inactivation or a secondary 
effect, possibly due to the redirection of the DNMT proteins to novel sites in 
TKO hESCs. On the other hand, CGIs are enriched in regulatory regions, 
and they showed increased methylation in TKO hESCs (Figure 2.3D). 
Additionally hyper-DMRs were enriched for regulatory regions such as 
promoters and enhancers (Figure 2.2C), with bivalent promoters showing 
the greatest magnitude of methylation increase (Figure 2.3D) and a greater 
fraction of bivalent promoters (compared to other regulatory regions) were 
associated with hyper-DMRs (Figure 2.3E). This hypermethylation was also 
observed at characteristic bivalent genes such as HOXA7 and HOXA9 (Pan 
et al., 2007)(Figure 2.4A). Indeed significant gain of methylation in TKO 
hESCs was found to center around genomic sites with both H3K4me3 and 
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H3K27me3 marks (Figure 2.3F). Finally, we performed genome wide 5hmC 
profiling through 5hmC-Seal (Song et al., 2011) (performed by Louis Dore 
and computational analysis by Heng Pan) and found that DNA 
hypermethylation in TKO hESCs was detected most strongly in regions that 
had 5hmC peaks in WT hESCs (Figure 2.3F), supporting our hypothesis that 
loss of TET is directly responsible for the gain of methylation.  
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Figure 2.3 Bivalent promoters gain methylation in TKO hESCs (A) Analysis of 
5mC (top) and 5hmC (bottom) in HUES8 WT and TET knockout hESCs by mass 
spectrometry. For all mass spectrometry analysis, 2 mutant lines were used for all 
KO genotypes except for TKO. For TKO lines, 2 different passages of the same line 
were used for mass spectrometry measurements. For significance tests black lines 
indicate comparisons to WT. Human fibroblasts were used as a negative control for 
mass spectrometry of 5hmC. (B) Total number of hyper-DMRs and hypo-DMRs (TKO 
vs. WT) for HUES8 TKO hESCs compared to HUES8 WT hESCs by whole genome 
bisulfite sequencing. (C) Enrichment of various regulatory regions in hyper-DMRs 
and hypo-DMRs by WGBS. (DHS) DNase I Hypersensitive sites. The definitions for 
the different genomic regions can be found in the Methods section. (D) Average 
percent DNA methylation change between HUES8 TKO and WT hESCs by whole 
genome bisulfite sequencing (WGBS) at different regulatory regions. The definitions 
for the different genomic regions can be found in the Methods section. (E) Fraction of 
genomic regions that show >5% increase in 5mC (Hyper) or a >5% decrease in 5mC 
(Hypo) in methylation between TKO and WT hESCs by WGBS of HUES8 WT and 
TKO hESCs. (F) Heat map of the average 5mC level differences between HUES8 
TKO and WT hESCs at the center of the annotated histone modifications.  
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Figure 2.4. Regulatory regions for developmental genes become hypermethylated in 
TKO hESCs. (A) Methylation level of HOXA7 and HOXA9 promoters in WT and TKO 
hESCs by WGBS. Methylation at a few specific CpGs (for which measurements in both WT 
and TKO hESCs are available) is shown in the bottom bar graph. The x-axis numbers 
indicate the position of CpG sites in the hg19 genome assembly. (B) Gene ontology 
analysis for genes associated with hypermethylated bivalent promoters (n=1693), genes 
associated with hypermethylated poised enhancers (n= 3570) and genes associated with 
hypermethylated active enhancers (n= 3805). Developmental categories are in red, FDR < 
.01 was set as a cutoff for bivalent promoters and poised enhancers, FDR < .05 was set as 
a cutoff for active enhancers. 
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 Gene Ontology (GO) analysis revealed that hypermethylated bivalent 
promoters in particular, but also hypermethylated poised enhancers (marked 
by H3K4me1 but not H3K27ac), were associated with developmental 
categories, suggesting that these methylation aberrations could be 
responsible for the differentiation defects of TKO hESCs (Figure 2.4B). 
 To further investigate the methylation changes at bivalent promoters 
we performed enhanced reduced representation bisulfite sequencing 
(ERRBS), which focuses on CGIs and thus increases sequencing coverage 
of promoter regions (Gu et al., 2011a) (computational analysis was 
performed by Heng Pan). We also generated another TKO clone in a 
different hESC background, MEL1, using different CRISPR gRNAs for TET1 
and TET3, to determine if the methylation changes we observed were 
reproducible in an independent TKO clone (Tables 2.1, 2.2). ERRBS 
analysis showed ~12,000 hyper-DMRs and an insignificant number of hypo-
DMRs in TKO lines compared to WT hESCs (Figure 2.5A). We further 
analyzed the methylation change based on promoter types: bivalent 
promoters (marked by H3K4me3 and H3K27me3), active promoters 
(marked by H3K4me3 and H3K79me2), initiated promoters (marked by 
H3K4me3 only) and silent promoters (based on the absence of H3K4me3) 
(Lu et al., 2014). Compared to other promoter types, bivalent and silent 
promoters showed greater magnitude of methylation increase in HUES8 and 
MEL1 TKO lines. Importantly we observed increasing fractions of bivalent 
promoters among promoters with greater methylation changes (Figure 2.5B-
E). Bivalent promoters constituted 60-74% of all promoters with >60% 
increase in DNA methylation, greatly exceeding the overall ~27% 
composition of bivalent promoters evaluated by ERRBS (Figures 2.5C, 
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2.5E). Overall about half of bivalent promoters showed hypermethylation by 
ERRBS and WGBS analysis (Figure 2.3E and Figure 2.5F). Although 
WGBS also showed that a fraction of promoters became hypomethylated 
after TET inactivation, this was not observed by ERRBS. The 
hypomethylation detected by WGBS is likely due to hypomethylation of non-
CGI CpGs that are technically within the promoter regions. We observed 
similar results in both HUES8 and MEL1 TKO hESCs, with 1,326 and 1,579 
bivalent promoters gaining methylation in each respective line. Individual 
bivalent promoters showed similar methylation changes between these two 
lines (Figure 2.5G) and 87% of the 1,326 hypermethylated bivalent 
promoters in HUES8 TKO hESCs also gained methylation in MEL1 TKO 
hESCs (Figure 2.5H). Overall these results indicate that the TET proteins 
are critical to preserve hypomethylation at bivalent promoters and in their 
absence a reproducible subset of bivalent promoters become aberrantly 
hypermethylated. 
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Figure 2.5 Hypermethylation at bivalent promoters is dramatic, robust and 
significant. (A) Total number of hyper-DMRs (TKO vs. WT) for HUES8 and MEL1 TKO 
lines compared to HUES8 and MEL1 WT lines by enhanced reduced representation 
bisulfite sequencing (ERRBS, right). (B) DNA methylation change between HUES8 TKO 
and WT hESCs by ERRBS at different promoter types. Box and whisker plots were 
generated using the methylation change at individual promoters. The error bars show 10 
and 90 percent confidence intervals and the bar at the center of the box and whisker plot 
indicates the median. The promoters are divided into four groups based on histone 
modification patterns. The details of promoter definitions can be found in the Methods 
section. (C) Representation of bivalent promoters among promoters that show different 
degrees of methylation change between HUES8 TKO and WT hESCs by ERRBS, n 
indicates the total number of promoters in each DNA methylation change group. (D) DNA 
methylation change between MEL1 TKO and WT hESCs by ERRBS at different promoter 
types. (E) Representation of bivalent promoters among promoters that show different 
degrees of methylation change between MEL1 TKO and WT hESCs by ERRBS, n indicates 
the total number of promoters in each DNA methylation change group. (F) Fraction of 
genomic regions that show >5% increase in 5mC (Hyper) or a >5% decrease in 5mC 
(Hypo) in methylation between TKO and WT hESCs by ERRBS of HUES8 and MEL1 WT 
and TKO hESCs. (G) Correlation between methylation level at bivalent promoters in HUES8 
WT, MEL1 WT, HUES8 TKO and MEL1 TKO hESCs. (H) Overlap of the bivalent promoters 
that show greater than 5% methylation change in HUES8 and MEL1 TKO lines compared to 
HUES8 and MEL1 WT lines. The p-value for the overlap between HUES8 and MEL1 
hypermethylation at bivalent promoters is given (Fisher’s exact test). Data are mean ± STD. 
ns, not significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (B, D). 
 
 
 
 
 
 
 
		
	 	59	
 
 
 
 
		
	 	60	
We also compared our data with previous mESC TKO data (Lu et al., 
2014). Out of the 732 bivalent promoters that become hypermethylated 
(>20% increase) in TKO mESCs, 517 of these 732 promoters are also 
bivalent in hESCs, out of which 289 (~%56) were associated with hyper-
DMRs in TKO hESCs. The remaining 215 promoters are not bivalent in 
hESCs, and only 55 (~25.6%) were associated with hyper-DMRs in TKO 
hESCs (Figure 2.6A). This indicates that bivalent promoters found in both 
mESCs and hESCs tend to show similar methylation changes after TET 
inactivation. 
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Figure 2.6 Bivalent promoters in TET TKO hESCs and mESCs show similar 
methylation changes. (A) Overlap between all hyper-DMR associated bivalent 
promoters in mESCs and their human counterparts in hESCs. 517 of the bivalent 
mESC promoters are also bivalent in hESCs and 215 of the bivalent mESC 
promoters are not bivalent in hESCs. We compared the overlap of mESC hyper-
DMRs to hESC hyper-DMRs within these two groups of promoters, the odds ratio 
and p-value are given. mESC data was taken from Lu et al., 2014. 
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2.2.2 Hypermethylation of the PAX6 P0 Promoter 
 TKO hESCs showed relatively few transcriptional changes compared 
to WT cells (Figure 2.7A) (RNA-Seq computational analysis was performed 
by Heng Pan). We found that hypermethylation of active promoters, initiated 
promoters, silent promoters and active enhancers was associated with a 
decrease in gene expression. In contrast, genes associated with 
hypermethylated bivalent promoters and poised enhancers did not show an 
overall change in expression in TKO hESCs (Figure 2.7B). 5mC MassArray 
Epityper analysis confirmed that the bivalent promoters of selected 
developmental genes (FOXA2, GATA2, PAX6, SOX10, SOX17) showed 
significant hypermethylation in TKO hESCs, whereas the active promoters 
for housekeeping and pluripotency genes did not (Figure 2.7C). As 
expected, the hypermethylated LEFTY2 enhancer (an active enhancer 
marked by H3K4me1 and H3K27ac) was associated with a significant 
decrease in gene expression, as has been previously described in TKO 
mouse embryos (Dai et al., 2016); whereas no expression change was 
detected for housekeeping and pluripotency genes (Figure 2.7D). Notably 
hypermethylation of the bivalent promoters was not associated with a 
consistent decrease in gene expression. For instance no change in PAX6 
expression was observed. A few bivalent promoter genes showed up- or 
downregulation, but the expression levels were generally low (Figure 2.7D). 
We believe that the change for some bivalent genes may be due to 
increased propensity of TKO cells hESCs to spontaneously differentiate into 
extra-embryonic tissues, as has been previously reported in single and 
double Tet knockout mESCs (Dawlaty et al., 2013; Dawlaty et al., 2011). We 
performed immunofluorescence of WT and TKO hESCs after 4 days of 
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culture. We found that TKO hESCs showed an increased number of cells 
that were positive for differentiation markers such as GATA6 and 
BRACHYURY (Figure 2.8A). Spontaneous differentiation typically occurs at 
the boundaries of hESC colonies and in fact the GATA6 or BRACHYURY 
positive TKO cells occurred at the boundary of TKO hESC colonies. Notably 
we did not observe GATA6 or BRACHYURY positive cells within the TKO 
hESC colonies. Thus we believe that the spontaneous differentiation of a 
minority of TKO cells is responsible for the increase in expression of some 
of the differentiation markers that we observed by RNA-Seq. 
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Figure 2.7 Gene expression changes in TKO hESCs. (A) Volcano plot of RNA-Seq data 
illustrates transcriptional changes in TKO compared to WT hESCs. Upregulated genes are 
shown as red dots and downregulated genes are shown as blue dots. Genes showing a 
counts difference larger than twofold were considered differentially expressed. n= 2 
independent experiments. (B) Left: Expression change for genes of hyper-DMR associated 
promoters. Significance tests are comparing active, initiated, bivalent and silent promoters 
to all the promoters together. The details of each of these classifications are provided in the 
Methods section. Right: Expression change for genes of hyper-DMR associated active 
enhancers and for genes of hyper-DMR associated poised enhancers. Significance tests 
are comparing genes associated with hyper-DMR enhancers to all the enhancers together. 
The details of each of these classifications are provided in the Methods section. (C) Heat 
map of MassArray analysis of 5mC at different active promoters (GAPDH, OCT4, NANOG 
and SOX2) and bivalent promoters (FOXA2, GATA2, SOX10, SOX17 and GATA6). Each 
row of the heat map represents either an individual CpG or a few CpGs that are located 
close together. The location of the CpGs with respect to the TSS is shown to the left of each 
heat map. For each cell line three biological replicates are shown as three columns. n= 3 
independent experiments. (D) Expression analysis by RNA-Seq for particular genes. Data 
are mean ± STD. ns, not significant. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA (B) 
and Student’s t test (C, D). 
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Figure 2.8 Expression of GATA6 and BRACHYURY in WT and TKO hESCs. (A) 
Immunofluorescence for OCT4 and GATA6 or OCT4 and BRACHYURY in WT and TKO 
hESCs grown in standard hESC culture. 
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Figure 2.9 Hypermethylation of the PAX6 P0 promoter. (A) Diagram of the PAX6 locus 
and the associated regulatory regions. Boxes on the horizontal line represent exons. Grey 
boxes represent the coding sequence. The two promoters that produce a full-length protein 
(P0 and P1) are shown by arrows. The 5 annotated enhancers are depicted as yellow 
boxes. (B) Heat map of MassArray analysis of 5mC at the PAX6 P0 promoter. Each row of 
the heat map represents either an individual CpG or a few CpGs that are located close 
together. The location of the CpGs with respect to the P0 TSS is shown to the left of the 
heat map. For each cell line three biological replicates are shown as three columns. n= 3 
independent experiments. (NE D4) Neuroectoderm differentiation day 4; (NE D10) 
Neuroectoderm Differentiation day 10. (C) Heat map of MassArray analysis of 5mC at the 
regulatory regions of the PAX6 locus. n= 1 independent experiment. (D) Heat map of 
MassArray analysis of 5mC at the PAX6 P0 promoter for WT, TET1 KO, TET1/2 DKO, 
TET1/3 DKO and TKO hESCs. n= 1 independent experiment. (E) Left: Analysis of 5hmC 
levels in MEL1 WT and MEL1 TKO hESCs by mass spectrometry. For MEL1 WT, 2 
different lines were used for mass spectrometry measurements. For MEL1 TKO, 2 different 
passages of the same line were used for mass spectrometry measurements. Human 
fibroblasts were used as a negative control for mass spectrometry of 5hmC. Right: Analysis 
of 5mC by mass spectrometry. (F) Heat map of MassArray analysis of 5mC at the PAX6 P0 
promoter in MEL1 WT and TKO hESCs. For each cell line three biological replicates are 
shown as three columns. n= 3 independent experiments. Data are mean ± STD. ns, not 
significant. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA (D, E) and Student’s t test 
(B, F). 
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We were intrigued that despite promoter hypermethylation, bivalent 
promoter genes such as PAX6 did not show a change in expression at the 
hESC stage (Figure 2.7D). Noticing that PAX6 (as well as FOXA2 and 
SOX10) failed to be upregulated upon spontaneous embryoid body 
differentiation (Figure 2.2E), we speculated that the hypermethylation at 
bivalent promoters could affect activation of gene expression following 
exposure to differentiation signals. We chose to focus on PAX6 as it is a 
critical gene for human neural development and is highly expressed during 
in vitro differentiation of hESCs into the neural lineage (Li et al., 2005; 
Pankratz et al., 2007; Zhang et al., 2010), thus allowing us to use neural 
differentiation to track the effects of TET deletion on PAX6 expression as 
well as cellular differentiation. PAX6 has well annotated promoters and 
enhancers (Figure 2.9A) (Anderson et al., 2002; Kammandel et al., 1999; 
Plaza et al., 1999; Xu and Saunders, 1998; Zheng et al., 2001). 5mC 
MassArray analysis of these regions revealed that only the bivalent P0 
promoter of PAX6 showed hypermethylation (Figure 2.9B-C). The severity of 
this hypermethylation showed a positive correlation with the loss of 5hmC 
(Figure 2.9D) and was recapitulated in the MEL1 TKO line (Figure 2.9E-F). 
We further generated two “TKO-repaired” lines through CRISPR/Cas9-
mediated homology directed repair for comparison with isogenic WT and 
TKO hESCs to rule out potential CRISPR off-target effects (Figure 2.10A). 
Repair of one TET1 allele to the WT sequence in TKO hESCs was sufficient 
to restore 5hmC to near WT levels by mass spectrometry (performed by 
Louis Dore) (Figure 2.10B), and importantly, it also reversed the PAX6 P0 
promoter hypermethylation (Figure 2.9B). Notably the TKO-repaired line was 
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able to form teratomas, indicating a rescue in their differentiation capacity 
(Figure 2.2D). 
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Figure 2.10 TET1 and 5hmC are present at the PAX6 P0 promoter. (A) Diagram of 
homology-directed repair (HDR) of the TET1 locus in TKO hESCs. The red line indicates 
the gRNA targeting sequence and the blue line is the adjacent PAM sequence. Red letters 
indicate mutations of the WT sequence. The sequences of the two repaired lines (TKO-r1, 
TKO-r2) are shown below. (B) Mass spectrometry analysis of 5hmC levels in WT, TET KO 
mutant lines, lines in which one allele of TET1 has been repaired (TKO-r) and lines which 
underwent HDR targeting but retained the TKO mutations in the TET1 locus (TKO-nr). For 
all mass spectrometry analysis, 2 mutant lines were used for all genotypes except for TKO. 
For TKO lines, 2 different passages of the same line were used for mass spectrometry 
measurements. Human fibroblasts were used as a negative control for mass spectrometry 
of 5hmC. For significance tests black lines indicate comparisons to WT. (C) Top panel: 
Analysis of 5hmC peak at the PAX6 P0 promoter by hMe-Seal in WT hESCs. The height of 
the 5hmC peak above the x-axis reflects the normalized tag count. Bottom panel: Analysis 
of TET1 peak at the PAX6 P0 promoter by TET1 ChIP-Seq in WT hESCs. The height of the 
5hmC peak above the x-axis reflects the normalized tag count. Shaded area represents the 
region of the PAX6 P0 promoter assayed for 5hmC by Epimark (D) and TET1 binding by 
ChIP-qPCR (E). The predicted P0 PAX6 transcript is shown on the bottom. (D) Analysis of 
percent 5hmC at the PAX6 P0 promoter by Epimark. n= 3 independent experiments. (E) 
ChIP-qPCR for TET1 in WT and TKO hESCs. n= 3 independent experiments. Data are 
mean ± STD. ns, not significant. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA (B, D) 
and Student’s t test (E).  
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Figure 2.11. Hyper-DMRs in TKO hESCs overlap with 5hmC and TET1 peaks in WT 
hESCs. (A) Overlap of 5hmC and TET1 peaks found at promoters. (B) Overlap between 
hyper-DMRs (TKO vs. WT) that occur at bivalent promoters with TET1 (left) and 5hmC 
(right) peaks at bivalent promoters in WT hESCs. (C) Percentage of TET1 peaks 
overlapping with 5hmC peaks in WT hESCs compared to randomly generated 5hmC peaks 
of equal number and height. (D) Analysis of TET1 (left) and 5hmC (middle) peaks at active, 
initiated, bivalent and silent promoters in WT hESCs. On the right are 5hmC and TET1 
peaks at bivalent promoters. The height above the x-axis reflects the normalized tag count. 
(E) Percent DNA methylation change (TKO – WT) in active, initiated, bivalent and silent 
promoters that have 5hmC peaks compared to promoters that don’t have 5hmC peaks. (F) 
ChIP-qPCR for H3K4me3 and H3K27me3 in WT and TKO hESCs. *P<0.05, **P<0.01, 
***P<0.001 by Student’s t test (F). 
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To confirm that the hypermethylation of the PAX6 P0 promoter is a 
direct consequence of losing the TET proteins, we performed locus-specific 
and genome-wide 5hmC profiling by the Epimark 5hmC Analysis Kit (Stroud 
H, 2011) and hMe-Seal (Song et al., 2011): both showed 5hmC enrichment 
at the PAX6 P0 promoter in WT hESCs (Figure 2.10C-D). We also detected 
TET1 binding at the PAX6 P0 promoter in WT hESCs by ChIP-Seq 
(computational analysis performed by Heng Pan) (Figure 2.10C) and ChIP-
qPCR (performed by Abhijit Shukla) (Figure 2.10E). We analyzed our TET1 
ChIP-Seq and 5hmC profiling further to determine if the locus specific 
hypermethylation that we observe is a direct consequence of the loss of the 
TET proteins. We found that approximately 51 percent of 5hmC peaks 
overlapped with TET1 binding (Figure 2.11A). The reasons why there may 
not be complete overlap between 5hmC and TET1 are explained further in 
the methods section. Moreover we found that approximately 92% and 50% 
of hyper DMRs found at bivalent promoters in HUES8 TKO hESCs 
overlapped with 5hmC and TET1 peaks, respectively (Figure 2.11A-B). The 
greater overlap between hyper-DMRs and 5hmC peaks, than between 
hyper-DMRs and TET1, is likely due to the production of 5hmC by TET2 and 
TET3. Globally, TET1 binds to bivalent, active and initiated promoters at the 
transcription start site. Binding of TET1 overlaps with 5hmC signals, which 
extends into the promoter and gene body (Figure 2.11D). The functional 
relevance of TET binding and 5hmC signal is supported by a greater 
methylation increase in TKO hESCs associated with bivalent promoters that 
have 5hmC peaks compared to bivalent promoters that don’t have 5hmC 
peaks (Figure 2.11E) Overall these findings support the conclusion that 
TET1 binding at bivalent promoters (such as the PAX6 P0 promoter) leads 
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to 5hmC production, and TET inactivation causes 5hmC depletion and 
aberrant promoter hypermethylation. Finally we performed ChIP-qPCR to 
determine whether loss of the TET proteins or hypermethylation at the locus 
affected the bivalent histone mark at the PAX6 P0 promoter. Although we 
did observe a decrease in both the H3K4me3 and H3K27me3 marks in TKO 
hESCs versus WT hESCs the results were not significant (Figure 2.11F). 
 
2.2.3 Impaired Neural Differentiation of TKO hESCs 
Our observation of bivalent promoter hypermethylation prior to 
differentiation suggests that hypermethylation of bivalent promoters at the 
ESC stage could have a direct impact on differentiation. Since PAX6 is 
expressed in early neuroectoderm (NE) derived from hESCs (Li et al., 2005; 
Pankratz et al., 2007), and it is shown to be both necessary and sufficient for 
NE formation from hESCs (Zhang et al., 2010), we speculate that 
hypermethylation of the PAX6 P0 promoter in TKO hESCs may impede 
hESC differentiation into the neural lineage. We investigated this further 
using the dual SMAD inhibition protocol for NE differentiation (Chambers et 
al., 2009) (Figure 2.12A).  
We were able to efficiently differentiate WT and TKO-repaired lines 
into PAX6 and SOX1-positive NE cells with appropriate downregulation of 
pluripotency markers such as OCT4 (Figure 2.12B). In contrast, TKO hESCs 
failed to form significant numbers of PAX6-positive cells at any point during 
the differentiation (Figure 2.12B-D) suggesting impaired acquisition rather 
than maintenance of the NE fate. Notably whereas WT cells lost OCT4 
expression by day 6 (Figure 2.12E), ~40% of TKO cells remained OCT4-
positive after 10 days of differentiation as shown by immunostaining and 
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FACS analysis (Figure 2.12E-F).  
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Figure 2.12 TKO hESCs show a defect in neuroectoderm differentiation. (A) Schematic 
for neuroectoderm (NE) differentiation. (B) Immunofluorescence of PAX6, SOX1 and OCT4 
at the endpoint of differentiation (D10) of WT, TKO and TKO-r1 cells. Unless otherwise 
noted the scale bar for all immunofluorescence images indicates 100 μm. (C) 
Representative FACS plots of PAX6 staining at D4, D6, D8 and D10 of WT and TKO cells 
(left panel). On the right is the quantification of PAX6-positive cells at D4, D6, D8 and D10 
of NE differentiation. n= 3 independent experiments. (D) Representative FACS plots of 
PAX6 staining at D10 of WT, TKO-r1 and TKO cells. On the bottom is the quantification of 
PAX6-positive cells at D10 of NE differentiation. n= 3 independent experiments. (E) OCT4 
immunofluorescence in WT and TKO cells at different timepoints of NE differentiation (D4, 
D6, D8 and D10 of NE differentiation). (F) Representative FACS plots of OCT4 staining at 
D10 of NE differentiation for WT, TKO-r1 and TKO cells. On the bottom is the quantification 
of OCT4-positive cells. n= 3 independent experiments. Data are mean ± STD. ns, not 
significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (D, F) and by 
Student’s t test (C). 
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Figure 2.13 Neural differentiation defect of TKO hESCs. (A) qPCR analysis for epiblast 
(OTX2), neuroectoderm (PAX6, SOX1 and OTX2) and neural crest (SOX10) markers in 
WT, TKO-r1, TKO-r2, and TKO-nr cells at four different time points of differentiation (D4, 
D6, D8, D10). (B) qPCR analysis for neural (FOXG1 and LHX2) and pluripotency (OCT4 
and NANOG) markers in WT and TKO cells at D10 of NE differentiation. (C) 
Immunofluorescence of PAX6, SOX1 and OCT4 at D10 of NE differentiation in MEL1 WT 
and MEL1 TKO cells. (D) Expression of neuroectoderm (PAX6 and SOX1) markers during 
NE differentiation of MEL1 WT and MEL1 TKO lines. n= 3 independent experiments. Data 
are mean ± STD. ns, not significant. *P<0.05, **P<0.01, ***P<0.001 by Student’s t test (B, 
D). 
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Analysis of additional markers as well as the MEL1 TKO line 
confirmed the NE differentiation defect of TKO hESCs (Figure 2.13A-D). We 
performed immunofluorescence for neural crest (SOX10 and TFAP2 
positive) and non-neural ectoderm (SOX10 negative and TFAP2 positive) 
cells. Interestingly TKO hESCs showed an absence of SOX10 positive cells 
but formed a similar number of non-neural ectoderm as WT hESCs. RT-
qPCR of GATA3 showed a similar expression of GATA3 at day 10 of 
differentiation of WT and TKO cells, supporting that non-neural ectoderm 
differentiation may not be affected in TKO hESCs (Figure 2.14A-B). At day 
10 of NE differentiation TKO cells showed increased expression for 
endoderm (GATA6) and mesoderm (BRACHYURY) compared to WT cells. 
This suggests that TKO cells may differentiate into these lineages instead of 
neuroectoderm; however, the upregulation of these markers in differentiated 
TKO cells (in comparison to WT hESCs) was low indicating limited 
differentiation into these lineages (Figure 2.14B). During differentiation TKO 
cells showed greater apoptosis than WT cells (Figure 2.14C), possibly 
because TKO hESCs were unable to differentiate into NE and cannot 
survive in NE differentiation media. Finally the NE phenotype of TKO hESCs 
could not be rescued by altering the starting density, indicating that this 
defect is not due to proliferation or colony forming differences between WT 
and TKO hESCs (Figure 2.14D). Notably, comparison of TKO and TET 
single and double knockout lines showed that the severity of the NE 
differentiation defect depended on the TET1/2/3 gene dosage. Loss of TET1 
had the largest effect on bulk 5hmC levels (Figure 2.3A) as well as NE 
differentiation as determined by FACS, immunostaining, and RT-qPCR 
analysis for PAX6 and SOX1 expression (Figure 2.15A-C).  
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Figure 2.14 Neural differentiation defect of TKO hESCs. (A) Immunofluorescence of a 
neural crest (SOX10 and TFAP2 positive) and a non-neural ectoderm (SOX10 negative and 
TFAP2 positive) at day 10 of NE differentiation in WT and TKO cells. (B) qPCR analysis for 
non-neural ectoderm (GATA2), endoderm (GATA6), mesoderm (BRACHYURY) and 
mesendoderm (GSC) markers in WT and TKO cells at D10 of NE differentiation. (C) 
Apoptosis analysis by FACS for Caspase-3. Representative FACS plots of Caspase-3 
staining at D4, D6, D8 and D10 of NE differentiation in WT and TKO cells. On the right is 
the quantification of Caspase-3 positive cells. n= 3 independent experiments. (D) PAX6 
positive cells at D10 of NE differentiation of WT, TKO, TKO-r1 and TKO-nr cells. 3 different 
starting densities are shown. n= 3 independent experiments. Data are mean ± STD. ns, not 
significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by Student’s t test (C). 
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Figure 2.15 Neuroectoderm differentiation is sensitive to the TET gene dosage. (A) 
Representative FACS plots of PAX6-positive cells at D10 of NE differentiation for TET KO 
mutants. (B) Immunofluorescence of PAX6, SOX1 and OCT4 at the endpoint of 
differentiation (D10) of TET KO mutants. (C) Expression of neuroectoderm (PAX6 and 
SOX1) markers at D10 of NE differentiation. For significance tests all comparisons are to 
WT. n= 3 independent experiments. Data are mean ± STD. ns, not significant. *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (C). 
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Figure 2.16 Differentiation of TKO hESCs into definitive endoderm and mesoderm 
lineages. (A) Immunofluorescence of SOX17, FOXA2 and OCT4 at day 5 of definitive 
endoderm differentiation. (B) FACS analysis for surface marker CXCR4 associated with 
definitive endoderm at day 5 of definitive endoderm differentiation. n= 3 independent 
experiments. (C) Expression of definitive endoderm (FOXA2, GATA4, GATA6, GSC, 
SOX17) and primitive endoderm (SOX7) markers at day 5 of definitive endoderm 
differentiation for WT and TKO cells. n= 3 independent experiments. (D) Expression of 
mesoderm (BRACHYURY, MIXL1 and N-CADHERIN) markers at different timepoints of 
mesoderm differentiation. n= 3 independent experiments. Data are mean ± STD. ns, not 
significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (B) or 
Student’s t test (C, D). 
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Finally we wanted to investigate whether TKO hESCs showed 
defects upon directed differentiation into additional lineages. TKO hESCs 
showed a differentiation defect into definitive endoderm (DE) by 
immunofluorescence (Figure 2.16A), flow-cytometry (Figure 2.16B) and RT-
qPCR (differentiations were performed with assistance of Qing Li) (Figure 
2.16C). Similar to the results with NE differentiation, upon differentiation to 
DE TKO cells showed reduced expression of differentiation markers 
(SOX17, FOXA2, CXCR4, GATA4, GATA6 and GSC) and greater number 
of OCT4 positive cells. Directed differentiation into mesoderm (performed by 
Chan-Jung Chan) showed a different result than with NE and DE. 
Interestingly TKO cells showed similar or even increased expression of 
mesoderm markers (BRACHYURY, MIXL1, N-CADHERIN) at the early time 
points of differentiation (day 2 and day 3) and reduced expression at later 
time points (day 4 and day 5) (Figure 2.16D). We did not observe an 
increase in methylation at BRACHYURY and MIXL1 bivalent promoters in 
our TKO hESCs. As a result is possible that TKO hESCs are able to 
increase expression of these genes upon the initiation of differentiation and 
allow initial differentiation into the mesoderm lineage. Other 
hypermethylated genes that are expressed at the later time points of 
differentiation (day 4 and day 5) may hinder further differentiation and lead 
to a decrease in expression of mesoderm markers.  
 
2.2.4 Promoter Hypermethylation Hinders PAX6 Expression Upon 
Differentiation 
PAX6 is expressed at a very low level in hESCs, and the P0 promoter 
hypermethylation in TKO hESCs had no effect on PAX6 gene expression in 
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hESCs (Figure 2.7D). We hypothesized that the hypermethylation of the 
PAX6 P0 promoter prevents activation of PAX6 expression upon 
differentiation and leads to the NE differentiation defect in TKO hESCs. 
Supporting this hypothesis, 5mC MassArray analysis showed aberrant 
hypermethylation at the PAX6 P0 promoter in TKO hESCs both before and 
during NE differentiation (Figure 2.9B). To establish direct causality we 
needed to determine whether loss of PAX6 expression accounts for the NE 
differentiation defect of TKO hESCs and then investigate whether the P0 
promoter hypermethylation is responsible for the loss of PAX6 expression.  
We first performed a rescue experiment in which we expressed the PAX6 
transgene under the control of a doxycycline inducible promoter in TKO cells 
during NE differentiation (Figure 2.17A). We targeted the doxycycline 
inducible PAX6 vector into TKO hESCs (TKO-PAX6) using a lentiviral 
construct (Figure 2.17B) and confirmed that doxycycline treatment induced 
PAX6 expression (Figure 2.17C-D). We treated TKO-PAX6 hESCs with 
doxycycline for different intervals during NE differentiation and found that 
continuous overexpression of PAX6 during the entire 10 days of NE 
differentiation was the most effective interval for rescuing the NE defect 
(Figure 2.17E). TKO cells exposed to doxycycline were able to upregulate 
NE markers SOX1 and FOXG1 and downregulate the pluripotency markers 
OCT4 and NANOG. However, SOX10 and endogenous PAX6 expression 
were not restored (Figure 2.18A-B). By ERRBS we found that compared to 
the promoters of SOX1 and FOXG1, the SOX10 and PAX6 promoters 
showed a much greater methylation increase in TKO hESCs, which may 
prevent their expression even when the PAX6 transgene is overexpressed.  
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Figure 2.17. Validation of PAX6 overexpression TKO line. (A) Schema for rescue of the 
NE differentiation defect in TKO hESCs using PAX6 overexpression. (B) Lentiviral construct 
to overexpress PAX6 in TKO cells. (C) PAX6 induction in TKO hESCs that had been 
infected with the PAX6 overexpression lentivirus after doxycycline (DOX) treatment. (D) 
Immunofluorescence for PAX6 in TKO hESCs that had been infected with the PAX6 
overexpression lentivirus after doxycycline (DOX) treatment. (E) TKO hESCs were infected 
with a lentiviral construct for PAX6 overexpression. Infected cells were differentiated to NE 
using the standard NE differentiation protocol. Cells were treated with doxycycline (DOX) to 
induce PAX6 for variable intervals during differentiation. 0-10: DOX treatment from D0 to 
D10, 2-10: DOX treatment from D2 to D10, 4-10: DOX treatment from D4 to D10, 6-10: 
DOX treatment from D6 to D10, 8-10: DOX treatment from D8 to D10.  
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Figure 2.18 Overexpression of PAX6 can partly rescue neuroectoderm differentiation 
in TKO cells. (A) qPCR analysis of neuroectoderm (SOX1, PAX6, FOXG1), neural crest 
(SOX10) and pluripotency (OCT4, NANOG) markers in WT and TKO cells without 
doxycycline (TKO) and with doxycycline treatment for 10 days (TKO +PAX6) at D10 of NE 
differentiation. For significance tests black lines indicate comparisons to WT. n= 3 
independent experiments. (B) Immunofluorescence of PAX6, SOX1 and OCT4 at the 
endpoint of differentiation (D10) of TKO cells without doxycycline treatment (TKO) and with 
doxycycline treatment for 10 days (TKO + PAX6). Data are mean ± STD. ns, not significant. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (A). 
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The above findings suggest that failure of PAX6 induction is largely 
responsible for the impaired NE differentiation observed in TKO hESCs. The 
failure of PAX6 induction could be due to hypermethylation of the PAX6 P0 
promoter. Alternatively, it could result from other causes, such as the failure 
to induce upstream transcription factors that activate PAX6 expression or 
perhaps a failure of exiting the pluripotency network. Thus we investigated 
whether reversing hypermethylation specifically at the PAX6 P0 promoter 
could rescue PAX6 induction during NE differentiation. We developed a 
targeted demethylation strategy by first fusing the TET1 catalytic domain 
(TET1CD) to a nuclease “dead” Cas9 (dCas9) (Figure 2.20A) and 
expressing this fusion protein in TKO hESCs. The procedure to generate 
TKO hESCs expressing the dCas9-TET1CD fusion are described in detail in 
the Methods section (Figure 2.19A-E). With the appropriate gRNAs this 
dCas9-TET1CD fusion protein can be recruited to target genomic sites 
where the TET1 catalytic domain can oxidize 5mC to 5hmC and induce DNA 
demethylation as shown in recent studies using similar strategies 
(Choudhury et al., 2016; Liu et al., 2016; Morita et al., 2016; Xu et al., 2016). 
We first tested 12 gRNAs that target the TET1 and 5hmC peak present at 
the PAX6 P0 promoter (Figure 2.20B) for their ability to induce indel 
mutations (Figure 2.20C). This was used as a way to screen effective 
gRNAs that we would then test using the dcas9-TET1CD fusion for their 
ability to induce DNA demethylation. We identified 7 gRNAs that were the 
most efficient at producing indel mutations and these gRNAs were 
transiently transfected into the TKO hESCs expressing the dCas9-TET1CD 
fusion to test their efficiency for targeted demethylation (Figure 2.20D). 
Bisulfite sequencing (Figure 2.20E) and 5mC MassArray (Figure 2.21A) 
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identified 3 gRNAs, Cr6, Cr7 and Cr9, that produced a significant decrease 
in methylation at the PAX6 P0 promoter in TKO hESCs compared to the 
non-transfected controls.  
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Figure 2.19. Targeting dCas9-TET1CD into TKO hESCs. (A) Schema to generate TKO 
hESCs that have doxycycline inducible expression of dCas-TET1CD. Because TKO hESCs 
were generated from the iCRISPR system it was necessary to first knock out the targeted 
Cas9 protein. After this Cas9 was inactivated the TKO hESCs were targeted with a 
lentivirus that contains a construct for doxycycline inducible expression of dCas9-TET1CD. 
(B) Schema to inactivate Cas9 in TKO hESCs. One CRISPR gRNA targeted the TRE 
promoter and the other targeted the beginning of the Cas9 protein. (C) Expression of Cas9 
in TKO clones that had mutations in either the TRE promoter (TKO-TRE-1 and TKO-TRE-2) 
or the beginning of the Cas9 protein (TKO-Cas9-1). (D) Western blot of Cas9 in TKO clones 
that had mutations in either the TRE promoter (TKO-TRE-1) or the beginning of the Cas9 
protein (Cas9 KO- TKO). (E) T7 endonuclease assay after transfection of TET2 gRNA in 
TKO clones that had mutations in either the TRE promoter (TKO-TRE-1) or the beginning of 
the Cas9 protein (Cas9 KO-TKO). 
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Figure 2.20. Targeted demethylation of the PAX6 P0 promoter using dCas9-TET1CD. 
(A) Diagram of the dCas9 TET1 catalytic domain fusion protein (dCas9-TET1CD). (B) 
Targeting regions for CRISPR gRNAs tested for PAX6 P0 promoter demethylation. The 
position of each gRNA in relation to the 5hmC peak is shown. The arrowhead indicates the 
first base pair of the gRNA and the base of the arrow indicates the 20th base pair that is 
adjacent to the PAM sequence. (C) T7 Endonuclease to test the efficiency of each CRISPR 
gRNA to generate indel mutations. Only gRNAs that could efficiently produce indel 
mutations were screened for targeted demethylation using the dCas9-TET1CD line. (D) 
Schema for testing the efficiency of targeted demethylation using the dCas9-TET1CD line. 
Genomic DNA was isolated on day 5 (D5) for methylation analysis by bisulfite sequencing. 
(E) Methylation at the PAX6 P0 promoter using bisulfite sequencing. Numbers in red 
indicate the average methylation in the PCR fragment, the number in parenthesis indicates 
the total number of sequences analyzed. CRISPR gRNAs written in blue were used further 
for targeted demethylation in TKO dCas9-TET1CD hESCs. 
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To enable persistent demethylation, we used a lentiviral vector to 
constitutively express the Cr6, Cr7 and Cr9 gRNAs in TKO hESCs with the 
doxycycline inducible dCas9-TET1CD fusion protein. Our strategy was to 
treat TKO hESCs with doxycycline prior to NE differentiation in order to 
express the TET1CD fusion protein and produce targeted demethylation at 
the PAX6 P0 promoter (Figure 2.21B). A number of controls were 
performed, including a no doxycycline control, a non-targeting gRNA control, 
and a control using dCas9-TET1CD mutated fusion protein (dCas9-
TET1CD/Mut), in which the TET1 catalytic domain has been inactivated by 
targeted mutagenesis (Figure 2.21C). After 10 days of doxycycline treatment 
we performed 5mC MassArray analysis at the PAX6 P0 promoter and 
observed demethylation at the PAX6 P0 promoter in TKO hESCs that 
expressed both the dCas9-TET1CD and the 3 PAX6 P0 gRNAs but not in 
the mutagenized dCas9-TET1CD/Mut control (Figure 2.21D-E). NE 
differentiation was then performed without further doxycycline treatment. 
dCas9-TET1CD TKO hESCs expressing PAX6 P0 gRNAs and treated with 
doxycycline prior to NE differentiation showed upregulation of PAX6 
expression after NE differentiation, while the controls did not (Figure 2.21F-
G). Thus the PAX6 promoter hypermethylation observed in undifferentiated 
TKO hESCs is directly responsible for the failure of PAX6 induction following 
NE differentiation.  
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Figure 2.21 Increased methylation at PAX6 P0 bivalent promoter leads to a failure of 
PAX6 induction in TKO hESCs undergoing neuroectoderm differentiation. (A) Heat 
map of MassArray analysis of 5mC in non-transfected TKO dCas9-TET1CD hESCs (NT) 
and TKO dCas9-TET1CD hESCs transfected with gRNAs targeting the PAX6 P0 promoter 
(Cr6, Cr7, Cr9). Each row of the heat map represents either an individual CpG or a few 
CpGs that are located close together. The location of the CpGs with respect to the TSS is 
shown to the left of the heat map. The binding site of gRNA Cr6 is shown by the arrowhead 
on the left side of the heatmap. The graph on the right shows the quantification of 
methylation in the region depicted in the heat map. For significance tests all comparisons 
are to the non-transfected control (NT). n= 2 independent experiments. (B) Schema for 
rescue of the NE differentiation defect in TKO hESCs using targeted demethylation of the 
PAX6 P0 promoter. (C) Diagram of the dCas9 TET1 catalytic domain fusion protein (dCas9-
TET1CD) and the dCas9 TET1 catalytic domain fusion protein in which the TET1 catalytic 
domain has been mutated (dCas9-TET1CD/Mut). (D) Diagram of the gRNAs (shown as 
blue arrows) designed to target the PAX6 P0 promoter in the region surrounding the 5hmC 
peak found in WT hESCs. Arrowhead indicates the 5’ end of the targeting gRNA. Regions 
previously analyzed for TET1 binding by ChIP-qPCR are enclosed by black rectangles. (E) 
Heat map of MassArray analysis of 5mC at the PAX6 P0 promoter for TKO hESCs that 
express PAX6 targeting gRNAs with either a dCas9-TET1CD/Mut (left) or a dCas9-TET1CD 
(right) fusion protein. Methylation analysis at the PAX6 P0 promoter was analyzed for these 
cell lines with and without doxycycline treatment. n= 3 independent experiments. (F) qPCR 
of PAX6 expression on D10 of NE differentiation for TKO hESCs that express PAX6 
targeting gRNAs with either a dCas9-TET1CD/Mut or a dCas9-TET1CD fusion protein. 
PAX6 expression was analyzed for these cell lines with and without doxycycline treatment 
prior to differentiation. n= 3 independent experiments. (G) Immunofluorescence of PAX6 on 
D10 of NE differentiation for TKO hESCs that express PAX6 targeting gRNAs with either a 
dCas9-TET1CD/Mut or a dCas9-TET1CD fusion protein. Also TKO hESCs expressing the 
dCas9-TET1CD fusion and a non-targeting gRNA were used as a control. PAX6 
immunofluorescence was analyzed for these cell lines with and without doxycycline 
treatment prior to differentiation. n= 3 independent experiments. Data are mean ± STD. ns, 
not significant. *P<0.05, **P<0.01, ***P<0.001 ****P<0.0001 by one-way ANOVA (A) or 
student’s t test (E, F). 
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We further tested dCas9-TET1CD mediated targeted demethylation 
on the hypermethylated bivalent promoter of SOX10, and the 
hypermethylated enhancer of LEFTY2 in TKO hESCs. We found that 
targeted demethylation of the hypermethylated LEFTY2 enhancer was able 
to increase expression of LEFTY2 in TKO hESCs. In contrast targeted 
demethylation of the hypermethylated SOX10 bivalent promoter had no 
effect on SOX10 expression at the hESCs stage but increased SOX10 
expression after differentiation, as seen with PAX6 (Figure 2.22A). These 
results support the conclusion that hypermethylation of a bivalent promoter 
impairs gene expression upon differentiation. Although the targeted 
demethylation induces significant increases in gene expression to similar 
degrees as reported in previous studies (Choudhury et al., 2016; Liu et al., 
2016; Morita et al., 2016; Xu et al., 2016), the expression did not reach WT 
levels. This may be due to incomplete demethylation. Additional chromatin 
changes at the target locus or elsewhere in TKO hESCs could also affect 
the target gene expression directly or indirectly. 
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Figure 2.22. Targeted demethylation of PAX6 and SOX10 promoters and LEFTY2 
enhancer. (A) Targeted demethylation at the bivalent promoters of PAX6 (left) and SOX10 
(middle) and the enhancer of LEFTY2 (right). For each locus the dCas9-TET1CD 
expressing TKO hESCs also expressed a non-targeting gRNA (NT) as a control. Top panel: 
Heat map of MassArray analysis of 5mC at bivalent promoters of PAX6 and SOX10 bivalent 
promoters and the enhancer of LEFTY2 after dCas9-TET1CD mediated demethylation 
either with non-targeting or targeting gRNAs. –DOX indicates that the cell lines were not 
treated with doxycycline and thus do not express dCas9-TET1CD. Each row of the heat 
map represents either an individual CpG or a few CpGs that are located close together. The 
location of the CpGs with respect to the TSS is shown to the left of each heat map. For 
each cell line and condition three biological replicates are shown as three columns, n= 3 
independent experiments. Bottom panel: qPCR analysis of targeted gene expression either 
in hESCs (blue) or after NE differentiation (red), n= 3 independent experiments. Data are 
mean ± STD. ns, not significant. *P<0.05, **P<0.01, ***P<0.001 ****P<0.0001 by student’s t 
test.  
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2.2.5 De novo methylation causes PAX6 promoter hypermethylation 
The DNA methyltransferases, DNMT1, DNMT3A and DNMT3B, are 
responsible for cytosine methylation. Thus we speculated that the 
hypermethylation of the PAX6 P0 promoter and the resulting NE 
differentiation defect could be due to increased expression or activity of the 
DNMTs in TKO hESCs. We first examined the effects of DNMT inhibitor 5-
Azadeoxycytidine (5-Aza) treatment on TKO hESCs (Figure 2.23A). 
Although we were limited to one day of 5-Aza treatment due to its 
cytotoxicity, TKO cells exposed to 10 nM 5-Aza prior to NE differentiation 
expressed NE marker SOX1 and downregulated pluripotency markers 
OCT4 and NANOG upon NE differentiation. However, no induction of PAX6, 
FOXG1 or SOX10 was observed (Figure 2.23B-C). We further confirmed 
that there was no significant increase in PAX6 positive cells by FACS 
analysis (Figure 2.24A). We believe this is because the limited 5-Aza 
dosage and exposure time is not sufficient to decrease methylation enough 
at loci such as PAX6, to allow transcriptional activation. This is supported by 
bisulfite sequencing of the PAX6 P0 promoter that did not show a significant 
decrease in methylation (Figure 2.24B). Interestingly WT cells showed a 
decrease in efficiency of NE differentiation at the highest 5-Aza dosage, 
possible due to toxicity effects (Figure 2.23B-C). 
Encouraged by these findings, we sought to determine which DNMT 
protein is responsible for the hypermethylation at the PAX6 P0 promoter in 
TKO hESCs. We speculated that the hypermethylation of the PAX6 P0 
promoter and the resulting NE differentiation defect could be due to 
increased expression or activity of the DNMTs in TKO hESCs. There were 
no differences in the expression of the DNMT genes between WT and TKO 
		
	 	98	
hESCs (Figure 2.25A); however, ChIP-qPCR analysis showed increased 
binding of DNMT3B (Figure 2.25B), but not DNMT1 or DNMT3A (Figure 
2.25C), at the PAX6 P0 promoter in TKO hESCs compared to WT hESCs.  
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Figure 2.23 Inhibition of DNMT by 5-Azadeoxycytidine partly rescues NE 
differentiation of TKO hESCs. (A) Schema for rescue of the NE differentiation defect in 
TKO hESCs using 5-Azadeoxycytidine (5-Aza) treatment. (B) Expression analysis at D10 
of NE differentiation for neuroectoderm (PAX6, SOX1, OTX2), neural crest (SOX10) and 
pluripotency (OCT4, NANOG) markers. WT and TKO hESCs were treated with different 
concentrations of 5-Aza prior to NE differentiation. (C) Immunofluorescence of PAX6, 
SOX1 and OCT4 at D10 of NE differentiation. WT and TKO hESCs were treated with 
different concentrations of 5-Aza prior to NE differentiation. n= 3 independent experiments. 
Data are mean ± STD. 
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Figure 2.24. PAX6 expression and methylation at the P0 promoter after 5-
Azadeoxycytidine treatment. (A) Left: Representative FACS plots of PAX6 
positive cells after treatment of WT and TKO hESCs with variable amounts of 5-
Azadeoxycytidine (5-Aza) prior to NE differentiation. Right: Quantification of PAX6 
positive cells after treatment of WT and TKO hESCs with variable amounts of 5-
Aza prior to NE differentiation. n= 3 independent experiments. (B) Methylation 
analysis of PAX6 P0 promoter by bisulfite sequencing after treatment with variable 
amounts of 5-Aza. The 4 sequences that were analyzed are shown.  
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Figure 2.25. Targeting DNMT proteins rescues NE differentiation. (A) Expression of 
DNMT1, DNMT3A and DNMT3B in WT and TKO hESCs by RNA-Seq analysis. n= 2 
independent experiments. (B) ChIP-qPCR for DNMT1 (left) and DNMT3A (right) at the 
PAX6 locus in WT and TKO hESCs. Primers are the same ones as used for Fig. 2f. n= 3 
independent experiments. (C) Schema for DNMT3B targeting in TKO hESCs. The CRISPR 
was designed to target the C5-methyltransferase enzymatic domain. The red line indicates 
the gRNA targeting sequence and the blue line is the adjacent PAM sequence. Data are 
mean ± STD. ns, not significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by Student’s 
t test (A, B).  
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Thus we decided to further investigate whether DNMT3B is responsible for 
the hypermethylation at the PAX6 P0 promoter in TKO hESCs through 
genetic deletion. By applying a CRISPR gRNA that targets the sequence 
corresponding to the cytosine C5-methyltransferase domain of DNMT3B 
(Figure 2.26A) in TKO hESCs, we generated a quadruple TET/DNMT3B 
knockout (QKO) line. QKO hESCs had a ~35% reduction in the methylation 
at the PAX6 P0 promoter compared to TKO hESCs (Figure 2.26B). 
Furthermore, there was a significant rescue of the NE differentiation 
phenotype compared to passage matched TKO hESCs: QKO cells formed 
PAX6 and SOX1 double positive cells (Figure 2.26C) and few cells 
remained OCT4-positive after 10 days of NE differentiation. RT-qPCR 
analysis also showed rescue of NE markers PAX6 and SOX1 and proper 
downregulation of pluripotency markers OCT4 and NANOG (Figure 2.26D).  
Our results suggest that DNMT3B activity at the PAX6 P0 promoter is 
responsible for the hypermethylation and NE differentiation phenotypes 
observed in TKO hESCs. In WT hESCs the TET proteins or the resulting 
5hmC marks actively block de novo methylation by DNMT3B to maintain a 
hypomethylated PAX6 P0 promoter and enable NE differentiation (Figure 
2.26E). 
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Figure 2.26 Genetic inactivation of DNMT3B can rescue the neuroectoderm 
differentiation defect of TKO hESCs. (A) ChIP-qPCR for DNMT3B at the PAX6 locus in 
WT and TKO hESCs. n= 3 independent experiments. (B) Heat map of MassArray analysis 
of 5mC at the PAX6 P0 promoter in WT, TKO and QKO hESCs. WT and TKO hESCs are 
passage-matched with the QKO hESCs. Each row of the heat map represents either an 
individual CpG or a few CpGs that are located close together. The location of the CpGs with 
respect to the TSS is shown to the left of the heat map. For each cell line three biological 
replicates are shown as three columns. Quantification of the percent methylation is shown 
on the right. n= 3 independent experiments. (C) Immunofluorescence of PAX6, SOX1 and 
OCT4 at D10 of NE differentiation in WT, TKO and QKO cells. (D) qPCR analysis of 
neuroectoderm (PAX6 and SOX1) and pluripotency (OCT4 and NANOG) markers in WT, 
TKO and QKO cells at D10 of differentiation. For significance tests black lines indicate 
comparison with WT. n= 3 independent experiments. (E) Model for TET and DNMT3B 
competition to regulate methylation at bivalent promoters. In WT hESCs TET1 or 5hmC 
functions to antagonize DNMT3B at the PAX6 bivalent promoter and prevents DNA 
hypermethylation. Upon NE differentiation PAX6 expression is activated and leads to the 
production of PAX6 and SOX1 double positive cells that are negative for the pluripotency 
marker OCT4. In TKO hESCs increased DNMT3B binding at the PAX6 bivalent promoter 
leads to increased DNA methylation. As a result PAX6 expression is not activated and 
ultimately few PAX6 or SOX1-positive cells are produced and a large number of cells still 
express the pluripotency marker OCT4. Data are mean ± STD. ns, not significant. *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (D) and by Student’s t test (A, B). 
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We performed ERRBS for passage-matched WT, TKO and QKO 
lines to investigate whether our findings at the PAX6 P0 promoter applies to 
other bivalent promoters (computational analysis was performed by Heng 
Pan). We found that QKO hESCs showed a global decrease in methylation, 
both within and outside of CpG islands, and in all promoter types. Bivalent 
promoters showed a larger decrease in methylation between QKO and TKO 
hESCs than active and initiated promoter types, but less than silent 
promoters (Figure 2.27A-C). Prior studies have suggested that DNMT3A 
and DNMT3B have redundant sites of action. We investigated DNMT3A 
expression in QKO hESCs to determine whether its expression may 
increase in order to compensate for loss of DNMT3B; however, we did not 
find a significant change in its expression (Figure 2.27D). Bivalent previously 
gained methylation in the TKO hESCs (compared to WT hESCs). 
Conversely, ~57% of the bivalent promoters that gained methylation after 
TET inactivation lost methylation after DNMT3B was mutated (Figure 
2.28C). Thus continuous DNMT3B activity is needed for the 
hypermethylation phenotype in TKO hESCs.   
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Figure 2.27 DNMT3B inactivation reduces methylation at bivalent promoters in TKO 
hESCs. (A) Average methylation at different genomic regions and bivalent promoters for 
WT, TKO and QKO hESCs by enhanced reduced representation bisulfite sequencing 
(ERRBS). Data are mean ± STD. n = 2 independent experiments. (B) Percent methylation 
in WT, TKO and QKO hESCs for active, initiated, bivalent and silent promoters. Error bars 
show 10 and 90 percent confidence intervals and the bar at the center of the box and 
whisker plot indicates the median. n = 2 independent experiments. (C) Percent methylation 
in WT, TKO and QKO hESCs in 10kb region surrounding active, initiated, bivalent and silent 
promoters. (D) DNMT1, DNMT3A, DNMT3B expression in WT, TKO and QKO hESCs by 
RT-qPCR. n = 3 independent experiments. ns, not significant. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 by one-way ANOVA (A, B, D). 
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Our results thus far indicate that DNMT3B is responsible for the 
majority of bivalent promoter hypermethylation that occurs after TET 
inactivation. We performed DNMT3B ChIP-Seq to identify bivalent 
promoters directly targeted by DNMT3B (computational analysis was 
performed by Heng Pan). DNMT3B shows relatively insignificant overall 
binding to promoter regions (Figure 2.28D) in WT and TKO hESCs, which is 
similar to previous results of DNMT3B ChIP-Seq in WT mESCs (Baubec et 
al., 2015). This may be due to weak DNMT3B binding, or technical 
difficulties of DNMT3B ChIP-Seq. Nevertheless, among promoters with 
DNMT3B peaks in TKO hESCs, 74% of the 293 bivalent promoters and 21% 
of the 1,017 non-bivalent promoters gained methylation after TET 
inactivation (Figure 2.28E). Furthermore bivalent promoters with DNMT3B 
peaks in TKO hESCs showed a greater methylation increase (TKO versus 
WT) and a greater methylation decrease (QKO versus TKO) than bivalent 
promoters that lacked DNMT3B peaks in TKO hESCs or non-bivalent 
promoters with DNMT3B peaks in TKO hESCs (Figure 2.28F). Thus 
DNMT3B binding correlates with more dynamic changes in DNA methylation 
at bivalent promoters and suggests that at these promoters the TET and 
DNMT3B proteins function in a competitive manner. 
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Figure 2.28 DNMT3B regulates methylation level at bivalent promoters. (A) Fraction of 
bivalent genes and total genes that overlap with hyper-DMRs (HUES8 and MEL1 TKO 
versus WT hESCs) and hypo-DMRs (HUES8 QKO versus TKO hESCs). Hyper-DMRs and 
hypo-DMRs are from ERRBS datasets. (B) Top: Overlap of bivalent promoters with hyper-
DMRs at promoter regions (TKO vs. WT) and hypo-DMRs at promoter regions (QKO vs. 
TKO). Bottom: Overlap of non-bivalent promoters with hyper-DMRs at promoter regions 
(TKO vs. WT) and hypo-DMRs at promoter regions (QKO vs. TKO). The odd’s ratio and p-
value for a comparison between bivalent and non-bivalent promoters is provided (Fisher’s 
exact test). (C) The overlap between hyper-DMR (TKO vs. WT) associated bivalent 
promoters and hypo-DMR (QKO vs. TKO) associated bivalent promoters. (D) Fraction of 
bivalent genes and total genes that overlap with hyper-DMRs (HUES8 and MEL1 TKO 
versus WT hESCs) and hypo-DMRs (HUES8 QKO versus TKO hESCs). Hyper-DMRs and 
hypo-DMRs are from ERRBS datasets. (E) Overlap between DNMT3B peaks in TKO 
hESCs and hyper-DMRs at bivalent promoters (top) and hyper-DMRs at non-bivalent 
promoters (bottom). (F) Left: Methylation change (TKO – WT) for bivalent and non-bivalent 
promoters that either have DNMT3B peaks in TKO hESCs (+DNMT3B) or do not have 
DNMT3B peaks in TKO hESCs (-DNMT3B). Right: Methylation change (QKO – TKO) for 
bivalent and non-bivalent promoters that either have DNMT3B peaks in TKO hESCs 
(+DNMT3B) or do not have DNMT3B peaks in TKO hESCs (-DNMT3B). Error bars show 10 
and 90 percent confidence intervals and the bar at the center of the box and whisker plot 
indicates the median. ns, not significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by 
one-way ANOVA (F). 
 
 
 
 
		
	 	109	
 
 
 
 
 
		
	 	110	
2.3 DISCUSSION 
Compared to enhancers, the majority of bivalent promoters do not 
show dramatic changes in DNA methylation during development (Jones, 
2012; Smith and Meissner, 2013). As a result it was unclear whether the 
methylation state of bivalent promoters is actively regulated and if it has 
functional relevance for cell differentiation. Previous studies have shown that 
the TET proteins regulate methylation at enhancers in developing mouse 
embryos and mESCs (Bogdanovic, 2017; Lu et al., 2014). Here we show 
that the TET proteins are also critical for maintaining a hypomethylated state 
at bivalent promoters in hESCs. In the absence of the TET proteins, 
aberrant hypermethylation of bivalent promoters leads to impaired gene 
activation upon exposure to differentiation signals. Importantly, the alteration 
of DNA methylation at bivalent promoters does not cause immediate 
changes in transcription but significantly impacts hESC differentiation. This 
suggests the need to revise the predominant approach that focuses on DNA 
methylation and other epigenetic changes with immediate impact on gene 
expression, as epigenetic changes may predict future cell behavior during 
embryonic development or adult stem cell differentiation. Broadly, the 
competitive balance between the TET proteins and de novo 
methyltransferases at bivalent promoters could facilitate rapid changes of 
their methylation state to either activate or silence transcription in a cell-
lineage and gene dependent manner. Although we focused on lineage 
regulators, such as PAX6, bivalent promoters may also regulate signaling 
pathways during development. Furthermore, we observed hypermethylation 
at enhancer regions after TET inactivation. TET activity at a variety of 
regulatory regions may modulate the expression of signaling pathways and 
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lineage regulators, all of which contribute to proper embryonic development 
and cellular differentiation.  
Previous studies have indicated that genomic regions marked by the 
H3K4me3 modification are refractory to de novo DNA methylation (Guo et 
al., 2014; Ooi et al., 2007). TET deletion causes bivalent promoter 
hypermethylation without causing apparent changes in H3K4me3 
occupancy. Thus TET or additional TET-dependent factors (including 5hmC) 
that frequently co-occur with H3K4me3 may mediate some of the effects 
reported to be associated with the H3K4me3 mark. Also intriguingly, this 
aberrant hypermethylation, once established in TKO hESCs, is not 
adequately maintained by DNMT1. Upon inactivation of DNMT3B in the 
TKO background we observed a global reduction of DNA methylation at 
bivalent promoters. Based on the >99.7% overall fidelity of DNMT1 in 
preserving methylation (Liao et al., 2015), DNMT1 would be expected to 
largely preserve the hypermethylation seen in TKO hESCs during the 
approximately 6 passages it took to generate and expand the QKO cells for 
analysis. The significant reversal of the hypermethylation phenotype at 
PAX6 and other bivalent promoters in QKO cells indicates the 
hypermethylation phenotype requires continuous DNMT3B activity. It also 
suggests that additional mechanisms, such as transient transcription (Di 
Ruscio et al., 2013), may inhibit DNMT1 activity at these loci. Alternatively, 
though not mutually exclusively, DNMT3B may function as both a de novo 
and maintenance methyltransferase at particular loci in ESCs, as previously 
suggested (Chen et al., 2003; Liang et al., 2002). Previous studies have 
shown that DNMT3A and DNMT3B share largely overlapping targets (Liao 
et al., 2015), yet deletion of DNMT3B alone in TKO hESCs was sufficient to 
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partially reverse bivalent promoter hypermethylation along with the 
associated NE differentiation defect. DNMT3B may have stronger 
preference or activity compared to DNMT3A at bivalent promoters such as 
PAX6, and such loci have been identified previously in hESCs (Liao et al., 
2015). Perhaps more likely, the rescue by DNMT3B deletion alone could be 
due to the relatively low DNMT3A expression compared to DNMT3B 
(Supplementary Fig. 9a) and the lack of compensatory increase of DNMT3A 
expression upon DNMT3B deletion (Supplementary Fig. 11d). Similarly a 
recent paper of TKO mouse embryos found that inactivating either DNMT3A 
or DNMT3B was able to rescue the gastrulation phenotype (Dai et al., 
2016). It is possible that in other cell types DNMT3A, along with or instead of 
DNMT3B, may counteract the TET proteins to regulate methylation (Rinaldi 
et al., 2016; Zhang et al., 2016).  
Our work highlights the utility of locus-specific epigenome editing 
tools to directly probe the functional consequences of epigenetic changes 
and to distinguish direct, locus-specific effects from indirect effects. The 
observation of specific instead of global hypermethylation in TKO hESCs 
suggests that the antagonistic relationship between TET and DNMTs may 
be regulated through recruitment of TETs and/or DNMTs in a locus-specific 
manner. Such competitive interplay and potential cooperative interactions 
between TETs and DNMTs may also occur at later stages of differentiation 
as recently shown in the hematopoietic system (Zhang et al., 2016). The 
expression of the individual TET genes can vary at different stages of 
development (Rasmussen and Helin, 2016), and each TET protein may 
have unique targets so that distinct sets of promoters are maintained in a 
hypomethylated/5hmC rich state depending on the cellular context. Similarly 
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the recruitment or enzymatic activity of the DNMTs may be locus-specific or 
influenced by the genomic distribution of transcription factors and histone 
modifications, which can change dramatically between cell types. It would 
be of great interest to investigate what factors determine whether the 
methylation state of a particular regulatory region is dynamically regulated or 
is relatively static, how different factors cooperate or counteract in different 
genomic contexts to establish the unique methylation state of regulatory 
regions, and ultimately how methylation states not only regulate but also 
predict (in the context of cell differentiation) cell-type specific transcriptional 
programs.  
 
2.4 MATERIALS & METHODS 
 
2.4.1 hESC Culture 
HUES8 (NIHhESC-09-0021) and MEL1 (NIHhESC-11-0139) hESCs 
were cultured on irradiated mouse embryonic fibroblasts (iMEFs) feeder 
layers in DMEM/F12 medium (Life Technologies, 12500-062) supplemented 
with 20% KnockOut Serum Replacement (Life Technologies, 10828028), 1X 
MEM Non-Essential Amino Acids (Life Technologies, 11140050), 1X 
GlutaMAX (Life Technologies, 35050079), 100U/ml Penicillin and 100 μg/ml 
Streptomycin (Gemini, 15070063), 0.055 mM 2-mercaptoethanol (Life 
Technologies, 21985023) and 10 ng/ml recombinant human bFGF (EMD 
Millipore, GF003AF). Cells were incubated at 37 °C with 5% (vol/vol) CO2, 
and media was changed daily. Cultures were passaged at a 1:6 - 1:12 split 
ratio every 4 - 6 days using TrypLE Express (Life Technologies, 12563-029). 
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5 µM Rho-associated protein kinase (ROCK) inhibitor Y-27632 (Selleck 
Chemicals, S1049) was added into the culture medium when passaging or 
thawing cells. Cells are regularly confirmed to be mycoplasma-free by the 
MSKCC Antibody & Bioresource Core Facility. 
 
2.4.2 Generation of TET mutant hESCs 
 
In vitro transcription of gRNAs. CRISPR gRNAs were designed to 
target the genomic sequence corresponding to the beginning of the catalytic 
domain for TET1, TET2, and TET3. For TET1 and TET3 the two gRNAs 
most efficient at producing indel mutations were used for the targeting 
experiments. For TET2 only one gRNA was found to be efficient at 
producing frameshift indel mutations. CRISPR gRNA design and testing was 
performed by Federico Gonzalez. A CRISPR gRNA used in a previous study 
was used to target the C5-methyltransferase domain of DNMT3B (Liao et 
al., 2015). The procedure to generate mutants has been previously 
described (Zhu et al., 2014). For each CRISPR a 20 bp T7 promoter was 
added to the 20 bp gRNA target sequence (Table 2.1) followed by a 80 bp 
constant gRNA backbone to form a 120 bp oligonucleotide. The T7-gRNA 
oligo nucleotide was amplified by PCR and the T7-gRNA PCR products 
were used as templates for in vitro transcription using the MEGAshortscript 
T7 kit (Life Technologies, AM1354M). The resulting gRNAs were purified 
using the MEGAclear kit (Life Technologies, AM1908M), eluted in RNase-
free water and stored at -80°C until use. 
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Table 2.1. CRISPR gRNA Sequences 
 
Gene Targeted CRISPR 
gRNA 
CRISPR gRNA Target 
Sequence 
TET1 CrT1A GCCCCAAGGTGTGTATAATA  CrT1B GGCCCATATTATACACACCT 
TET2 CrT2A CTTATGGTCAAATAACGACT 
TET3  CrT3A GTCATCTACACGGGGAAGGA  CrT3B GATCGAGAAGGTCATCTACA 
TET1  
(HDR correction of the TET1 
mutation) 
TET1 HDR CCCAAGGTGTGTATAAATAT 
DNMT3B DNMT3B Cr TCATTCTTTGATGCTATCAC 
Cas9 Cas9 Cr TTTCGCCGCTGTCGAACAGC 
PAX6 P0 Promoter  
(targeted demethylation) 
Cr6 CCTAGCTCCCCTCCAGGACC 
Cr7 TTACCAAGAAACTAGGTCAC 
Cr9 CTAGCTGGCCAGTTTCTGTC 
SOX10 Promoter  
(targeted demethylation) 
Cr8 CACAGTAAGAGAGACTTCTC 
LEFTY2 Distal Enhancer 
(targeted demethylation 
Cr1 GAGAAGCAGAGCAGGAAGTC 
Non-targeting Control 
(targeted demethylation) 
HBB TTTGCATATTCTGGAGACGC 
 
Transfection of gRNAs or gRNA + ssDNA. HUES8 and MEL1 
iCas9 hESCs (Gonzalez et al., 2014) or HUES8 TKO hESCs were treated 
with ROCK inhibitor and doxycycline one day before transfection. For 
transfection, confluent cells were dissociated using TrypLE (Life 
Technologies, 12563-029), replated at a 1:6 ratio in iMEF-coated 24-well 
plates and transfected in suspension with gRNAs or a mixture of gRNA and 
ssDNA. A second transfection was performed 24 hours later. Transfection 
was performed using Lipofectamine RNAiMAX (Life Technologies, 13778-
150) following the manufacturer’s guidelines. For each targeting, TET1, 
TET2, TET3, DNMT3B gRNAs, each at a 10 nM final concentration, were 
used. For repair of the TET1 allele in TKO hESCs, gRNAs and ssDNA (of 
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TET1 WT sequence) were transfected at a 10nM and 20nM concentration, 
respectively. Lipofectamine RNAiMAX and gRNA or gRNA + ssDNA were 
diluted separately in Opti-MEM (Life Technologies, 31985070), then mixed 
together, incubated for 5 min, and added drop-wise to cultured hESCs.  
Isolation, expansion and identification of mutant clones. Two 
days after the last gRNA transfection, hESCs were dissociated into single 
cells and replated at ~ 2,000 cells per 10-cm dish. Cells were allowed to 
grow until colonies from single cells became visible (~10 days). At this 
stage, single colonies were manually picked, mechanically disaggregated 
and replated individually into 96-well plates. Colonies were amplified and 
analyzed by Sanger sequencing at the 3 TET and the DNMT3B loci for the 
presence of mutations. Clonal cell lines carrying the desired mutations or 
TKO hESCs in which one TET1 allele was repaired were amplified and 
frozen down. For all targeting experiments (TET, DNMT3B and HDR repair 
of TET1) we also isolated and froze down lines that had undergone the 
targeting procedure, but whose genomic sequence was not changed. These 
lines were used as passage-matched controls for methylation analysis and 
differentiation (Table 2.2). 
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Table 2.2. TET Knockout Mutant lines 
 
hESC Line TET1 
genotype 
TET2 
genotype 
TET3 
genotype 
CRISPR gRNAs 
HUES8 WT WT WT WT CrT1B, CrT2A, CrT3B 
HUES8 TET1 
KO -8bp/-8bp WT WT 
CrT1B 
HUES8 TET2 
KO WT -16bp/-16bp WT 
CrT2A 
HUES8 TET3 
KO WT WT -4bp/-4bp 
CrT3B 
HUES8 TET1/2 
DKO -13bp/-1bp -4bp/-11bp WT 
CrT1B, CrT2A 
HUES8 TET1/3 
DKO +1bp/+1bp WT -4bp/+1bp 
CrT1B, CrT3B 
HUES8 TET2/3 
DKO WT -8bp/+1bp -4bp/-4bp 
CrT2A, Cr3B 
HUES8 TKO +1bp/+1bp +1bp/+1bp -4bp/+1bp CrT1B, CrT2A, CrT3B 
MEL1 WT WT WT WT CrT1A, CrT2A, CrT3A 
MEL1 TKO +1bp/+1bp -5bp/-1bp -1bp/+1bp CrT1A, CrT2A, CrT3A 
 
2.4.3 hESC Differentiation 
Teratoma. Confluent hESCs grown on a MEF feeder layer were 
collected by 1 mg/mL Collagenase type IV (Life Technologies, 17104-019) 
treatment, and suspended in PBS. One quarter of the cells from a confluent 
100 mm dish (approximately 2.5-3 million hESCs) was injected 
subcutaneously to the dorsal flank of a SCID mouse (NOD.Cg-Prkdc{scid} 
Il2rg{tm1Wjl}/SzJ (Stock #: 005557), Jackson Laboratory). Palpable tumors 
were typically observed 1-2 months after injection. Tumor samples were 
usually collected in 2-3 months, fixed in 4% paraformaldehyde and 
processed for paraffin embedding and hematoxylin and eosin staining 
following standard procedures. Mice injected with TKO hESCs were 
sacrificed 6 months after injection and dissected to confirm that teratomas 
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had not formed. All mouse procedures were performed following NIH 
guidelines, and were approved by the local Institutional Animal Care and 
Use Committee (IACUC), the Institutional Biosafety Committee (IBC) as well 
as the Embryonic Stem Cell Research Committee (ESCRO). 
Embryoid Body. hESCs were expanded onto a 10 cm2 dish on an 
iMEF feeder layer. Once the cells were confluent they were dissociated 
using 1 mg/mL Collagenase type IV (Life Technologies, 17104-019) and 
removed using a cell scraper. Cells were spun down at 200 g for 5 minutes 
and washed with phosphate buffered saline solution (PBS). This was 
repeated 2 times for a total of 3 washes. The cell clumps were then plated 
into 6-well low attachment plate in hESC media that lacks bFGF. One 10 cm 
dish gave enough cells for one 6 well plate. The cells were kept in the 6 well 
low attachment plate for a total of 5 days after which time they formed 
embryoid bodies. After 5 days the EBs were transferred to a 24 well dish 
that has been coated with Geltrex (Life Technologies, A15696) for 
attachment and differentiation. The cells were kept in the 24 well dish for 7 
days total with media change every 2 days. The media remained hESC 
media without bFGF. 
Neuroectoderm Differentiation. 90% confluent hESC cultures were 
disaggregated using TrypLE (Life Technologies, 12563-029) for 5 minutes 
and washed using hESC media. The cells were plated on Matrigel (BD, 
354234) coated dishes in hESC media with ROCK-inhibitor at a density of 
180,000–200,000 cells/cm2. After 12 hours, differentiation into 
neuroectoderm was initiated by switching to knockout serum replacement 
(KSR) media with 10 μM TGF-b inhibitor SB431542 (Tocris 161410) and 
100 nM BMP inhibitor LDN193189 (Axonmedchem, 1509).  On day 1 and 
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day 2 of differentiation, the media was removed and fresh KSR with 10 μM 
SB431542 and 100 nM LDN193189 was added. Starting on day 4 of 
differentiation an increasing amount of N2 media was added to the KSR 
media every two days, while maintaining 10 μM SB431542 and 100 nM 
LDN193189. On day 4 a 3:1 mixture of KSR/N2 media was added. On day 6 
a 1:1 mixture of KSR/N2 media was added and on day 8, a 1:3 mixture of 
KSR/N2 media was added. The cells were isolated for analysis on day 10 of 
differentiation. KSR media contains Knockout DMEM (Life Technologies, 
10829018), Knockout Serum Replacement (Life Technologies, 10828028), 
1X MEM Non-Essential Amino Acids (Life Technologies, 11140050), 1X 
GlutaMAX (Life Technologies, 35050079), and 2-mercaptoethanol (Life 
Technologies, 21985023). N2 media contains DMEM/F12 medium (Life 
Technologies, 12500-062), glucose (Sigma, G8270), sodium bicarbonate 
(Sigma, S5761), putrescine (Sigma, P5780), progesterone (Sigma, P8783), 
sodium selenite (Sigma, S5261), apo-transferrin (Sigma, T1147), and insulin 
(Sigma, I2643). 
Definitive Endoderm Differentiation. Definitive endoderm 
differentiation was performed with the assistance of Qing Li. HUES8 hESCs 
were converted to E8 feeder free culture prior to definitive endoderm 
differentiation. When cells reached 80-90% confluence they were treated 
with TRYPLE to dissociate into single cells for passaging. Approximately 
0.15 million hESCs were plated in one well of the six-well plates with 10 μM 
Rho-associated protein kinase (ROCK) inhibitor in 2 ml E8 media. 24 hours 
later, cells were washed with PBS once and the culture media was changed 
to Advanced RPMI (Thermo Fisher Scientific 12633012) with 
penicillin/streptomycin (Thermo Fisher Scientific 15070063), Glutamax 
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(Thermo Fisher Scientific 35050079), 0.003% BSA (Thermo Fisher Scientific 
15260037), 5 μM CHIR-99021(Tocris 4423) and 100ng/ml Activin A 
(Peprotech 12014E). In the next 2 days, culture medium was changed to 
Advanced RPMI with penicillin/streptomycin, Glutamax, 0.2% FBS and 100 
ng/ml Activin A. Cells were collected for immunofluorescence, RT-qPCR and 
FACS analysis after 5 days of differentiation. 
Mesoderm Differentiation. Mesoderm differentiation was performed 
by Chan-Jung Chang. hESCs were differentiated as spin embryoid bodies 
(EBs) in APEL medium. Briefly, cells were dissociated into single cells with 
accutase and plated at 3000 cells per well in round-bottom low-attachment 
96-well plates in APEL medium containing 30 ng/ml bone morphogenetic 
protein 4 (BMP4) and 10nM Y-27632. The plates were centrifuged at 800g 
for 5 minutes to induce EB aggregation. After 24 hours, the medium was 
replaced by APEL medium containing 30ng/mL BMP4 and 50ng/mL FGF2. 
After 2 days, the cytokine cocktail was changed to: 20 ng/ml vascular 
endothelial growth factor (VEGF), 10 ng/ml FGF2, 100 ng/ml stem cell factor 
(SCF), 20 ng/ml Flt3 ligand (Flt3L), 20 ng/ml thrombopoietin (TPO), 40 ng/ml 
IL-3.  
 
2.4.4 Dot Blot 
Genomic DNA was extracted using the DNeasy Blood & Tissue Kit 
(Qiagen, 69504) following manufacturer’s guidelines and diluted to 200 ng/µl 
and 100 ng/µl in 20 µl total volume. 5 µl of 0.5 M NaOH was added to each 
sample and the samples were incubated at 99°C for 5 minutes. Samples 
were cooled on ice, spun down and neutralized with 2.5 µl of 6.6 M 
Ammonium Acetate. 2.75 µl of each mixture was spotted on a nitrocellulose 
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membrane and allowed to air dry. The membrane was baked for 2 hours at 
80°C and then incubated in blocking buffer for 2 hours at RT. 5hmC 
antibody (Active Motif, 39769) at a 1: 10,000 dilution in blocking buffer was 
added to the membrane and incubated overnight at 4C. The membrane was 
washed in phosphate buffered saline (PBS) with 0.1% Tween 20 (PBSTw), 
3 times for 15 minutes each and then incubated with HRP Goat anti-Rabbit 
IgG (Active Motif, 15015) in blocking buffer for 2 hours at RT. The 
membrane was washed again 3 times in PBSTw, and then once in ddH2O 
for 5 minutes. Luminata Crescendo Western HRP Substrate (Millipore, 
WBLUR0100) was used for detection. 
 
2.4.5 Mass Spectrometry Quantification of 5mC and 5hmC 
Mass spectrometry was performed by Louis Dore. 4 μg of genomic 
DNA was denatured for 5 minutes at 95°C, then sequentially digested with 
nuclease P1 (Wako Chemicals, 0218055501), Crotalus adamanteus venom 
phosphodiesterase (Sigma, P3243), and E.coli alkaline phosphatase 
(P5931, Sigma). Digested nucleosides were desalted, filtered and analyzed 
by UHPLC/MS/MS on an Agilent 1290 with UHPLC coupled to a 6460 Triple 
Quadrupole LC/MS system using multiple reaction monitoring and the 
following ion transitions: dC, 228.1à112.1; mdC, 242.1à126.1; hmdC, 
248.1à142.1. Molar quantities of dC, mdC, and hmdC were determined by 
fitting signal intensities to a standard curve of known concentrations. mdC 
and hmdC quantities were expressed as a molar ratio compared to total dC, 
mdC, and hmdC present in each sample. 
 
2.4.6 Pluripotency and Lineage Marker Staining 
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Alkaline Phosphatase Staining. The VECTOR Red Alkaline 
Phosphatase (AP) Substrate Kit (Vector Labs, SK-5100) was used. Cultured 
hESCs were washed once with PBS and then incubated with substrate 
working solution for 30 minutes. Cells were washed 3 times with PBS and 
images were taken. 
Immunofluorescence staining. Cells were fixed with 4% 
paraformaldehyde for 10 minutes, washed once with PBS and 
permeabilized in PBST (PBS + 0.15% Triton-X) for 15 minutes. Blocking 
was done for 5 minutes at RT with blocking solution (5% donkey serum in 
PBST). Primary and secondary antibodies were diluted in blocking solution. 
Primary antibodies were incubated at RT for 1 hr. The following primary 
antibodies were used at a 1:100 dilution: OCT4 (Santa Cruz, sc-5279), 
NANOG (CosmobioJapan, RCAB0004P-F), and SOX2 (Santa Cruz, sc-
17320). The following antibodies were used at a 1:500 dilution: PAX6 
(Covance, PRB-278P) and SOX1 (R&D Systems, AF3369). After primary 
antibody staining the cells were washed three times with PBST and then 
incubated with the appropriate Molecular Probes Alexa Fluor dye conjugated 
secondary antibodies (Life Technologies, AF3369) and DAPI for 1 hour at 
RT. 
 
2.4.7 FACS Analysis 
Intracellular marker. NE differentiated cells at the desired time point 
were disaggregated with TrypLE for 5 minutes and washed with cold FACS 
buffer: 5% Fetal Bovine Serum (Life Technologies, 261400799) in PBS. 
Cells were pelleted by centrifugation and washed again with FACS buffer. 
Each sample was resuspended in FACS buffer and incubated with a 
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Live/Dead Fixable stain (Life Technologies L34964, 1:1,000) for 30 minutes 
at RT. Afterwards cells were washed with FACS buffer and resuspended in 
fixation solution (eBioscience, 00-5523-00) for 1 hour at RT. Cells were 
washed with permeabilization buffer (eBioscience, 00-5523-00) and then 
resuspended in permeabilization buffer and the appropriate antibody: OCT4-
APC (eBioscience 50-5841-82, 1:25) or PAX6 (Covance PRB-278P, 1:400) 
for 1 hour at RT. For OCT4 flow analysis the cells were washed with FACS 
buffer and analyzed by FACS. For PAX6 flow analysis, cells were washed 
with FACS buffer and then incubated with the appropriate Molecular Probes 
Alexa Fluor dye conjugated secondary antibody (Life Technologies A21206, 
1:500) for 1 hour at RT. Cells were then washed with FACS buffer and 
analyzed by FACS. 
Surface marker. Confluent hESCs were disaggregated with TrypLE 
for 5 minutes and washed with cold FACS buffer. Cells were pelleted by 
centrifugation and washed again with FACS buffer. Each sample was 
resuspended in FACS buffer with the appropriate conjugated antibody: Tra1-
60-FITC (BD Biosciences, 560380) or Tra1-81-FITC (BD Biosciences, 
560194). Cells were incubated in FACS buffer with the antibody for 30 
minutes on ice. After staining cells were washed two times with FACS buffer 
and resuspended in FACS buffer with DAPI and analyzed by FACS. 
 
2.4.8 Quantitative RT-qPCR 
Total RNA was isolated with the RNeasy Mini Kit (Qiagen, 74136). 
DNA was removed from RNA samples using genomic DNA eliminator spin 
columns. cDNA was produced from RNA using SuperScript III Reverse 
Transcriptase kit (Life Technologies, 18080051) or High Capacity cDNA 
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Reverse Transcriptase kit (Life Technologies, 4368813). Quantitative real-
time PCR was performed in triplicate using ABsolute QPCR SYBR Green 
Low ROX Mix (Thermo Scientific, AB4322B). Primers used for qRT-PCR are 
in Table 2.3. Please note that the primer pair we used for PAX6 binds to 
Exon 6, as a result it downstream of the PAX6 promoters (P0 and P1) and 
will not differentiate between P0 and P1 transcripts. 
 
Table 2.3. qPCR Primers 
Gene or 
Genomic 
Region 
Forward Primer Reverse Primer 
BRACHYUR
Y 
ACCCAGTTCATAGCGGTGAC CCATTGGGAGTACCCAGGTT 
DNMT1 AGGCGGCTCAAAGATTTGGAA GCAGAAATTCGTGCAAGAGATTC 
DNMT3A AGTACGACGACGACGGCTA CACACTCCACGCAAAAGCAC 
DNMT3B GACTGCTTGGAATACAATAGGA GCACCACAAAACATCTTCTTT 
FOXA2 GGGAGCGGTGAAGATGGA TCATGTTGCTCACGGAGGAGTA 
FOXG1 CCGCACCCGTCAATGACTT CCGTCGTAAAACTTGGCAAAG 
GAPDH GGAGCCAAACGGGTCATCATCTC GAGGGGCCATCCACAGTCTTCT 
GATA3 TCTGACAGTTCGCACAGGAC AAAATGAACGGACAGAACCG 
GATA4 AAAGAGGGGATCCAAACCAG TTGCTGGAGTTGCTGGAAG 
GATA6 GTGCCCAGACCACTTGCTAT TGGAATTATTGCTATTACCAGAG
C 
GSC AACGCGGAGAAGTGGAACAAG CTGTCCGAGTCCAAATCGC 
LEFTY2 CTCCAACGCCAGGAACC GACATGGAGGAGCTGGTCA 
LHX2 CCAAGGACTTGAAGCAGCTC GTAAGAGGTTGCGCCTGAAC 
NANOG GCCTGGTTGCCTCATGTTATTATG
C 
CCATGGAGGAAGGAAGAGGAGAG
A 
OCT4 TGGTCCGAGTGTGGTTCTGTAA TGTGCATAGTCGCTGCTTGAT 
OTX2 CATGCAGAGGTCCTATCCCAT AAGCTGGGGACTGATTGAGAT 
PAX6 TGGGCAGGTATTACGAGACTG ACTCCCGCTTATACTGGGCTA 
PAX6 3’UTR 
(Endo) 
ATTGTGTTAATTCAGTCAGTG CCCAGTGGTACAATACAGGAC 
SOX1 AACACTTGAAGCCCAGATGGA GCAGGCTGAATTCGGTTCTC 
SOX7 CATGCAGGACTACCCCAACT ACTCACCCCTGTCCTCCTTC 
SOX10 CTTTCTTGTGCTGCATACGG AGCTCAGCAAGACGCTGG 
SOX17 GGCGCAGCAGAATCCAGA CCACGACTTGCCCAGCAT 
Epimark: 
PAX6 P0  
GGCAGGAATCATTTTTAGGAGGA CCTGGAGAGACCTTTGGCCTA 
ChIP qPCR: 
PAX6 P0  
Promoter 1 
CCTCCCACTGGCCACTCTAGT TAGGGGCTTACCAAGAAACTA 
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2.4.9 Epimark 
 
In addition to base level genome-wide 5hmC profiling, 5hmC at the 
PAX6 P0 promoter was validated using the Epimark 5hmC and 5-mC 
Analysis kit (NEB, E3317S) according to the manufacturer’s protocol. Briefly 
genomic DNA was extracted using the DNeasy Blood & Tissue Kit (Qiagen, 
69504) following manufacturer’s guidelines. 10 ug of DNA for each sample 
was divided into 6 tubes. The first 3 tubes were treated with beta-
glucosyltransferase (BGT) overnight. 2 of the 6 total tubes were digested 
with MspI (one tube had been treated with BGT whereas the other had not), 
Table 2.3. 
(Continued)  
 
  
ChIP qPCR: 
PAX6 P0 
Promoter 2 
CCCCGCCTGCTTATCTGCCTG CTTCTCCCTCGGCGACCCCAG 
ChIP qPCR: 
PAX6 P0 
Promoter 3 
CGGGAAGAAGGGCACCGCGGG AGTCTGTGCTACCCCGGGCTG 
ChIP qPCR: 
PAX6 P1 
Promoter 1 
CCTAAGCTGGACTCGGGACTC CCGCCGCTGTGCTCTGTGTCT 
ChIP qPCR: 
PAX6 P1 
Promoter 2 
GTCTGCTCAGTCCACGGAGGC GGAGTGTACTGAGGTGTGTCC 
ChIP qPCR: 
PAX6 P1 
Promoter 3 
CTCGCCTCCACCGCTCCTCAC GAGAGCGAGCGGTGCATTTGC 
ChIP qPCR: 
E -6k 
Enhancer 
CATCCTTTCCTTCTTTCTGCT CGTCCCCGCCGTGCAAAGAGA 
ChIP qPCR: 
E 156k 
Enhancer 
ACTTAAATGCCTCAAACTTTT TCTTGTAAATGAGTAGCCTAT 
ChIP qPCR: 
NANOG 
Promoter 
GATGGGGGAATTCAGCTCAGG GTCTCTCTTAATCAGCACAGT 
ChIP qPCR: 
HERVK 
AGAGGAAGGAATGCCTCTTGCAGT TTACAAAGCAGTATTGCTGCCCG
C 
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2 of the 6 tubes were digested with HpaI (one tube had been treated with 
BGT whereas the other had not) and two of the tubes were undigested. After 
overnight digestion we performed qRT-PCR analysis. The primers for 
analysis are found in Table 2.3. 
 
2.4.10 RNA-Seq 
For RNA-Seq total RNA was isolated with the RNeasy Mini Kit 
(Qiagen, 74136) from HUES8 WT and TKO hESCs (n=2 each). RNA 
samples were submitted to the MSKCC Integrated Genomics Core for 
library prep and sequencing.  
RNA-seq data analysis was performed by Heng Pan. RNA-seq data 
was aligned to the hg19 reference genome using Bowtie. Read counts were 
derived from HTSeq.scripts.count module in HTSeq-0.6.0 with default 
parameters in a non-directional model (Anders et al., 2015). Differentially 
expressed genes were generated by DESeq2-1.4.5 in R (Love et al., 2014). 
Up regulated genes were decided by logFC > 2 and p-adj < 0.1 (n=134). 
Downregulated genes were decided by logFC < -2 and p-adj < 0.1 (n=233). 
 
2.4.11 5hmC Profiling 
5hmC-Seal was performed by Louis Dore as previously described 
(Song et al., 2011). 40 μg of genomic DNA was sonicated to ~200-400bp 
fragments using a Diagenode Bioruptor Sonicator. Sonicated DNA was then 
labeled with azide glucose in a 1 hour reaction at 37°C catalyzed by 
recombinant b-GT utilizing UDP-6-N3-glucose as the sugar donor. The 
reactions were cleaned up using a Zymo DNA Clean & Concentrator kit 
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(Zymo, D4003), then a biotin moiety was added to the azide-labeled DNA 
via a copper-free click chemistry reaction with DBCO-S-S-PEG3-Biotin in 
water at 37°C for 1 hr. Reactions were once again cleaned with the Zymo kit 
and then bound to Dynabeads MyOne Streptavidin C1 beads (Life 
Technologies, 65001) for 15 minutes at RT and washed 5 times with binding 
buffer (5mM Tris-HCl, pH7.5, 0.5mM EDTA, 1M NaCl, 0.01% Tween 20). 
Bound DNA was eluted by reducing the disulfide in the biotin linker with 
100mM DTT for 2h at RT with gentle rotation. Eluted DNA was cleaned on a 
Micro Bio-spin Column (BioRad, 7326204) to remove DNA and then purified 
by the Zymo kit. Libraries were constructed from eluted DNA by end repair, 
A-tailing, and adapter ligation, followed by 4 cycles of PCR, size selection 
via agarose gel electrophoresis, 12 additional PCR cycles, and a final size 
selection via agarose gel electrophoresis. Library quantity and quality were 
analyzed by Bioanalyzer prior to sequencing on an Illumina HiSeq 2500. 
Sequence alignment and peak identification were performed as previously 
described (Song et al., 2011). Peak calling was performed by macs14 1.4.2 
with default parameters. 
2.4.12 Whole Genome Bisulfite Sequencing (WGBS) and Enhanced 
Reduced Representation Bisulfite Sequencing (ERRBS). 
For WGBS, genomic DNA was isolated from HUES8 WT and HUES8 
TKO hESCs. Genomic DNA was sheared using E220 focused-ultrasonicator 
(Covaris) to 250-350bp fragments. After end-repair and TruSeq adapter 
(Illumina) ligation the DNA-libraries were denatured followed by treatment 
with bisulfite (Zymo Research, D5020) for 30 min at 65C. Single stranded 
DNA was purified using silica gel columns and amplified using HiFi Uracil+ 
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polymerase (Kapa biosciences, KK2802). The amplified libraries were 
quantified and mixed equimolarly for sequencing on Illumina HiSeq2500 by 
the MSKCC Integrated Genomics Core. One replicate for HUES8 WT and 
HUES8 TKO was submitted for sequencing. 
For ERRBS, genomic DNA was isolated from HUES8 WT, HUES8 
TKO and HUES8 QKO hESCs. Genomic DNA was submitted to the Weill 
Cornell Medical College Epigenomics Core for ERRBS. Two independent 
replicates each for HUES8 WT, TKO and QKO cells were submitted for 
sequencing. 
WGBS and ERRBS data were analyzed by Heng Pan. WGBS data 
were aligned to the bisulfite-converted hg19 reference genome using 
Bismark v0.13.0 (Krueger et al., 2011). We extracted the methylation status 
with the bismark_methylation_extractor script in Bismark (Krueger et al., 
2011). Only CpGs with at least 3 covered reads were used for downstream 
analysis. The WCMC Computational Genomics Core Facility supported 
alignment and methylation extraction for ERRBS data (Akalin et al., 2012). 
DMRs were defined as regions containing at least five differentially 
methylated CpGs (DMCs, false discover rate=20%, Chi square test) and 
whose total methylation difference was more than 10% (Pan et al., 2015). 
For Figures 1h and Extended Data Fig. 3b-c hypermethylation was defined 
as a 5% increase in methylation in order to set a uniform cutoff for 
comparison between different promoters or cell lines. For whole genome 
bisulfite sequencing only one replicate was used but the use of five or more 
DMCs partially overcomes the statistical limitation of individual Chi square 
tests based on a n=1 sample, as the latter should be cautiously interpreted 
in the absence of multiple measurements from independent samples. DMRs 
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calling was performed with RRBSeeqer with default parameters. DMRs were 
annotated using ChIPseeqerAnnotate from ChIPseeqer package 
(Giannopoulou et al., 2011). Methylation of a specific region was calculated 
by averaging the methylation levels of all covered CpGs in that region.  
Genomic regions for CpGs are defined as the following definitions. 
CpG islands (CGI) are defined as annotations from refSeq. CGI shores are 
defined as the region encompassing 1 kb upstream and downstream of 
known CGIs. Non-CGIs are defined as at least 10 kb away from known 
CGIs. Promoters are defined as the region encompassing 2 kilobases (kb) 
upstream and downstream from the transcription start site (TSS) from 
refSeq. The following characteristics were used to classify promoters as 
active, initiated, bivalent and silent. Active promoters are associated with 
H3K4me3 (in 1.5 kb region flanking the TSS) and H3K79me2 (in 5 kb 
downstream from the TSS). Initiated promoters are associated with 
H3K4me3 (in 1.5 kb region flanking the TSS). Bivalent promoters are 
associated with H3K4me3 and H3K27me3 (in 1.5 kb region flanking the 
TSS). Silent promoters were not associated with H3K4me3 (in 1.5 kb region 
flanking the TSS). With WGBS (HUES8 TKO vs. HUES8 WT) 6,695 active 
promoters, 989 initiated promoters, 3,327 bivalent promoters and 4,707 
silent promoters were analyzed. With ERRBS (HUES8 TKO vs. HUES8 WT) 
6,450 active promoters, 846 initiated promoters, 3,234 bivalent promoters 
and 1,476 silent promoters were analyzed. With ERRBS (MEL1 TKO vs. 
MEL1 WT) 6,420 active promoters, 3,222 bivalent promoters, 835 initiated 
promoters and 1,413 silent promoters were analyzed. 
Enhancers are required outside of promoters and exons (RefSeq). 
Poised enhancers were identified as regions overlapping with H3K4me1 
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peaks only. Active enhancers were identified as regions overlapping with 
H3K4me1 and H3K27ac peaks. 
 Overlap of 5mC change with histone marks was determined using 
previous ChIP-Seq datasets for histone marks (H3K4me1: GSM 733782; 
H3K4me2: GSM 733670; H3K4me3: GSM 733657; H3K27me3: GSM 
733748; H3K27ac: GSM 733718; H3K9me3: GSM 1003585; H3K36me3: 
GSM 1003585; H3K79me2: GSM 1003547). Peak calling was performed by 
ChIPseeqer-2.1 with default parameters (Giannopoulou et al., 2011). 
 
2.4.13 ChIP-Seq 
ChIP-Seq was performed for TET1 (WT hESCs) and DNMT3B (WT 
and TKO hESCs). WT and TKO hESCs were cultured in standard hESC 
media, as described above. ~5 × 107 cells were fixed, washed and snap-
frozen according to the Cell Fixation protocol from Active Motif 
(http://www.activemotif.com/documents/1848.pdf). Immunoprecipitation and 
DNA sequencing was done by Active Motif. 
ChIP-Seq data analysis was performed by Heng Pan. ChIP-Seq data 
was aligned to the hg19 genomes using bowtie-0.12.9 with default 
parameters except --n 2 and --best. Peak calling and read density in peak 
regions were performed by macs14 1.4.2 with default parameters. The 
technical success of the ChIP-Seq was confirmed by using standard quality 
control measures and determining the overlap between TET1 binding and 
the presence of 5hmC. We observed that 52.6 % of 5hmC peaks associated 
with gene promoters overlapped with TET1 peaks (Figure 2.11A), which is 
similar to previous results obtained from TET1 ChIP-Seq in mouse 
embryonic stem cells (Williams et al., 2011, Xu et al., 2011). Approximately 
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75% of TET1 peaks overlapped with 5hmC peaks present in HUES8 WT, in 
contrast only 25% of TET1 peaks overlapped with randomly generated 
5hmC peaks (Figure 2.11C). Random peaks were generated with 
ChIPseeqerCreateRandomRegions in ChIPseeqer-2.1 with default 
parameters. The lack of a complete overlap between 5hmC and TET1 could 
be due to a number of factors including: 5hmC production by TET2 and 
TET3, rapid turnover of 5hmC and reduced binding of TET1 to 5hmC. Peaks 
from ChIP-Seq were annotated using ChIPseeqerAnnotate from ChIPseeqer 
package (Giannopoulou et al., 2011). 
 
2.4.14 5mC Methylation Analysis by MassArray 
hESCs were disaggregated using TrypLE and genomic DNA was 
extracted using the DNeasy Blood & Tissue Kit (Qiagen, 69504) following 
manufacturer’s guidelines. MassArray Epityper analysis was performed 
using the WCMC Epigenomics core. MassArray Epityper analysis consists 
of bisulfite treatment of genomic DNA, followed by PCR for the specific 
region of analysis, base specific cleavage that differentiates between 
previously methylated and unmethylated DNA and finally MALDI-TOF mass 
spectrometry (Ehrich et al., 2005). Primers used for mass array 5mC 
methylation analysis are found in Table 2.4. Genomic coordinates of regions 
assayed by MassArray are provided in Table 2.5. 
Table 2.4. 5mC MassArray Bisulfite Sequencing Primers 
 
Gene or Genomic 
Region 
Forward Primer Reverse Primer 
PAX6 P0 Promoter 1 AGGAAGAGAGAGTTTTTTTTAAGGTTGGTGGTAGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
CTTCCTAACTAACCAATTTCTATCC  
PAX6 P0 Promoter 2 AGGAAGAGAGAGTATTTTGTTGGGTTGTAGGGATT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CCTCCCACTAACCACTCTAATCTA 
PAX6 P0 Promoter 3 AGGAAGAGAGATTTTAGGATATTTGAGGTTGGAGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CCAAAAAACAACTCCAAACAAC 
PAX6 P0 Promoter 4 AGGAAGAGAGTTTTAATTTGAAAGTGATAGTGGTGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AACAAAACAAAAAATCAAATCCAA 
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PAX6 P0 Promoter 5 AGGAAGAGAGGGTGTGAGGGAAAAATAGGTATAGAT 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
TCTAAATAATCACCCTATCCCCTC 
E -6k Enhancer 1 AGGAAGAGAGTTGTTGTTTGATTTTGAATATGAATAG 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
CTAAAAACCCCTAAAACAAAAAAA 
E -6k Enhancer 2 AGGAAGAGAGTTGTTTTTTTGTTTTAGGGGTTTTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAACCTTAACCTAACTTACACCCC 
E -6k Enhancer 3 AGGAAGAGAGGTAGGATTTGTTGGGAAAAAGGTAT 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
TAAACAAAAAAACCCCTTCTAACC 
E -6k Enhancer 4 AGGAAGAGAGGAGGTTTTGGTTTAGGTTTTTTTTG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CTACCTAACTTTAAATATAAACAATCACA 
E -6k Enhancer 5 AGGAAGAGAGGTTTAGGTTTTTTTTGATTGGGATT 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
AAAAAATAAATTTCTTCCCCTCCC 
E -6k Enhancer 6 AGGAAGAGAGTGTAATTTGTAATTATTGTTTTTTATGTGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
AATCTTCTCCCAACCTCCCTACTA 
E -6k Enhancer 7 AGGAAGAGAGTTTTTTGTGATAAAGGTTTGTAGTTGTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CCAAACCAAAACCTCCTCAATAC 
E -6k Enhancer 8 AGGAAGAGAGGGAGTGGAGATTTTTTGGTTTTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AACCTTTAAACTCAACCCTTACTTTT 
E 156k Enhancer 1 AGGAAGAGAGTGGGTTAAATTTAGTTTTATGTTGTTG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CTTTAAAACACTTTAAACTCCCTTCC 
E 156k Enhancer 2 AGGAAGAGAGTGTTTTTTAGGTTGGAGTATAGTGA 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
CACCTTAACCTCCCAAAATACTAA 
E 156k Enhancer 3 AGGAAGAGAGATTATTTTGGTTGGTTAGGTTGGTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CCTTCCAAAAATAAAATACCCAAAA 
E 156k Enhancer 4 AGGAAGAGAGGTTTTTAATAGTTTTTGGAAATAAAGATAG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
ACTCACACCTATAATCTCAACACTTT 
E 156k Enhancer 5 AGGAAGAGAGGGTTGGATGAGAAAATATGTGTATATAATG 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
ATAAACCAAATCCAACTCCATATT 
E 156k Enhancer 6 AGGAAGAGAGTTGGTTTTTTATGTTGGTTGTAAAAA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
ATAAAACCCTATCTCTACTAAAAATTCAA 
E 156k Enhancer 7 AGGAAGAGAGAAGAAATAGTTTTATTTTAGGTTAGGAAA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AACTCAAACAATCCTCCTACCTC 
E Ele4h Enhancer 1 AGGAAGAGAGTTAATTTTAGAGAATAGGGAGAGGGA 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
CACAAAATAACAAAACTACCACAAA 
E Ele4h Enhancer 2 AGGAAGAGAGTTTGTGGTAGTTTTGTTATTTTGTGA 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
TTTCTAAAACAACCTTTCTTTTTCC 
E Ele4h Enhancer 3 AGGAAGAGAGGTTTTGGTGAGGGTTTTTTTT CAGTAATACGACTCACTATAGGGAGAAGGCTTAACTCCCTATTCAACTCTCCTCTC 
E Ele4h Enhancer 4 AGGAAGAGAGTTTGGTATTAGTAGATTGGGAATTG 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
TTCTCCAACAAAACAAAACCTAAC 
E Ele4h Enhancer 5 AGGAAGAGAGTTTTGGTATTAGTAGATTGGGAATTGT 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
CCACCTCTAAACACAAAAAACTT 
E Ete1 Enhancer 1 AGGAAGAGAGGTTGTAGATTTGGGAATAGGTAGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
AACCAAATTTAAAAATCACCCTCT 
E Ete1 Enhancer 2 AGGAAGAGAGTTTATGATTGGAGGAGAAGGTTTAT 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
ATCCCCTTAATAAATCAAAAAAAA 
E Ete1 Enhancer 3 AGGAAGAGAGTGGAAGTTTATTTTTAGGAGTGGAA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CCTAAACACCCTCTTTTCTTATCATTA 
E Ete1 Enhancer 4 AGGAAGAGAGGGTAGGGGAAGTGGTAGATTTGAT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CCCAAAAAAATAACTAACCAACCT 
E Ete1 Enhancer 5 AGGAAGAGAGATTTTTGTTTTGGTTTTTTTTGGTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
CCTTTAAAACTTCCCTCTTAAAAA 
E Ete1 Enhancer 6 AGGAAGAGAGTTTTTAAGAGGGAAGTTTTAAAGGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
ATCTCCATTCCAAAATAACCAAAC 
E Ete1 Enhancer 7 AGGAAGAGAGGGTTTGTAGGATATTGATTTGTTGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAAACTAACCCTAAAACCCTCCTC 
E Ete1 Enhancer 8 AGGAAGAGAGGGTTGTTAGTTTGGGTGGTGTTAT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
ATTAAAACAAACTATTCCCAACCC 
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E Ete1 Enhancer 9 AGGAAGAGAGTTTTTTTATAGAATTTGGATGATTGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
CTCACAAAAAATAACTTCCAAACC 
E Ete1 Enhancer 10 AGGAAGAGAGTTTAGTTATTTGTGATAGGTGTTGGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAATCTAAATAATAATTCCAATCATCCA 
E Ete1 Enhancer 11 AGGAAGAGAGTTTTTTAGGTTTTTTGGGAGTATTTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAAAAAATCCACTTCCCACTAC 
E Ete1 Enhancer 12 AGGAAGAGAGTGTTTTTTTAGTGAGTTAGGGAAGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAATCCCAACACCTATCACAAAT 
E Ete1 Enhancer 13 AGGAAGAGAGGGTTGTAAAGTGTAGATGGTTGGAT 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
CCTTCCCTAACTCACTAAAAAAAC 
E Ete1 Enhancer 14 AGGAAGAGAGGTTTTGAGTTGGGAGTAGGGG CAGTAATACGACTCACTATAGGGAGAAGGCTATCCAACCATCTACACTTTACAACC 
E Ete1 Enhancer 15 AGGAAGAGAGGGATTATGGTAAGGTTTAGGTTTAGA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CCAAAAAACAACTCCAAACAAC 
E P1 Promoter E1 
Enhancer 1 
AGGAAGAGAGGGGTGTAAGTTTTTGTGTTGT
TTTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CCTCTCCAACCAAAACTATACCTC 
E P1 Promoter E1 
Enhancer 2 
AGGAAGAGAGGAGGTATAGTTTTGGTTGGAG
AGGT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
ATAAAACACACACACACACACACA 
E P1 Promoter E1 
Enhancer 3 
AGGAAGAGAGGGTAGGGAGGTTGAAATGAAG
TAGT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CCCCACCTCTAACTAAAACC 
E P1 Promoter E1 
Enhancer 4 
AGGAAGAGAGTTGGAGGATGATGATAGAGGT
TAGGT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAACATCCTTTCTAATTATCACAACTTC 
E P1 Promoter E1 
Enhancer 5 
AGGAAGAGAGTTGTTTTGTATAAAGTAATAT
TTTGTGTGA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAAATAACTACAACCAACACACCT 
E P1 Promoter E1 
Enhancer 6 
AGGAAGAGAGGGTGAGGATTTTTTAGGGTTT
TTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
ATCCTTTCTTACCAACTCCAAAAC 
E P1 Promoter E1 
Enhancer 7 
AGGAAGAGAGGGTGAGGATTTTTTAGGGTTT
TTTA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
TCCTAACAACTCCATTCCAACTAC 
E P1 Promoter E1 
Enhancer 8 
AGGAAGAGAGGGATTGAGTAGATTTAGGAGA
GGGA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAAACACAACTCTAACTAAAAAAACCC 
E P1 Promoter E1 
Enhancer 9 
AGGAAGAGAGTTTTGGTAATAGTTGAAGGGG
AGTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
AAAAAACCCTAAAAAATCCTCACC 
E P1 Promoter E1 
Enhancer 10 
AGGAAGAGAGGTTTTGTTTTGGGGTGTGTAT
AGTA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AACAACTCCCCTTCAACTATTACC 
E P1 Promoter E1 
Enhancer 11 
AGGAAGAGAGGGTTGTTGGGTTTTAGGTAGG
AA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AACACACCTCAATACACTCCAAAA 
GAPDH Promoter 1 AGGAAGAGAGTTTAGAAAGGTAGGGTTAGGGATTG 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
AATATACCTTTCATTCCATCCAAC 
GAPDH Promoter 2 AGGAAGAGAGGTTGGATGGAATGAAAGGTATATTG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AACAAAAACCTAAAAAAAACCCAT 
GAPDH Promoter 3 AGGAAGAGAGGAGATGTTAGGAGTTAGGAGATGGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
CCCAAAACTAAACTATAAACAACAAAA 
OCT4 Promoter 1 AGGAAGAGAGGATTAGATTTTGGATTGATTGGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
ATTAAAAAACAAAAAACAATCCCC 
OCT4 Promoter 2 AGGAAGAGAGTGTTTTTTAGGAATTTAGGTGTTTGA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAAAAAATAAAAACCAACCCCTT 
OCT4 Promoter 3 AGGAAGAGAGGTTTAATGGTGGTGGTAATGGTGTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CAAAACCTAAAAAAATACCAAAAA 
NANOG Promoter 1 AGGAAGAGAGTGTGGGAGTAAAGTTAGTTGTTTTG 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
ATCTATCCCTCCTCCCAAATAATC 
NANOG Promoter 2 AGGAAGAGAGTTTTTGTATTTTGTTTTTGGGTTTG 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
TTAATAACCTTAACAACCCCCACT 
NANOG Promoter 3 AGGAAGAGAGAATTTTTTGAATTTGGGAGGTAGAG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAAAACATAACAAATCACCAAACC 
NANOG Promoter 4 AGGAAGAGAGGGGTATATTTTTTATTGATTTATTTTTGTG 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
AACTAAAACTACAAACACCCACCA 
SOX2 Promoter 1 AGGAAGAGAGAAAGATTTTAATAAGAGAGTGGAAGGAA 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
ACAAAACCAACCCTAACATTTTC 
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Table 2.4 
(Continued) 
  
SOX2 Promoter 2 AGGAAGAGAGGTGGGATGTTAGGAAGTTGAAATTAT 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
TAAAAAACCCAAACCTCTATCCTC 
SOX2 Promoter 3 AGGAAGAGAGGGATAGAGGTTTGGGTTTTTTAATTT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AACCAACCTACCAACCACTAAAA 
FOXA2 Promoter 1 AGGAAGAGAGTGGTTTGGATATTTTATAAAGAGGGT 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
AAATAAACACCCACATAAACTCACA  
FOXA2 Promoter 2 AGGAAGAGAGTTTTTATTTTGTTTTTGGGTGGAA 
CAGTAATACGACTCACTATAGGGAGAAGGCTC
CTAAAAATTAAAACTCCAAAAAAACC 
FOXA2 Promoter 3 AGGAAGAGAGTGTAGATTTGAGAGTTTTGGGGTTA 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
CTCTATCCTCTCTATCTTCCAAAAAA 
FOXA2 Promoter 4 AGGAAGAGAGTTTAATAAAATGGAAAGGGAAGGGT 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
AAAACCCCAACCCCTAAATTCTAC 
FOXG1 Promoter 1 AGGAAGAGAGTAATTGGATTAGGTTTAAAAATGGAA 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
TAACAAAAACCCCTAAAACTCTCC 
FOXG1 Promoter 2 AGGAAGAGAGGGAGTTGTAGGTTGTTAGTGGTTGT 
CAGTAATACGACTCACTATAGGGAGAAGGCTT
ATCAAAACCTTCTCCTCATCCTTA 
FOXG1 Promoter 3 AGGAAGAGAGGGGAGTGAGGAGATTTTATATAGAGG 
CAGTAATACGACTCACTATAGGGAGAAGGCTA
CAACCACTAACAACCTACAACTCC 
 
Table 2.5. Genomic Coordinates for Promoters and Enhancers 
 
Region Genomic Coordinates (GRCh37/hg19) 
PAX6 P0 Promoter Chr11: 31839283-31840731 
PAX6 P1 Promoter Chr11: 31832705-31834156 
PAX6 156k Enhancer Chr11: 31679370-31690371 
PAX6 Ele4h Enhancer Chr11: 31825691-31825906 
PAX6 E1E Enhancer Chr11: 31832708-31832765 
PAX6 Ete1 Enhancer Chr11: 31837446-31839211 
PAX6 -6k Enhancer Chr11: 31847524-31848122 
SOX10 Promoter Chr22: 38380465-38381233 
LEFTY2 Promoter Chr1: 226129154-226131027 
LEFTY2 Enhancer proximal Chr1: 226132079-226134622 
LEFTY2 Enhancer distal Chr1: 226138153-226139319 
GAPDH Promoter Chr12: 6642271-6643589 
OCT4 Promoter Chr6: 31138570-31139891 
NANOG Promoter Chr12: 7940446-7941959 
SOX2 Promoter Chr3: 181428186-181429721 
FOXA2 Promoter Chr20: 22566291-22567649 
FOXG1 Promoter Chr14: 29233677-29234801 
SOX17 Promoter Chr8: 55369986-55370476 
GATA2 Promoter Chr3: 128211937-128212937 
GATA6 Promoter Chr18: 19747670-19749477 
 
2.4.15 PAX6 Overexpression Lentivirus Construct and Generation of 
PAX6 Overexpression hESCs 
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To generate the PAX6 overexpression construct PAX6 cDNA from 
D10 of WT NE differentiation was tagged with a 2A-GFP sequence and 
inserted into a lentiviral backbone. The 2A-GFP sequence was amplified 
from the OCT4-eGFP-PGK-Puro plasmid (Addgene, plasmid # 31937) using 
primers that contain BamHI (Forward) and AscI sites (Reverse). The PAX6 
cDNA PCR product was cloned into the pENTR-dTOPO vector (Thermo 
Fisher Scientific, K240020). Digestion of the PAX6-pENTR-dTOPO vector 
and the 2A-GFP PCR product with BamHI and Asc1 was followed with 
ligation to form the PAX6-2A-GFP-pENTR-dTOPO vector. The PAX6-2A-
GFP insert was then transferred into a doxycycline inducible lentiviral 
backbone through a LR reaction. Primers used for cloning are listed in Table 
2.6. 
 
Table 2.6. Primers for cloning PAX6 overexpression vector, dCas9 
TET1 catalytic domain fusion (dCas9-TET1CD) and mutagenesis of 
dCas9-TET1CD 
 
 
2.4.16 Colony Forming Assay 
hESC cells were washed with PBS, treated with TrypLE for 5min at 
37°C, then collected with fresh hESC medium, passed through a 40um cell 
strainer to make sure cells were single cells, and then counted. Five 
thousand cells were plated in a 10cm dish previously coated with iMEF with 
Cloning Construct Forward Primer Reverse Primer 
2A-GFP construct GGATCCGCCACTAACTTCTCCC
TGT 
GGCGCGCCTTACTTGTACAGCT
CGTCCAT 
PAX6 cDNA construct CACCGAATTCATGCAGAACAGT
CACAGCGGA 
GGATCCCTGTAATCTTGGCCAG
TATTG 
TET1 catalytic domain 
(for dCas9-TET1CD) 
ACTGAGGCCGGCCAGCTGCCCA
CCTGCAGCTGTCTT 
TTCTTGGCCGGCCTCAGACCCA
ATGGTTATAGG 
TET1 catalytic domain 
mutagenesis 
GGACTTCTGTGCTCATCCCTAC
AGGGCCATTCACAACAT 
ATGTTGTGAATGGCCCTGTAGG
GATGAGCACAGAAGTCC 
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Rock inhibitor. Cell were grown for two weeks, then stained with alkaline 
phosphatase (AP) and counted.   
 
2.4.17 Cloning dCas9 TET1 Catalytic Domain Fusion and Site-Directed 
Mutagenesis 
The TET1 catalytic domain was amplified using forward and reverse 
primers that contain the Fse1 restriction site from the pJFA274 plasmid 
(Addgene, plasmid # 49239). This PCR product was then digested with 
Fse1. The dCas9-krab construct was cloned from the pHR-SFFV-dCas9-
BFP-KRAB plasmid (Addgene, Plasmid # 46911) into the pENTR-dTOPO 
vector (Thermo Fisher Scientific, K240020). The KRAB protein was removed 
by Fse1 digestion and the Fse1-digested TET1 catalytic domain PCR 
product was ligated to produce the dCas9-TET1 catalytic domain fusion 
vector (dCas9-TET1CD). This cloning was performed by Abhijit Shukla. 
Primers used for cloning are listed in Table 2.6.  
 The TET1 catalytic domain, from the dCas9 TET1 catalytic domain 
fusion vector (described above), was mutated at two sites (H1671A and 
D1673A) to produce a catalytic null control (dCas9-TET1CDmut). 
Mutagenesis was performed using the QuikChange II XL Site-Directed 
Mutagenesis kit (Agilent Technologies, 200521) according to the 
manufacturer’s protocol. The primers used for mutagenesis are in Table 2.6. 
 
2.4.18 Targeting dCas9-TET1CD into TKO hESCs 
The dCas9-TET1CD was cloned into the pINDUCER lentiviral 
backbone (Addgene, Plasmid # 46948) under the control of doxycycline 
inducible promoter. This lentiviral backbone also constitutively expresses 
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GFP, which allows us to isolate infected cells. Prior to infection of TKO 
hESCs with pINDUCER-dCas9-TET1CD, the already AAVS1-integrated 
Cas9 was inactivated through CRISPR targeting of the beginning of the 
Cas9 protein (Figure 2.19A). The gRNA used to inactivate Cas9 is listed in 
Supplementary Table 1. Knockout of Cas9 was confirmed using RT-qPCR 
(Figure 2.19C, performed by Bobbie Pelham-Weber), western blot (Figure 
2.19D, performed by Virginia Teijeiro) and T7 Endonuclease assay (Figure 
2.19E, performed by Bobbie Pelham-Weber). Cas9 knockout clones were 
isolated and infected with virus containing the pINDUCER-dCas9-TET1CD 
construct. Infected cells were isolated by FACS sorting of GFP-positive 
cells. These cells were expanded and frozen down. 
 After identifying a CRISPR gRNAs that produce demethylation at the 
PAX6 P0 promoter, SOX10 promoter and LEFTY2 enhancer we cloned 
these CRISPR gRNAs into the piCRg Entry vector (Addgene, Plasmid # 
58904). For the PAX6 P0 promoter we identified 3 gRNAs (Cr6, Cr7, Cr9) 
that were able to produce demethylation. We also cloned a gRNA that 
targets the HBB promoter into the piCRg Entry vector as a non-targeting 
control. We performed golden gate cloning to attach the gRNAs together in 
tandem. An LR reaction (Thermo Fisher Scientific, 11791100) was then 
performed to transfer the U6 promoter and either the tandem array of Cr6, 
Cr7 and Cr9 gRNAs for the PAX6 P0 promoter or the individual gRNAs for 
SOX10 and LEFTY2 into a lentiviral backbone containing a hygromycin 
selection cassette. TKO hESCs containing the dCas9-TET1CD were then 
infected by the lentivirus. Infected cells were isolated by 4 days of 
hygromycin selection (40 μg/mL) and then amplified and frozen down. As 
described in the text targeted clones were treated with doxycycline for 10 
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days prior to methylation analysis and RNA expression analysis at the hESC 
stage. For PAX6 and SOX10 targeted demethylation the cells were also 
differentiated using the standard NE differentiation protocol. 
 
2.4.19 Generation of TET1-3xFlag tagged hESCs 
We targeted the TET1 N-terminus to generate a TET1-3xFlag line. 4 
gRNAs were tested and gRNA 2, which showed the greatest efficiency was 
used for targeting (Appendix 1A). A 200 base pair single strand DNA donor 
in which a 69 base pair 3xFlag sequence is inserted immediately after the 
ATG start and separated from the rest of the coding sequence using a 12 
base pair linker sequence. Targeted clones were identified using PCR 
primers that flank the target site (Appendix 1B). Clones were sequenced to 
verify there were no mutations in the coding sequence on both TET1 alleles 
(Appendix 1C) and an immunoprecipitation was performed to ensure that 
immunoprecipitation of the Flag tag leads to an increase in the overlapping 
band of TET1 (Appendix 1D).  
 
2.4.20 ChIP-qPCR 
Confluent hESCs from a 100 mm dish were used for 2 
immunoprecipitations. ChIP was performed using the SimpleChIP Plus 
Enzymatic Chromatin IP kit (Cell Signaling Technology, 9003S) according to 
the manufacturer protocols. The antibodies used for ChIP were: H3 (Cell 
Signaling Technology, 9003S), IgG (Cell Signaling Technology, 9003S), 
TET1 (Genetex, GTX627420), DNMT1 (Active Motif, 39204). DNMT3A 
(Abcam, ab2850), and DNMT3B (Novus Biologicals, NB100-56514). Primers 
for ChIP-qPCR are provided in Table 2.3. 
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2.4.21 Statistical Analysis 
Data are presented as mean ± STD (unless otherwise noted) and 
were derived from at least three independent experiments. Data on 
replicates (n) is given in figure legends. Statistical analysis was performed 
using the Student’s t-test (comparing two groups) or one-way comparison 
ANOVA (comparing multiple groups against one group). Variance was 
similar between the groups that are being compared. Distribution of the raw 
data approximated normal distribution (Kolmogorov–Smirnov normality test) 
for data with sufficient number of replicates to test for normality. No method 
of randomization was performed and investigators were not blinded to the 
genotypes of cell lines. Statistical analysis for whole genome bisulfite 
sequencing, ERRBS and RNA-Seq data are described in those separate 
methods section. 
 
2.4.22 Data Availability 
All sequencing datasets are available under the Gene Expression 
Omnibus accession GSE89728. 
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CHAPTER 3: Conclusions & Perspectives 
  
3.1    SUMMARY 
The TET proteins (TET1, TET2 and TET3) catalyze the oxidation of 
5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which can 
serve as an intermediate in DNA demethylation. Previous studies have 
focused on TET action at enhancers and found clear examples in which loss 
of the TET proteins causes hypermethylation and dysregulated gene 
expression. However, the importance of TET activity at promoters remains 
ambiguous. Bivalent promoters have the H3K4me3 and H3K27me3 marks 
on the same or adjacent nucleosomes. They are present in embryonic stem 
cells and adult stem cells, and they typically regulate developmental genes. 
Similar to active promoters, bivalent promoters are hypomethylated; 
however, unlike active promoters, which support productive gene 
transcription, the hypomethylated state at bivalent promoters is associated 
with negligible gene transcription. Thus at bivalent promoters the importance 
of DNA methylation for gene expression regulation is not readily apparent. 
Moreover it is unclear if the DNA methylation state of these promoters is 
actively regulated and whether this regulation is necessary to maintain 
developmental regulators in a “poised state”. 
 
The key findings from this project were: 
 
1. TET inactivation leads to hypermethylation of bivalent 
promoters in human embryonic stem cells. We inactivated the 
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TET genes in hESCs (TKO hESCs) and observed by whole 
genome bisulfite sequencing (WGBS) that bivalent promoters 
showed the greatest methylation increase compared to other 
genomic regions. Furthermore enhanced reduced representation 
bisulfite sequencing (ERRBS) in two independent TKO lines 
showed that a similar subset of approximately half of bivalent 
promoters become hypermethylated after loss of the TET 
proteins.  
2. Hypermethylation of bivalent promoters leads to gene 
repression upon differentiation. The consequences of bivalent 
promoter hypermethylation on gene transcription are not known. 
At the hESC stage, in which expression of bivalent genes is low, 
we observed that some hypermethylated bivalent genes showed 
variable changes (both up and down) in gene expression. Upon 
differentiation hypermethylated bivalent genes (PAX6, SOX10) 
critical for the neural lineage failed to be expressed leading to 
defects in differentiation. 
3. Loss of TET1 and 5hmC is directly responsible for 
hypermethylation at bivalent promoters. TET1 ChIP-Seq and 
global 5hmC profiling showed that TET1 and 5hmC localize to 
bivalent promoters in WT cells. Furthermore TET1 and 5hmC 
positive sites overlapped significantly with hypermethylation after 
TET inactivation. 
4. The de novo methyltransferase DNMT3B is responsible for 
the gain of methylation in bivalent promoters. 57% of the 
regions that gained methylation in TKO hESCs lost methylation 
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after inactivation of DNMT3B in TKO hESCs. Furthermore ChIP-
Seq of DNMT3B in TKO hESCs showed that DNMT3B binding 
correlated with a greater methylation increase in TKO hESCs and 
greater methylation loss in QKO (TET1/2/3 TKO, DNMT3B KO) 
hESCs. 
 
Whereas previous work has focused on the bivalent histone marks for 
regulating gene expression from bivalent promoters this project showed that 
the methylation of bivalent promoters is also actively regulated and 
significantly impacts gene expression upon differentiation. This also 
expands the functional role of the TET proteins during development. 
Besides their documented function in the active demethylation of enhancers 
we show here that they are also critical to maintain hypomethylation at 
bivalent promoters.  
 
3.2    FUTURE DIRECTIONS 
 
3.2.1 Identify Proteins that may be Involved in the Recruitment of 
DNMT3B and TET1 to Bivalent Promoters 
It is unclear why certain genomic loci are more prone to dynamic 
changes in DNA methylation and what are the molecular mechanisms that 
underlie competition between the TET and DNMT proteins to determine 
methylation levels at these loci. Focusing specifically on bivalent promoters 
it would be interesting to determine whether recruitment of the TET and 
DNMT proteins by a third protein may explain the competition between TET 
and DNMT (Appendix 2A). The first candidate we chose to study is the 
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polycomb repressive complex, PRC2. PRC2 itself is present at bivalent loci 
as it is responsible for deposition of the H3K27me3 mark. Furthermore 
previous studies have found interaction between PRC2 and TET1 and 
PRC2 and DNMT3A/DNMT3B in mESCs (Neri et al., 2013a; Neri et al., 
2013b). We generated a 3x flag tagged TET1 hESC line to first perform co-
immunoprecipitation experiments (Appendix 2B). We detected interaction 
between PRC2 and DNMT3B but limited interaction between PRC2 and 
TET1 (Appendix 2C). It is possible that TET1 is recruited by another protein 
instead of PRC2. It would thus be useful to perform mass spectrometry 
analysis of the 3xFlag-TET1 line to identify potential interacting partners that 
may function to recruit TET1 to specific genomic regions. 
We decided to investigate further the interaction between PRC2 and 
DNMT3B. We had already observed that inactivating DNMT3B in the TKO 
background reduced methylation at bivalent loci, among other regions. We 
wanted to determine whether inactivation of PRC2 in the TKO background 
might provide more precise loss of DNA hypermethylation at bivalent 
promoters as it may abrogate DNMT3B recruitment specifically to these 
regions. We decided to target two different components of PRC2, the 
catalytic component EZH2 and the DNA binding component SUZ12. We 
generated CRISPRs that could produce indel mutations at the start codons 
of both EZH2 and SUZ12; however, upon targeting we obtained few clones 
that had frameshift mutations in both alleles (Appendix 3A). It is possible 
that inactivating EZH2 has a lethal phenotype as suggested by previous 
studies (Collinson et al., 2016). We continued to culture the WT and TKO 
lines that showed frameshift mutations in both alleles of SUZ12. 
Unfortunately upon further sequencing we found that the mutations in all of 
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the lines lie in a SUZ12 pseudogene that shares the first 12 exons of the 
functioning SUZ12 gene (Appendix 3B). We are currently generating 
additional targeting CRISPR gRNAs, to reattempt the inactivation of SUZ12 
in the TKO background. We aim to identify interacting partners of TET1 and 
DNMT3B and determine whether they function to recruit these proteins to 
bivalent promoters. This may explain the specificity of hypermethylation that 
we observe in TKO hESCs. 
 
3.2.2 Investigate Changes in Chromatin Environment Upon TET 
Inactivation 
We focused on changes in DNA methylation upon inactivation of the 
TET genes. It is likely however that there are additional changes in the 
chromatin as there is significant crosstalk between DNA methylation and 
other epigenetic modifications. We aim to investigate this further using 
genome-wide ChIP-Seq analysis in WT and TKO hESCs to determine 
whether the distribution of certain histone marks (H3K4me1, H3K4me3, 
H3K27me3, H3K27ac) and chromatin modifiers (EZH1, SUZ12, DNMT1, 
DNMT3A) are altered upon TET inactivation. We will also perform ATAC-
Seq to determine if there are changes in the chromatin accessibility for 
biologically relevant loci. 
 
3.2.3 Investigate the Mechanisms Underlying Heterogeneity in the 
Gain of Methylation after TET Inactivation 
Among bivalent promoters we observed large variability in the gain of 
methylation. Approximately half of the bivalent promoters in two hESC 
backgrounds showed greater than 5% increase in methylation between TKO 
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and WT lines, and among these approximately 10% showed a greater than 
60% increase in methylation. It would be interesting to explore why these 
particular promoters were vulnerable to such large increases in methylation. 
It is possible that transcription factor binding, local chromatin environment or 
chromatin 3D structure or configuration may influence whether a particular 
locus is protected from or vulnerable to aberrant hypermethylation. The TKO 
hESCs offer a useful platform as we could manipulate these variables in 
TKO hESCs to explore whether we can cause hypermethylation at 
previously resistant loci. 
 
3.2.4 Investigate Hypermethylation Patterns and Consequences in 
Other Progenitor Populations Upon TET Inactivation 
It is unclear whether the observations we made at the hESC stage 
regarding the hypermethylation of bivalent promoters is also observed in 
other progenitor cell types. Furthermore it is unknown whether 
hypermethylation at bivalent promoters in other progenitors would also 
produce differentiation defects due to impaired activation of the 
differentiation genes associated with these promoters. hESCs are an ideal 
platform to study this question because they have the potential to 
differentiate into a variety of tissues. We are currently working on an 
inducible system that would enable us to immediately inactivate the TET 
genes at different stages of differentiation and thus observe the effect of the 
loss of the TET proteins in different cellular contexts. In our first attempt to 
generate such a platform we infected our iCRISPR hESCs (in which Cas9 is 
doxycycline inducible) with a lentiviral construct containing the three TET 
gRNAs in tandem, each under the control of its own individual U6 promoter 
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(Appendix 4A). After establishing one clone we found that doxycycline 
treatment led to progressive depletion of 5hmC, consistent with the loss of 
the TET proteins (Appendix 4B). Upon T7 endonuclease analysis we found 
that indel mutations were generated in the TET1 and TET3 loci, but not at 
the TET2 locus (Appendix 4C). We are currently investigating why there is 
no functional TET2 gRNA and exploring alternative strategies to develop a 
true inducible TKO line. 
We believe the question of whether our observations are reproducible 
in other progenitor cells is particularly important due to the prevalence of 
mutations in the DNA methylation and demethylation pathways in a variety 
of cancers. Ideally we would want to investigate cell populations that are 
particularly prone to transformation upon disruption of TET or TET-
interacting pathways, such as hematopoietic stem cells and neural stem 
cells. A better understanding of the molecular mechanisms that drive cancer 
progression could potentially enable the design of more efficacious 
therapeutics. 
 
3.3     CONCLUSIONS 
 
The TET enzymes oxidize 5-methylcytosine to 5-hydroxymethylcytosine, 
which can lead to DNA demethylation. Previous studies in mice and mESCs 
have suggested that the TET proteins are critical for proper embryonic 
development and differentiation. However, the mechanisms underlying 
these defects have proven elusive to isolate. It is also unclear whether 
observations found in mice and mESCs will be similar in studies using 
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hESCs. Finally the mechanisms that produce this locus specific 
hypermethylation and the factors that lead to the variable gain of methylation 
between loci are unknown. 
Here we show that we can produce viable hESCs after TET inactivation. 
Although the TKO hESCs do not show a global methylation change they do 
exhibit prominent bivalent promoter hypermethylation without overall 
corresponding gene expression decrease in the undifferentiated state. 
Focusing on the bivalent PAX6 locus, we find that TET1 binding and 5hmC 
signal present at the P0 promoter in WT hESCs is lost in TKO hESCs. 
Instead TKO hESCs show increased DNMT3B binding that is associated 
with PAX6 P0 promoter hypermethylation, which then precipitates a neural 
differentiation defect and failure of PAX6 induction during differentiation. 
Using recently developed targeted demethylation strategies we can achieve 
locus-specific demethylation of the PAX6 P0 promoter, which improves 
expression of PAX6 after differentiation. Furthermore global inactivation of 
DNMT3B in TKO hESCs partially reverses the hypermethylation at the 
PAX6 promoter and improves differentiation to neuroectoderm. Notably we 
found that approximately 90% of the bivalent promoters that gained 
methylation after TET inactivation lose methylation upon depletion of 
DNMT3B. This suggests that DNMT3B is responsible for the gain of 
methylation at these bivalent promoters and is even acting to preserve this 
aberrant hypermethylation during hESC culture.  
Finally TET1 and 5hmC ChIP-Seq showed that TET1 or 5hmC is found 
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in approximately 90% of the bivalent promoters that gain methylation in TKO 
hESCs. This indicates that the hypermethylation at bivalent promoters is the 
direct consequence of losing TET1 and 5hmC. Although DNMT3B ChIP-Seq 
showed limited binding of DNMT3B to promoters, we did find that DNMT3B 
binding correlates with gain of methylation after TET inactivation. We are 
currently exploring ways in which DNMT3B may be recruited to bivalent 
promoters and investigating whether technical limitations with ChIP-Seq 
prevented us from detecting these events. 
 Taken together we observed that TKO hESCs show significant bivalent 
promoter hypermethylation. Using the bivalent PAX6 P0 promoter we found 
that this is associated with reduced gene expression of the associated gene 
upon differentiation. This hypermethylation is lost, both at the PAX6 
promoter and bivalent promoters in general, upon inactivation of DNMT3B. 
Finally this hypermethylation in TKO hESCs correlates with TET1 binding in 
WT cells and DNMT3B binding in TKO hESCs. From these results we 
conclude that TET proteins safeguard bivalent promoters from silencing by 
de novo methylation to ensure robust lineage-specific transcription upon 
differentiation.  
 
 
 
 
 
CHAPTER 4: Generation of Pluripotency Reporter hESCs 
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4.1  INTRODUCTION 	
Human embryonic stem cells (hESCs) are capable of unlimited self-
renewal in culture while maintaining the potential to differentiate into any cell 
type present in the human body and thus provide researchers great 
opportunities for human developmental studies, disease modeling, and cell-
replacement therapies (Zhu and Huangfu, 2013). All these applications 
benefit from lineage-specific knockin reporters that allow real-time 
observation of gene-expression dynamics, cell-lineage tracing, and isolation 
of a specific cell population of interest from a heterogeneous differentiation 
culture for downstream analysis. However, creating knockin alleles in 
hESCs is usually a lengthy and technically challenging process. Because of 
the low efficiency of homologous recombination, the donor vector needs to 
contain a drug-resistance gene for enrichment of cells with the correct 
integration. Due to the concern that the insertion of a drug-resistance 
cassette may interfere with the expression of the reporter gene or 
neighboring genes, it is usually necessary to remove the drug-resistance 
cassette through a second electroporation step followed by isolation of 
clonal lines and further characterization (Davis et al., 2008). Thus, 
substantial time and effort is needed to generate a knockin reporter hESC 
line through this two-step procedure. 
The development of engineered “genomic scissors” that introduce 
site-specific DNA double-strand breaks (DSBs), including zinc finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), 
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and more recently the clustered regularly interspaced short palindromic 
repeat (CRISPR)/CRISPR-associated (Cas) system, has greatly facilitated 
gene targeting in hESCs (Kim and Kim, 2014). Repair of a DSB by non-
homologous end joining (NHEJ) often results in insertion and/or deletions 
(indels) that can be used to knock out a target gene in hESCs (Ding et al., 
2013a; Ding et al., 2013b; Gonzalez et al., 2014). Alternatively, homology-
directed repair (HDR) can be employed to efficiently incorporate exogenous 
sequences such as a fluorescent reporter into a specific genomic locus in 
hESCs (Hockemeyer et al., 2009; Hockemeyer et al., 2011; Merkert et al., 
2014). Despite the significant improvement, a drug-resistance cassette is 
still required for generating knockin reporters of genes that are not 
expressed in undifferentiated hESCs. 
To overcome these limitations, we made use of the CRISPR/Cas 
system, in which the CRISPR RNA (crRNA) and trans-activating crRNA 
(tracrRNA) duplex or a single chimeric guide RNA (gRNA) recognizes a 20-
nucleotide (nt) DNA sequence upstream of the 5′-NGG-3′ protospacer 
adjacent motif (PAM) and directs the DNA endonuclease Cas9 for site-
specific cleavage (Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013). 
Based on this, we have developed an efficient genome-editing platform in 
hESCs, which we named iCRISPR (Gonzalez et al., 2014). Through 
TALEN-mediated gene targeting in the AAVS1 locus, we have created 
hESC lines (referred to as iCas9 hESCs) that allow robust, doxycycline-
inducible expression of Cas9. By transfecting iCas9 hESCs with gRNAs, the 
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iCRISPR system enables efficient NHEJ-mediated gene disruption as well 
as HDR-mediated precise nucleotide modifications in the presence of short 
single-stranded DNA (ssDNA) donors (∼100 nt). 
We reasoned that the iCRISPR system would also facilitate the 
generation of knockin reporter alleles using longer double-stranded (dsDNA) 
donors and may further enable the identification of correctly targeted hESC 
lines without drug selection. Thus, this work explores the utility of iCRISPR 
for targeting fluorescent reporters into two endogenous loci, OCT4 
(POU5F1) and NANOG, and demonstrates the generation of knockin hESC 
lines without drug selection. Further characterization of the OCT4 (POU5F1) 
reporter lines confirmed the creation of multiple hESC reporter lines with no 
undesired mutations in the targeted loci or any potential off-target sites 
analyzed, supporting the broad application of this approach for efficient 
generation of knockin alleles in hESCs. 
 
4.2 RESULTS 
 
4.2.1 CRISPR/Cas-Mediated Targeting of the OCT4 Locus 
 
We first evaluated the efficiency of the CRISPR/Cas system for 
making knockin reporter alleles by targeting the OCT4 locus using drug 
selection. HUES8 hESCs were co-electroporated with two plasmids: one 
expressing Cas9 and a crRNA/tracrRNA duplex targeting OCT4 and the 
other containing the fluorescent reporter and a drug-resistance cassette as 
the HDR template (Appendix 5A). We used a donor plasmid, 2A-eGFP-
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PGK-Puro (Hockemeyer et al., 2011), in which the last OCT4 coding codon 
is fused in frame with a 2A sequence followed by eGFP (2A-eGFP) and a 
loxP-flanked (floxed) puromycin-resistance gene expressed from the 
constitutive PGK promoter (PGK-Puro) (Appendix 5A). This strategy 
minimizes any potential impact on the endogenous protein and is applicable 
to targeting both silent and expressed genes. CRISPR gRNAs that target 
the stop codon of OCT4 were cloned into the px260 vector (Appendix 5B) 
and then tested for efficiency in forming indel mutations (Appendix 5C). PCR 
and Southern blot analysis identified eight correctly targeted clones without 
random transgene integration from a total of 288 puromycin-resistant clones 
screened (Appendix 5D and Appendix 6A). The targeting efficiency (2.8%) 
was comparable to the efficiencies observed with TALENs and ZFNs using 
similar targeting strategies (Hockemeyer et al., 2009; Hockemeyer et al., 
2011). Despite correct targeting, we failed to detect eGFP expression in any 
of the targeted lines. This is likely caused by the presence of the drug-
resistance cassette as observed for other genes (Davis et al., 2008). Indeed, 
after Cre-mediated excision of the PGK-Puro cassette, all resulting OCT4-
eGFP lines showed proper co-expression of eGFP with pluripotency 
markers OCT4, SOX2, and NANOG (Appendix 6B-D). These results 
highlight the necessity of removing the drug-resistance cassette for proper 
reporter gene expression. 
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4.2.2 Selection-free Targeting of the OCT4 Locus using a Mini-vector 
Donor 
 
To further explore the possibility of making knockin reporter alleles 
without drug selection, we designed a “mini-vector” donor plasmid, 2A-
mOrange, which is similar to 2A-eGFP-PGK-Puro except that there is no 
PGK-Puro cassette and eGFP was replaced by mOrange (Appendix 7A). 
We also replaced the crRNA/tracrRNA duplex cr1-dp with the single gRNA 
cr1 targeting the same sequence (Appendix 7B), as the chimeric version 
works more efficiently than the original duplex design (Jinek et al., 2012). 
Similar to the experiment with the 2A-eGFP-PGK-Puro donor, we co-
electroporated HUES8 hESCs with a plasmid expressing Cas9/gRNA and 
the new 2A-mOrange mini-vector (Appendix 7A). In contrast to the absence 
of fluorescence after integration of the 2A-eGFP-PGK-Puro cassette, 
integration of the 2A-mOrange cassette resulted in mOrange expression in 
∼0.001% of cells as detected by fluorescence-activated cell sorting (FACS) 
(Appendix 7C). One may enrich mOrange-expressing cells for establishing 
OCT4 reporter lines. However, this low efficiency is impractical for genes not 
expressed in undifferentiated hESCs, as one has to rely on randomly picking 
individual colonies to establish clonal lines.  
Our recent study shows that the iCRISPR platform enables efficient 
gene editing using short ssDNA HDR templates (Gonzalez et al., 2014), 
prompting us to further optimize the iCRISPR platform for HDR using longer 
circular dsDNA donor vectors. After optimizing transfection conditions, we 
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co-transfected doxycycline-treated HUES8 iCas9 cells twice in 2 days with 
the OCT4 cr1 gRNA and the 2A-mOrange mini-vector using Lipofectamine 
3000 (Appendix 7D, Appendix 8A-B performed by Zhengrong Zhu). FACS 
analysis identified ∼0.4% mOrange-expressing cells from the HUES8 iCas9 
targeting and ~.24% mOrange-expressing cells from the MEL1 iCas9 
targeting (Appendix 7E), supporting the general utility of this new approach 
in diverse human pluripotent stem cell (hPSC) backgrounds. In contrast 
electroporation of the HUES8 iCas9 without doxycycline treatment did not 
show a detectable number of mOrange positive cells (Appendix 7F). The 
much-improved efficiencies can be partially attributed to the integration of 
Cas9 in the genome as a ∼5- to 6-fold increase of mOrange+ cells was 
observed compared to the control condition where iCas9 hESCs (not treated 
with doxycycline) were transfected with Cas9/gRNA and the donor vector 
using Lipofectamine 3000 (Appendix 7F). The use of Lipofectamine 
transfection also substantially increased the targeting efficiency compared to 
the electroporation method (Appendix 7E-F). There may be other ways to 
improve the transfection efficiency (e.g., through nucleofection) to achieve 
similar results with or without the use of iCas9 hESCs (Byrne et al., 2015). 
We picked ten colonies from individual FACS-isolated mOrange+ cells and 
identified six correctly targeted clones by PCR and Southern blot analysis 
(Appendix 9A-B). All six lines co-expressed mOrange with pluripotency 
markers such as OCT4, SOX2, and NANOG and displayed normal hESC 
morphology (Appendix 9C). We further examined the OCT4-mOrange hESC 
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reporter lines along with the OCT4-eGFP lines for reporter gene expression 
after differentiation. After 3 days of treatment with BMP4 and SB431542, a 
TGFβ inhibitor (Hou et al., 2013), hESCs exhibited a differentiated 
morphology, and eGFP and mOrange expression were downregulated in the 
respective OCT4-eGFP and OCT4-mOrange hESC reporter lines with 
concomitant loss of endogenous OCT4 expression as determined by 
immunostaining and FACS analysis (Appendix 10A-B). Thus, the OCT4-
eGFP and OCT4-mOrange reporters faithfully reflect endogenous gene 
expression during the maintenance and differentiation of hESCs. 
We next investigated whether the relatively high targeting efficiency 
was achieved at the expense of undesirable mutations at the OCT4 locus or 
any off-target sites. All eight OCT4-eGFP and six OCT4-mOrange lines 
examined showed the expected sequence at the junction between the 
endogenous OCT4 sequence and the inserted sequence. This is reassuring, 
as we made sure that the donor template did not contain the CRISPR target 
sequence to prevent undesired mutagenesis after reporter gene integration. 
However, Indel mutations were detected in the non-targeted allele in two of 
the six OCT4-mOrange reporter lines examined (Appendix 10C). These 
findings underscore the necessity of thorough sequence analysis for 
eliminating clones with undesired mutations in the non-targeted allele, a 
point not widely recognized with the CRISPR/Cas-mediated targeting 
strategy. We also sequenced seven predicted off-target sites based on the 
12-bp seed sequence important for target recognition (Jiang and Pugh, 
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2009; Jinek et al., 2012). Examination of six OCT4-mOrange and eight 
OCT4-eGFP lines revealed no mutations except that three OCT4-eGFP 
lines carried mutations at the POU5F1P4 locus, which shares the same 20-
nt target sequence with the intended target (Table 4.1). 
 
Table 4.1 Sequencing analysis of potential off-target sites in OCT4-
eGFP and OCT4-mOrange reporter lines  
Gene CRIPSR Target 
Sequence-PAM 
Sequencing results in  
OCT4-eGFP reporter lines 
 Sequencing 
results in 
OCT4-mOrange 
reporter lines 
1 2 4 5 6 7 9 1
0 
 3 5 6 7 8 1
0 
OCT4  TCTCCCATGCATTCAA
ACTG-AGG 
               
DLG2 AAGCTCAGGCATTCAA
ACTG-TGG 
- - - - - - - -  - - - - - - 
GPHN GCCCTCAGGCATTCA
AACTG-TGG 
- - - - - - - -  - - - - - - 
IMMP2L TAGACTTAGCATTCAA
ACTG-AGG 
- - - - - - - -  - - - - - - 
PEMT GCACCCTAGCATTCAA
ACTG-TGG 
- - - - - - - -  - - - - - - 
POLR2J
4 
AAGGAGAAGCATTCAA
ACTG-TGG 
- - - - - - - -  - - - - - - 
POU5F1
P4 
TCTCCCATGCATTCAA
ACTG-AGG 
- HE
T* 
- HOM
** 
- HOM*
** 
- -  - - - - - - 
SLC33A
1 
CAGAAATGGCATTCAA
ACTG-CGG 
- - - - - - - -  - - - - - - 
-: Both alleles are wild-type; HET: One allele has a mutation; HOM: Both alleles have 
mutations; 
* 6 bp insertion; ** 4 bp deletion; *** 10 bp deletion. 
 
 
4.2.3 Selection-free Targeting of the NANOG Locus using a Mini-
vector Donor 
Finally we targeted the NANOG locus to generate an individual 
NANOG reporter line and a dual reporter, which has fluorescent proteins, 
targeted to both the OCT4 and NANOG loci. For the OCT4 locus we 
continued to use the 2A-mOrange mini-vector that we previously used 
(Appendix 7A). For the NANOG locus we designed a mini-vector donor 
plasmid, 2A-ppGFP, which does not have a drug selection cassette and in 
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which the 2A-ppGFP is flanked by sequences homologous to the NANOG 
loci (Appendix 11A). We tested a number of CRISPR gRNAs that target the 
stop codon of NANOG and identified 3 that efficiently produced indel 
mutations (Appendix 11B). CRISPR gRNA 330-1 was used for targeting 
experiments. We tested whether we could target 2A-mOrange and 2A-
ppGFP into the OCT4 and NANOG loci respectively using a single 
transfection that includes OCT4 and NANOG targeting gRNAs and donor 
vectors. Unfortunately upon FACS Analysis we did not observe any 
mOrange and ppGFP double positive cells indicating that the procedure is 
not efficient enough for two integration events in a single cell (Appendix 
11C). We decided to isolate GFP positive cells to expand. These cells would 
be used as single NANOG-ppGFP reporters and also used for OCT4 2A-
mOrange targeting to produce a dual reporter cell line. Genomic DNA for 
one such GFP positive clone was isolated and upon sequencing it showed 
correct integration of the 2A-ppGFP sequence into the NANOG locus 
(Appendix 11D). This clone was targeted with the OCT4 gRNA and the 2A-
mOrange donor vector. Isolation, expansion and sequencing of a mOrange 
and GFP double positive clone showed correct integration of the 2A-
mOrange sequence into the OCT4 locus (Appendix 11E). 
 
4.3 DISCUSSION 
 
Here, we demonstrate the generation of hESC reporter lines without 
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the use of drug selection for both active and silent genes through the use of 
the iCRISPR system. Selection-free gene targeting eliminates the need for 
removal of drug-resistance cassette after identification of correctly targeted 
clones, and mini-vector donors with short homology arms (∼500–1,000 bp 
each) are convenient to make. Thus, this method significantly reduces the 
time and effort required for establishing hESC reporter lines. Additionally, 
conventional gene-targeting strategies typically use the Cre-loxP strategy to 
remove drug-resistance cassettes, which leaves behind a 34-bp loxP “scar” 
in the endogenous locus. Although not an issue in most cases, this residual 
sequence could interfere with the expression of the targeted gene in some 
situations (Meier et al., 2010). In comparison, our strategy eliminates the 
need for the selection cassette and thereby minimizes the alteration of the 
endogenous locus. Although we focused on creating promoter-fusion 
reporters, the same knockin approach can be readily applied to making 
protein-fusion reporters for visualizing protein subcellular localization, 
precisely deleting or replacing specific genomic sequences, and introducing 
or correcting disease-associated mutations. 
It is known that gene-targeting efficiencies can vary significantly 
depending on the target locus, though the exact reason is unclear. 
Traditional gene targeting relies on drug selection; thus, the relative 
targeting efficiencies after drug selection depends, at least in part, on the 
expression of the drug-resistance gene from the targeted locus. Because 
the expression of drug-resistance gene may differ significantly between 
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expressed and silent loci, the relative targeting efficiency after drug selection 
for a lineage-specific gene may appear much lower compared with a 
pluripotency gene. For certain loci, the drug-resistance gene may be 
expressed at such low levels that hinder the identification of a correctly 
targeted clone using the drug-selection method (Rostovskaya et al., 2012). 
Because our targeting approach obviates drug selection, it may overcome 
such bias and facilitate the generation of reporter alleles for genes that were 
previously difficult to target. One may further use this ability to measure 
absolute targeting frequencies to compare HDR efficiencies across different 
genomic contexts. 
There have been concerns about potential off-target mutagenesis 
with the CRISPR/Cas system (Cho et al., 2014; Fu et al., 2013; Hsu et al., 
2013; Pattanayak et al., 2013). Our analysis so far did not reveal any off-
target mutations at sites without perfect complementarity with the CRISPR 
target sequence. However, we cannot exclude the possibility of off-target 
mutations elsewhere in the genome, and a thorough analysis may be 
necessary before the reporter lines are used in future studies. The 
CRISPR/Cas system is continuously improved with the development of 
better algorithms for CRISPR design and off-target prediction. It is 
reassuring that a recent high-coverage whole-genome sequencing study 
failed to detect significant incidence of off-target mutations in CRISPR-
targeted hPSC lines (Veres et al., 2014). On the other hand, we noticed that 
some correctly targeted clones carried mutations in the non-targeted allele, 
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though the targeting efficiency is sufficiently high that one could simply 
discard the minority of clones carrying mutations. One may also target intron 
regions with low-sequence conservations to further mitigate any concerns 
associated with Indel mutations in the non-targeted allele. 
Our selection-free targeting approach enables rapid generation of knockin 
reporter lines, though it also requires either using established iCas9 cells or 
creating new iCas9 lines in a desired hPSC background. The upfront effort 
for generating iCas9 cells is relatively small due to the efficient TALEN-
mediated AAVS1-targeting approach, and it is possible to establish an iCas9 
line in about 1 month (Gonzalez et al., 2014). Once an iCas9 line is 
established, it can be used for making different types of reporters. Our 
previous study has shown that Cas9 activity is tightly regulated by 
doxycycline treatment, and established iCas9 lines exhibit no apparent 
chromosomal aberrations or defects in the maintenance of the pluripotent 
state (Gonzalez et al., 2014). A recent study also observed no adverse 
effects in constitutive Cas9-expressing mice (Platt et al., 2014). An 
additional benefit of using iCas9 hPSCs for making reporter lines is that the 
cells can be conveniently used for a variety of downstream genetic studies 
using gene-editing approaches we already established (Gonzalez et al., 
2014). Thus, we expect this selection-free knockin strategy to further 
facilitate the use of hESCs for developmental studies, disease modeling, 
and cell-replacement therapy. 
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4.4	 MATERIALS & METHODS 
 
 
4.4.1 Generation of constructs  
To generate CRISPR plasmids expressing Cas9 and the 
crRNA/tracrRNA duplex targeting specific genomic loci, 30-bp protospacer 
sequences were cloned into the px260 (Addgene: 42229) as previously 
described (Cong et al., 2013). Briefly, vectors were digested with BbsI, 
treated with Antarctic Phosphatase, and gel purified. A pair of 
oligonucleotides containing the 30-bp protospacer sequence was annealed 
generating BbsI overhangs, and cloned into BbsI-digested, 
dephosphorylated vectors.  The same procedure was also used to generate 
CRISPR plasmids expressing Cas9 and the chimeric gRNA with the 
difference that a pair of oligonucleotides containing the 20-bp protospacer 
sequence was cloned into the piCRg Entry plasmid (Addgene: 58904). The 
sequences for all oligonucleotides used for generating the CRISPR 
constructs are listed in Table 4.2.  
For generation of OCT4-eGFP hESC reporter lines, the OCT4-2A-
eGFP-PGK-Puro plasmid (Addgene: 31938) was used. The left homology 
arm is 697 bp and the right homology arm is 699 bp. The OCT4-mOrange 
hESC reporter lines were made using the OCT4-2A-mOrange targeting 
vector. To generate the OCT4-2A-mOrange targeting vector, an NheI-
2AmOrange-AscI cassette was PCR amplified using the mOrange-pBAD 
plasmid template (Addgene: 54751) and primers Nh2AOr-F and AscOr-
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R. Next, the NheI-2A-mOrange-AscI PCR fragment and the OCT4-2A-
eGFP-PGK-Puro plasmid were digested with NheI and AscI and ligated. The 
NANOG-ppGFP hESC reporter lines were made using the NANOG-2A-
ppGFP targeting vector. To generate the NANOG-2A-ppGFP targeting 
vector, an Nhe1-2AppGFP-BglII cassette was PCR amplified using a 
pCR2_NhPTVppGFP_BglII, with primers NhPTV_F and Bg_ppGFP_R. 
NANOG homology arms were PCR amplified from HUES8 genomic DNA 
and cloned into the pBlueScript SKII (+) plasmid to generate the pBS-
NANOG plasmid. The left homology arm is 811 bp and the right homology 
arm is 1014 bp. The reverse primer for the 5’ homology arm contained a 
NheI site and the forward primer for the 3’ homology arm contained a BglII 
site. The Nhe1-2AppGFP-BglII cassette and the pBS-NANOG plasmid were 
digested by NheI and BglII and ligated to generate the NANOG-ppGFP 
targeting vector. The primers used for construction of donor plasmids are 
given in Table 4.3. 
Table 4.2. PCR Primers for generating templates for gRNA in vitro 
transcription 
Gene CRISPR target sequence (5’ of 
PAM) 
CRISPR specific forward primer (5’ to 3’) 
OCT4   cr1 TCTCCCATGCATTCAAACTG F: 
TAATACGACTCACTATAGGGTCTCCCATGCATTCAAACTG 
NANOG cr1 ACTCATCTTCACACGTCTTC F:  
TAATACGACTCACTATAGGGACTCATCTTCACACGTCTTC 
Universal reverse primer gRNA-R: AAAAGCACCGACTCGGTGCC 
 
 
 
 
 
 
Table 4.3. PCR Primers for donor plasmid construction 
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Donor 
plasmid 
Primer sequence (5’ to 3’) 
OCT4  Nh2AOr-F TTCTAGCTAGCACCGGTGCCACGAACTTCTCTCT 
 AscOr-R CTTATGGCGCGCCTTACTTGTACAGCTCGTCCAT 
NANOG 5’HA-F GGTACCTAGCCTGTAGCGAACTCCTG 
 5’HA-R GCTAGCCACGTCTTCAGGTTGCATGTT 
 3’HA-F AGATCTAGATGAGTGAAACTGATATTACT 
 3’HA-R GCGGCCGCCTTCTCCACCCCAACCAAAAA 
 2A-ppGFP-F CAGTGCTAGCGCCACTAACTTCTCCCTGTT 
 2A-ppGFP-R TCAGTCGGCGCGCCTTACTTGTACAGCTCGTCCA 
 
 
Table 4.4. PCR primers for genotyping 
Gene Primer sequence (5’ to 3’) 
OCT4 F: AGTCCAAAGCTTGCCCTTGTCACC 
 GFP-R: AGCTCCTCGCCCTTGCTCACC 
 mOr-R: GAGGTGATGTCCAACTTGATGCCGA 
NANOG F: TTTGTAGACACAGTGTTTCCTC 
 R: GCAGTGTCCTCAGCTAATTTC 
 
 
Table 4.5. PCR primers for generating Southern blot probes 
Gene Probe Primer sequence (5’ to 3’) 
OCT4 External F: CCAGTGGGAGTCAGTGGGGCT 
  R: GTCCGACTCCCAAGAGGTCACAG 
 Internal Puro F: TGACCGAGTACAAGCCCACGG 
  
Internal mOrange 
R: TCGTAGAAGGGGAGGTTGC 
F: TGGCCATCATCAAGGAGTTCA 
R: CTTCTTCTGCATTACGGGGCCG 
NANOG External F: ACCTCCTGGGTTCAAGGGATT 
  R: GAGGAAACACTGTGTCTACAAA 
 Internal GFP F: GTTCATCTGCACCACCGG 
  R: CGCGCTTCTCGTTGGGGT 
 
 
4.4.2 Cell culture 
HUES8 (NIHhESC-09-0021) and MEL-1 (NIHhESC-11-0139) hESCs 
were cultured on irradiated mouse embryonic fibroblasts (iMEFs) feeder 
layers in DMEM/F12 medium (Life Technologies) supplemented with 20% 
KnockOut Serum Replacement (Life Technologies), 1X MEM Non-Essential 
Amino Acids (Life Technologies), 1X GlutaMAX (Life Technologies), 
100U/ml Penicillin and 100 μg/ml Streptomycin (Gemini), 0.055 mM 2-
mercaptoethanol (Life Technologies) and 10 ng/ml recombinant human 
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basic FGF (EMD Millipore). Cells were incubated at 37 °C with 5% (vol/vol) 
CO2, and media was changed daily. Cultures were passaged at a 1:6 - 1:12 
split ratio every 4 - 6 days using 0.05% trypsin/EDTA. 5 µM Rho-associated 
protein kinase (ROCK) inhibitor Y-27632 (Selleck Chemicals) was added 
into the culture medium when passaging or thawing cells.  
293T cells were maintained in DMEM supplemented with 15% fetal 
bovine serum, 1X GlutaMAX, 1X MEM NEAA and 1mM Sodium Pyruvate 
(Life Technologies). 
For differentiation of OCT4 reporter lines, undifferentiated hESCs 
cultured on iMEF feeder layer were first adapted to the feeder-free E8 
culture. Briefly, hESCs were passaged using 0.05% trypsin/EDTA and 
plated at a 1:3 split ratio on Matrigel (BD Biosciences) coated plates in E8 
medium (Stem Cell Technologies). Cells were incubated at 37 °C with 5% 
(vol/vol) CO2, and media was changed daily. After 2 passages in E8 
medium, the cells were differentiated: 2 days after passaging, cells were 
treated with 10 μM SB431542 (Sigma Aldrich) and 10 ng/mL BMP4 (R&D 
Systems) to initiate differentiation. After 3 days of this treatment, eGFP and 
mOrange fluorescence was analyzed by flow cytometry and fluorescence 
microscopy.   
 
4.4.3 In vitro transcription of gRNAs  
A T7 promoter was added to gRNA templates by PCR amplification 
on piCRg Entry vectors using CRISPR-specific forward primers and a 
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universal reverse primer gRNA-R (Table S2). T7-gRNA PCR products were 
used as templates for in vitro transcription using the MEGAshortscript T7 kit 
(Life Technologies). The resulting gRNAs were purified using the 
MEGAclear kit (Life Technologies), eluted in RNase-free water and stored at 
-80°C until use. 
 
4.4.4 Electroporation  
HUES8 hESCs were pre-treated with Rho-associated protein kinase 
(ROCK) inhibitor Y-27632 (Selleck Chemicals) 24 hours before 
electroporation. On the day of electroporation, hESCs were disassociated 
into single cells with 0.25% Trypsin/EDTA and filtered through a 40 µM cell 
strainer to remove cell clumps. 10 million cells were re-suspended in 800 µL 
cold PBS and mixed with targeting and donor plasmids (10 µg CRISPR 
targeting plasmid and 40 µg donor plasmid). Cells were electroporated using 
the Gene Pulser XCeII (Bio-Rad) at 250 V, 500 µF in a 0.4 cm Gene Pulser 
cuvette (Bio-Rad). Cells were recovered and re-plated on irradiated mouse 
embryonic fibroblast (iMEF) coated plates with ROCK inhibitor.  
For the generation of OCT4-eGFP lines, two days after 
electroporation cells were treated with puromycin (0.5 µg/mL) for three days. 
Two weeks after electroporation individual colonies were picked and 
expanded for PCR genotyping, Southern blot analysis and sequencing for 
the establishment of reporter lines. Three of the correctly targeted clones 
(#1, #4 and #7) were electroporated with Cre recombinase following the 
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same procedure described above. After electroporation with 50 µg of Cre 
recombinase plasmid, the cells were recovered and replated on iMEF with 
ROCK inhibitor. 3 days after electroporation, GFP-expressing (GFP+) cells 
were observed. GFP+ cells were isolated by FACS and plated at a low 
density (2,000 cell/10cm dish) for subsequent picking and expansion of 
individual clones. 
 
4.4.5 Transfection  
HUES8 and MEL-1 iCas9 hESCs (Gonzalez et al., 2014) were 
treated with ROCK inhibitor and doxycycline one day before transfection. 
Different transfection reagents were tested for efficiency for delivering 
gRNAs and plasmid DNA into hESCs (Appendix 8). Lipofectamine 3000 was 
determined to be the most effective reagent for transfection. For 
transfection, cells were dissociated using TrypLE (Life Technologies), 
replated at 200,000 hESCs per well in iMEF-coated 12-well plates and 
transfected in suspension with gRNAs and donor plasmid. A second 
transfection was performed 24 hours later. Transfection of the gRNAs and 
donor plasmid into hESCs was performed using Lipofectamine 3000 (Life 
Technologies) following manufacturer’s guidelines. For each targeting, 
gRNAs at a 10 nM final concentration and 5 µg of donor plasmid were used. 
Lipofectamine 3000 and gRNA + donor plasmid were diluted separately in 
Opti-MEM (Life Technologies), mixed together, incubated for 5 min, and 
added drop-wise to cultured hESCs. 
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4.4.6 Assessment of Indel mutations using the Surveyor Nuclease 
Assay 
80-90% confluent 293T cells in 6-well dishes were transfected using 
JetPrime transfection reagent (Polyplus) following manufacturer’s 
guidelines. For each well, a total of 2 µg CRISPR plasmid was transfected. 
After transfection the cells were incubated at 37 °C for 2 days prior to 
genomic DNA extraction. The Surveyor Kit (Transgenomic) was used to test 
the efficiency of each crRNA for producing indels. Genomic DNA was 
extracted using the DNeasy Blood & Tissue Kit (Qiagen) following the 
manufacturer’s protocol. The genomic region flanking the CRISPR target 
site for each gene was PCR amplified. For Surveyor analysis 16 µL of PCR 
product (at 25 ng/µL) was denatured and re-annealed in JumpStart buffer to 
a total volume of 20 µL using the following protocol: 95 °C, 5 min; 95–85 °C 
at −2 °C/s; 85–25 °C at −0.1 °C/s; hold at 4 °C. 10 µL of hybridized PCR 
products was treated with 1 µL of Surveyor Enhancer S and 1 µL of 
Surveyor Nuclease S at 42°C for 60 minutes. The reaction was stopped by 
adding 1.2 µL of Stop solution to each tube. Products were then analyzed on 
2.5% agarose gel and imaged with a Gel Doc gel imaging system (Bio-Rad). 
Quantification was based on relative band intensities using ImageJ. Indel 
mutation percentage was determined by the formula: 100 x (1 - (1 - (b + c) / 
(a + b + c))1/2), where a is the integrated intensity of the undigested PCR 
product, and b and c are the integrated intensities of each cleavage product. 
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4.4.7 Southern Blot Analysis 
The external and internal probes were generated by PCR using the 
PCR DIG Probe Synthesis Kit (Roche). For the external probes we used 
HUES8 genomic DNA as the template. For internal probe generation we 
used the OCT4 2A-eGFP-PGK-Puro donor, OCT4-2A-mOrange donor and 
PDX1-2A-eGFP donor templates. For membrane hybridization, 5 µL of 
denatured DIG-labeled PCR product was added to 20 mL of hybridization 
buffer. 
To identify correctly targeted hESC lines, genomic DNA was 
extracted using the DNeasy Blood & Tissue Kit (Qiagen). For PCR 
genotyping the PCR primers listed in Table 4.4 were used. For southern blot 
analysis 5-10 µg of genomic DNAs was digested overnight with the 
appropriate restriction enzymes (OCT4 external and mOrange internal: 
BamHI, puromycin internal: EcoRI, PDX1 external: ApaLI, eGFP internal: 
ApaLI) and then migrated in 1% agarose gels. The gel was denatured, 
neutralized, and transferred overnight by capillarity on Hybond-N 
membranes (GE Healthcare) using 10x SSC transfer buffer. Hybridization 
with the external or the internal probe was carried out overnight at 65 °C. 
Probes were detected using an AP-conjugated DIG-Antibody (Roche) using 
CDP-Star (Roche) as a substrate for chemiluminescence as per 
manufacturer’s instructions. The PCR primers used for generation of 
southern blot probes are given in Table 4.5. 
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4.4.8 Immunofluorescence Staining 
For immunostaining, cells were fixed with 4% paraformaldehyde for 
10 minutes, washed once with phosphate buffered saline (PBS) and 
permeabilized in PBST (PBS + 0.1% Triton) for 15 minutes.  Blocking was 
done for 5 minutes at RT with blocking solution (5% donkey serum in 
PBST). Primary and secondary antibodies were diluted in blocking solution. 
Primary antibodies were incubated at RT for 1 hr. The following primary 
antibodies were used at a 1:100 dilution: OCT4 (mouse monoclonal, Santa 
Cruz sc-5279); NANOG (rabbit polyclonal, CosmobioJapan REC-
RCAB0004P-F); SOX2 (goat polyclonal, Santa Cruz sc-17320), RFP (rabbit 
polyclonal, Life Technologies R10367), GFP (rabbit polyclonal, Life 
Technologies A-6455). The PDX1 antibody was used at a 1:500 dilution 
(goat polyclonal, R&D AF2419). After primary antibody staining the cells 
were washed three times with PBST and then incubated with the 
appropriate Molecular Probes Alexa Fluor dye conjugated secondary 
antibodies (Life Technologies) for 1 hr. 
 
4.5 CONCLUSIONS  
The development of new gene-editing tools, in particular the 
CRISPR/Cas system, has greatly facilitated site-specific mutagenesis in 
human embryonic stem cells (hESCs), including the introduction or 
correction of patient-specific mutations for disease modeling. However, 
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integration of a reporter gene into an endogenous locus in hESCs still 
requires a lengthy and laborious two-step strategy that involves first drug 
selection to identify correctly targeted clones and then excision of the drug-
resistance cassette. Through the use of iCRISPR, an efficient gene-editing 
platform we recently developed, this study demonstrates a knockin strategy 
without drug selection for both active and silent genes in hESCs. Lineage-
specific hESC reporter lines are useful for real-time monitoring of cell-fate 
decisions and lineage tracing, as well as enrichment of specific cell 
populations during hESC differentiation. Thus, this selection-free knockin 
strategy is expected to greatly facilitate the use of hESCs for developmental 
studies, disease modeling, and cell-replacement therapy. 
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5.0 APPENDIX 
Appendix 1. 
 
 
Appendix 1. Generation and validation of TET1-3XFlag Tag lines. (A) T7 
Endonuclease assay for different CRISPR gRNAs that target the stop codon of 
TET1. CRISPR gRNA 2 was used for targeting. (B) Top: schematic of insertion of 
the Flag tag into the TET1 locus. The flag tag is inserted immediately after the start 
codon and separated from the coding sequence by a 12 bp linker sequence. Red 
box indicates the putative DNA binding domain of TET1. Arrowheads indicate the 
PCR primer pairs used for genotyping and identification of targeted clones. The WT 
allele shows a PCR product that is 542 bp while the allele with the Flag tag 
insertion produces a PCR fragment that is 623 bp long. Bottom: PCR genotyping of 
two positive clones. (C) Sequencing of PCR fragments from (B) of clone 1 (C1) 
indicates that there are 3 base pairs that are deleted prior to the start codon in the 
targeted allele. Similar mutations were observed in the second clone (C2). No 
mutations were observed in the non-targeted (WT) allele. The targeting sequence 
of the CRISPR gRNA used (Cr2) is shown. (D) Immunoprecipitation and western 
blot for the two targeted clones (C1 and C2). Asterisks indicate the expected band.  
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Appendix 2. Co-immunoprecipitation of PRC2 and DNMT3B (A) Model for 
recruitment of TET1 and DNMT3B to bivalent promoters such as the PAX6 P0 
promoter. In WT hESCs TET1 and DNMT3B compete for recruitment to bivalent 
promoters leading to hypomethylated promoters. After TET inactivation DNMT 
proteins is increasingly recruited to bivalent promoters leading to hypermethylation. 
(B) Schema for generation of the TET1-3xFlag line. CRISPR gRNA Cr2, which 
targets the start codon is shown. A 200 nucleotide ssDNA donor was used that 
contains a 69 bp 3xFlag sequence and 12 bp linker sequence. The bottom shows 
insertion of the 3xFlag into the endogenous TET1 locus immediately after the ATG 
start codon and separated from the remainder of the TET1 coding sequence by a 
12 bp linker sequence. Top: schematic of insertion of the Flag tag into the TET1 
locus. The flag tag is inserted immediately after the start codon and separated from 
the coding sequence by a 12 bp linker sequence. (C) Co-immunoprecipitation and 
western blot of PRC2 and TET1-Flag and DNMT3B in WT, TKO and QKO hESCs.  
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Appendix 3. CRISPR targeting of EZH2 and SUZ12 start codons. (A) Left: T7 
Endonuclease I assay for CRISPR gRNAs that target the genomic sequences of 
EZH2 (Top) and SUZ12 (Bottom) start codons. Right: Generation of mutants after 
CRISPR gRNA targeting in WT and TKO hESCs. (B) Top: SUZ12 gene with exons 
shown as blue box. The start codon and stop codon are indicated along with the 
CRISPR gRNAs that target exon 1. The PCR primers used for genotyping are 
indicated as arrows. Bottom: SUZ12 pseudogene that shares exons 1-9 with the 
SUZ12 gene. The binding of the CRISPR gRNAs and PCR genotyping to the 
SUZ12 pseudogene are also indicated.  
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Appendix 4. Generation of inducible TKO hESCs. (A) Model of inducible TKO 
hESCs in which Cas9 is induced by doxycycline treatment and TET1, TET2 and 
TET3 gRNAs are expressed constitutively by U6 promoters. (B) 5hmC staining in 
WT, TKO hESCs and the inducible TKO line before doxycycline treatment (D0), 
after 4 days (D4) and 7 days (D7) of doxycycline treatment. (C) T7 Endonuclease I 
assay for indel formation at TET1, TET2 and TET3 loci in inducible TKO line before 
doxycycline treatment (D0), after 4 days (D4) and 7 days (D7) of doxycycline 
treatment.  
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Appendix 5. 
Appendix 5. CRISPR/Cas-Mediated Targeting of the OCT4 Locus through Drug 
Selection. (A) Schematics of the targeting strategy. In the presence of the donor plasmid, 
HDR results in the replacement of the OCT4 stop codon with 2A-eGFP-PGK-Puro. The 
PCR primers (F + GFP-R) used for genotyping are indicated with red arrowheads. OCT4 
cr1-dp (the duplex version) targets a 30-nt sequence (indicated with a green line) upstream 
of the PAM sequence (indicated with a purple line). In all targeting schematics here and 
after, boxes are exons, filled blue boxes indicate the coding sequence (CDS), connecting 
lines are introns, the stop codon (TGA) is labeled in red, HL and HR indicate left and right 
homology arms, and the Southern blot external and internal probes are indicated with red 
bars. (B) The vector map of the px260 plasmid for expressing Cas9 and crRNA/tracrRNA. 
(C) Four crRNAs were designed to target the stop codon of the OCT4 locus. Each crRNA 
was cloned into the px260 vector and transfected into 293T cells. Two days after 
transfection genomic DNA was collected and Surveyor analysis was used to estimate the 
efficiency of each CRISPR in generating indels. Asterisks indicated the cleavage products 
and the estimated Indel frequencies were labeled in blue. CTRL: px260 vector control; U: 
undigested control; D: digestion reaction with Surveyor nuclease. (D) PCR genotyping 
results showing 10 positive clones (indicated by red asterisks) identified based on the 
presence of a correct PCR product (811 bp). 
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Appendix 6. Validation of OCT4 locus targeting using CRISPR/Cas9 and drug 
selection. (A) Southern blot analysis using the external probe (WT: 4,173 bp; GFP+Puro: 
6,835 bp) and the internal puromycin probe (GFP+Puro: 2,415 bp) identified eight correctly 
targeted clones, which are labeled in red. WT, wild-type allele; GFP+Puro, correctly 
targeted allele with puromycin-selection cassette. (B) Three of the correctly targeted clones 
(nos. 1, 4, and 7) were electroporated with Cre recombinase. Four days after 
electroporation, eGFP+ cells were isolated using FACS. (C) For each clone (nos. 1, 4, and 
7) electroporated with CRE recombinase, two GFP+ clones were picked (e.g., C1.1 and 
C1.2 for clones derived from no. 1), and Southern blot analysis using the external probe 
(WT: 4,173 bp; GFP+Puro: 6,835 bp; GFP only: 5,015 bp) and the internal puromycin probe 
(GFP+Puro: 2,415 bp) showed correct removal of the puromycin-selection cassette. A clone 
(C1) prior to Cre electroporation was used as the Pre-Cre control. GFP+Puro, targeted 
allele prior to Cre-mediated excision of the PGK-Puro cassette; GFP only, targeted allele 
after Cre-mediated excision. (D) OCT4-eGFP reporter hESCs were stained for pluripotency 
markers OCT4, NANOG and SOX2, which overlapped with GFP expression. The GFP 
signal was detected using a GFP antibody. Scale bar = 100 µm.  
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Appendix 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7. Targeting the OCT4 Locus without Drug Selection. (A) Schematics of the 
targeting strategy without drug selection. In the presence of the donor plasmid, HDR results 
in the replacement of the stop codon with 2A-mOrange. OCT4 cr1 targets a 20-nt sequence 
upstream of the PAM sequence. The PCR primers (F + mOr-R) used for genotyping are 
indicated with red arrowheads. (B) The vector map of the piCRg Entry plasmid for 
expressing Cas9 and the chimeric gRNA. (C) FACS analysis for OCT4-mOrange 
expressing cells in HUES8 cells after electroporation of the OCT4-mOrange donor and the 
Cas9/gRNA plasmids. (D) Timeline for establishing hESC reporter lines using iCas9 
hESCs. (E) FACS enrichment for OCT4-mOrange+ cells after transfection of the OCT4-
mOrange donor plasmid and the OCT4-targeting gRNA into HUES8 iCas9 cells (top) and 
MEL1 iCas9 cells (bottom) treated with doxycycline. (F) Top: FACS analysis for OCT4-
mOrange expressing cells in HUES8 iCas9 cells without doxycycline treatment after 
electroporation of the OCT4-mOrange donor and the Cas9/gRNA plasmids. Bottom: FACS 
analysis for OCT4-mOrange fluorescence in doxycycline-treated HUES8 iCas9 cells co-
transfected with the OCT4-mOrange donor plasmid and the OCT4-targeting gRNA, 
compared to HUES8 iCas9 cells (not treated with doxycycline) co-transfected with the 
Cas9/gRNA and the donor plasmids using Lipofectamine 3000. 
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Appendix 8. 
Appendix 8. Optimizing co-transfection of DNA and RNA into hESCs. 
(A) FACS analysis of hESCs co-transfected with Alexa 555 dsRNA and a GFP-expressing 
plasmid (~ 10 kb) using four commonly used transfection reagents along with 
electroporation. Lipofectamine 3000 consistently performed better than the other 
conditions. Although comparable efficiencies could sometimes be achieved using JetPrime 
(as shown here), the outcomes were variable and appeared to relate to the amount of DNA 
used for transfection. (B) Stronger GFP expression was detected in hESCs transfected 
with Lipofectamine 3000, suggesting that increased copy number of GFP-expressing 
plasmid was transfected into the cell. 
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Appendix 9. Validation of OCT4 locus targeting using CRISPR/Cas9 without drug 
selection. (A) Ten colonies were randomly picked from individual FACS-enriched 
mOrange+ cells. Southern blot analysis using the external probe (WT: 4,173 bp; 
mOrange: 4,963 bp) and the internal mOrange probe (mOrange: 4,963 bp) 
identified six correctly targeted clones, which are labeled in red. mOrange: correctly 
targeted allele. (B) PCR genotyping for OCT4-mOrange gene targeting. Correctly 
targeted clones are indicated in red. (C) OCT4-mOrange reporter hESCs were 
stained for pluripotency markers OCT4, NANOG and SOX2, which overlapped with 
mOrange expression. Scale bar = 100 µm. 
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Appendix 10. 
 
 
 
Appendix 10. Characterization of OCT4-mOrange Reporter Lines. (A) OCT4-eGFP and 
OCT4-mOrange hESCs were treated with SB431542 and BMP4 to initiate differentiation. 
Three days after this treatment, the cells displayed concomitant loss of OCT4 protein 
expression with GFP or mOrange by immunostaining. An RFP antibody was used to detect 
mOrange expression, whereas the GFP expression was detected directly. The scale bar 
represents 100 μm. (B) Three days after SB431542 and BMP4 treatment, flow cytometry 
analysis showed a loss of GFP and mOrange, verifying that OCT4-eGFP and OCT4-
mOrange reporter hESCs can respond to differentiation cues and that GFP and mOrange 
accurately reflects OCT4 expression. (C) Sequencing results of the non-targeted allele and 
at the junction of correctly targeted allele in OCT4-eGFP and OCT4-mOrange reporter 
lines. 
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Appendix 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 11. Generation of NANOG reporter lines. (A) A total of eleven crRNAs were 
designed to target the stop codon of the NANOG locus. Three crRNAs were cloned into the 
px330 vector and eight crRNAs were cloned into the px260 vector and transfected into 
293T cells. Two days after transfection genomic DNA was collected and Surveyor analysis 
was used to estimate the efficiency of each CRISPR in generating indels. Asterisks indicate 
the cleavage products. 330 backbone: px330 vector control; 260 backbone: px260 vector 
control. (B) Schematics of the targeting strategy without drug selection. In the presence of 
the donor plasmid, HDR results in the replacement of the stop codon with 2A-ppGFP. 
NANOG cr1 targets a 20-nt sequence upstream of the PAM sequence. The PCR primers 
used for genotyping are indicated with red arrowheads. (C) FACS enrichment for OCT4-
mOrange+ or NANOG-ppGFP+ cells after transfection of the OCT4-mOrange, NANOG-
ppGFP donor plasmids and the OCT4-targeting and NANOG-targeting gRNAs into HUES8 
iCas9 cells treated with doxycycline. GFP positive cells were sorted and expanded for 
further analysis and targeting. (D) Top: Brightfield and GFP fluorescence for one of the GFP 
positive sorted and expanded clones. Bottom: sequencing at the NANOG locus showed 
correct integration of the 2A-ppGFP donor. The non-targeted allele of NANOG was 
unchanged. (E) Targeting of the GFP positive targeted clone from (D) was targeted with 
OCT4 gRNA and the 2A-mOrange donor vector. GFP and mOrange double positive cells 
were sorted and expanded. Sequencing of one such clone showed correct integration of the 
2A-mOrange donor into the OCT4 locus. The non-targeted allele of OCT4 was unchanged. 
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